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Abstract 
Gold nanoparticles (AuNPs) have attracted significant interest for biosensing 
applications because of their distinctive optical properties including light scattering. 
Dynamic light scattering (DLS) is an analytical tool used routinely for measuring the 
hydrodynamic size of colloids and nanoparticles in liquid environment. By combining 
the light scattering properties of AuNPs with DLS, a label-free, facile and sensitive 
assay has been developed. There have been several reports showing that NP-
coupled DLS size shift assays are capable of quantitative analysis for target analytes 
ranging from metal ions to proteins as well as being a tool for biomolecular 
interaction studies.  
The principle of the assay developed is to immobilise bioreceptors 
(antibodies, oligonucleotides or synthetic binding proteins) specific to the target 
analyte onto AuNPs to produce nanobiosensors. When the analyte is added to the 
system, binding of the target protein to the immobilised bioreceptors leads to a size 
increase of the functionalised AuNPs. The hydrodynamic diameter (DH) can then be 
measured by DLS for complete quantitation. However, the ability to use synthetic 
binding proteins (Affimers) in optical sensing has not been investigated. Here, anti-
myoglobin (Mb) Affimers were selected by biopanning of a phage display library and 
subcloned into a bacterial plasmid for expression in a prokaryotic system. These 
Affimers were then expressed and characterised before being used as bioreceptors 
in the NP-coupled DLS size shift assay. The Affimer functionalised AuNPs were 
compared to those using polyclonal antibodies (IgG) as bioreceptors.  
The Affimer nanobiosensors could selectively detect Mb with a limit of 
detection of 554 fM when multiple Affimer clones were immobilized onto the AuNPs, 
which was comparable to IgG based nanobiosensors (LOD = 148 fM). These findings 
suggest that in general a polyclonal reagent is optimum for the assay. In addition, 
other factors, such as AuNP size and concentration, related to the assay were 
investigated. The detection range of the size shift assay could be tailored to each 
analyte by selecting the appropriate AuNP size and concentration. This fundamental 
data will serve as a base for future studies of using Affimers in DLS based sensing 
applications.  
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Chapter 1 Introduction 
1.1 Overview 
Nanoparticles (NPs) are particles with sizes ranging from 10 to a few 100s of 
nm. They possess unique characteristics in between those of bulk materials and 
molecular scale materials. NPs have attracted massive interests for biomedical 
applications e.g. for cellular imaging or biosensing, especially with their distinctive 
optical properties. Metal nanoparticles, particularly gold, have been extensively 
studied because of their facile synthesis and modifiable surface chemistry. In 
biosensing applications, gold nanoparticles (AuNPs) were first introduced as optical 
labels, electrochemical markers or signal amplifiers (Pissuwan et al., 2010; Kaittanis 
et al., 2010). However, in the past decade, the trend has shifted to a designed 
biosensing assay using AuNPs as a platform not just as a signal amplifier. With their 
unique optical properties, they allow various detection systems to be established.  
Dynamic light scattering (DLS) is an analytical tool used routinely for 
measuring the hydrodynamic size of colloids and nanoparticles in a liquid 
environment. By combining the light scattering properties of AuNPs with DLS, a label-
free, facile and sensitive assay can be developed. One of the most interesting assays 
is the NP-coupled DLS size-shift assay. The principle is to conjugate bioreceptors on 
AuNPs. When the target analyte is added to the system, the binding of the target 
and immobilised binding protein will lead to size increase or aggregation of AuNPs. 
The size increase then can be measured by DLS for complete quantitation. The 
concept of this assay was previously investigated and proved that it is possible with 
various type of bioreceptors, mostly antibodies (Abs).  
There are some disadvantages regarding antibodies, e.g. they are large 
multimeric molecules, expensive to produce and with reproducibility issues and so 
there has been attention to find an alternative to antibodies. Amongst antibody 
mimetics, synthetic binding proteins are undergoing intense development. The 
Affimer is one of synthetic binding proteins that exhibits the promising property of 
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being an effective bioreceptor with similar or better specificity to antibodies, but is 
more easily produced and more thermodynamically and chemically stable.  
The challenge in developing assays is to produce a stable detection probe 
with reliable binding property as the key principle relies on the specific binding event 
between the bioreceptors on NP surfaces and the target analyte. Work in this thesis 
has been carried out to investigate whether the Affimer can be used as bioreceptors 
in a nanoparticle size-shift assay. The work involved screening of the Affimers library 
for Affimer that bound equine heart myoglobin and characterizing them for size-shift 
assay applications. Myoglobin from equine heart was selected as a model analyte 
because it is an inexpensive and common protein, but is also an important biomarker 
for skeletal and cardiac muscle damage. With more stable bioreceptors, it is 
expected that this will open up more opportunities to develop cheaper and more 
robust assay systems. 
  
4 
 
1.2 Biosensing system 
A biosensor is an analytical platform involving three main components 
(Figure 1-1), which are the recognition element, transduction and output systems. 
The recognition process utilizes the specific binding of an analyte – both biological 
and chemical – to a biomolecule often called a bioreceptor. This process is known as 
the biorecognition event. After the specific binding phenomenon occurs, a 
transducer system plays an important role in converting this event into a measurable 
signal that is proportional to the amount of analyte. Finally, those signals are 
amplified and displayed by the proper signal processing instrument. 
 
Figure 1-1 The overview of biosensing platform. 
 
The biosensing field has grown rapidly since its concept was first introduced 
worldwide by Clark and Lyons (1962). They developed a biosensing device for 
glucose detection, which was based on electrochemical detection of oxygen using 
suitable immobilised enzymes. Since then, these biosensor has become a promising 
platform for detection of innumerable analytes. The main application that draws 
researchers’ attention is the diagnostics via determination of various disease 
biomarkers as well as in drug discovery. However, the applications of biosensing 
platforms are not restricted to the biomedical field but includes wide range of 
applications in other fields such as food industries, environmental monitoring and 
even national security (Luong et al., 2008).  
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1.2.1 Classification of biosensing platform 
Biosensing platforms can be classified using several principles. However, the 
biological recognition process and the signal transduction method are the two main 
criteria used for categorization. 
1.2.1.1 Electrochemical sensing 
Electrochemical techniques for transduction processes in biosensors have 
been used for a long time and this approach was the first ever transducer element 
introduced alongside the biosensor concept (Rushworth et al., 2013). Also, 
electrochemical techniques are sensitive but with reasonable cost. This kind of 
system can be miniaturized into a hand-held device or even implantable biosensors, 
which are suitable for lab-on-a-chip development. However, some electrochemical 
biosensor systems, such as impedimetric biosensors, still face problems with 
consistency when it comes to repetitive analysis (Luong et al., 2008; Pavesi and 
Fauchet, 2008). There are several types of electrochemical techniques; 
amperometric, potentiometric, impedimetric or conductometric systems. 
Amperometric techniques directly convert the reaction rate of biomolecular event 
into a quantifiable current. Potentiometric biosensors, by comparison measures a 
voltage change across the electrode surface. Impedimetric sensors measure the 
change of impedance across the electrode surfaces, whereas, the method that 
utilizes sensing materials and measures their capabilities to transport charge is 
known as conductometric biosensor (Yoo and Lee, 2010). 
 
1.2.1.2 Electromechanical sensing 
Another type of transduction is found in electromechanical biosensors. These 
sensors measure the change of mass on the sensor surface due to biomolecular 
recognition. They can be categorized into several subgroups, such as quartz crystal 
microbalances (QCM), acoustic wave sensors, microcantilever sensors and others. 
QCM – the most common technique – measures decrease in frequency that 
corresponds to change in mass of an oscillating crystal when bound to an analyte 
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(Tamayo et al., 2013; Rushworth et al., 2013), while acoustic wave sensors measure 
the overall change of sensor resonant frequency by using piezoelectric materials as 
a sensor surface. The frequency of oscillation depends on the material’s mass. Thus, 
as analytes bind to the material, the mass will be increased and frequency reduces. 
The concentration of extra mass can be calculated using the change in frequency 
from the Sauerbrey equation (Chambers et al., 2008) . To fulfil the assumptions 
required for the equation, however, mass adsorbed must be small compared to the 
mass of the quartz crystal used, also the Sauerbrey equation only applies to rigid 
bodies. Therefore, QCM with dissipation monitoring or QCM-D was developed to 
solve this problem for soft materials (such as films, polymers and some biological 
macromolecules) or in a liquid environment as these samples or conditions always 
violate the rules of the Sauerbrey equation. With QCM-D, dissipation is monitored 
alongside the frequency by measuring the amplitude of oscillatory decay, which 
enables the viscoelasticity to be revealed (Dixon, 2008). The last subgroup utilizes 
cantilever flexibility as a key component. There are two modes of operation; (i) 
bending (or static) mode, which measures the deflection of the cantilever when the 
analyte binds and (ii) resonant (or dynamic) mode, in which measuring the resonant 
frequency change when analyte binds. This type of biosensor is highly sensitive, 
label-free and can be miniaturized (Tamayo et al., 2013). 
 
1.2.1.3 Optical sensing 
Optical biosensors can be roughly classified into label-based and label-free 
systems. Label-based platforms are systems that utilize optical labels, i.e. 
chromophores or fluorophores, as a transducer element. Sometimes the systems are 
based on the fact that many biomolecules have intrinsic fluorescence or synthetic 
fluorophores can be attached to be used as probes. Tagging a ligand with a 
fluorophore or development of a fluorescent analogue can require a multifaceted 
and time-consuming approach, which makes sensor fabrication more complicated 
(Pavesi and Fauchet, 2008; Shinde et al., 2012). Frequently, colored matrices or 
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interferents can compromise assay results and therefore label-free platforms are 
preferable. 
Surface plasmon resonance (SPR) is a well-known label-free technique for 
measuring biomolecular interactions, providing kinetic parameters as well as 
concentration analysis. In a recent times, SPR is able to perform calibration-free 
concentration analysis (CFCA). This method allows the active concentration of 
analyte to be determined without a calibration curve. It is based on mass transport 
limitations. This condition is when the binding rate is proportional to the transport 
rate of the analyte to the sensor surface. The active concentration can be calculated 
directly from the slopes of the curve by injecting the analyte at two different flow 
rates (e.g. 5 and 100 µl/min), (Visentin et al., 2016). Moreover, SPR imaging is also 
developing. This is used in a microarray format and combines the sensitivity of SPR 
and spatial imaging (Damborsky et al., 2016). SPR techniques dominate the market 
for optical sensing because they can provide the real-time quantitative analysis with 
very high sensitivity. Also, SPR has a high-throughput potential as it is an automatic 
system. Nevertheless, there are some drawbacks of using SPR, as it requires an 
expert operator for measurement and data analysis. Additionally, the cost of SPR 
equipment and consumables (“chips”) is considerable, similar to most optical 
sensing systems. Furthermore, the technique itself cannot differentiate the effect of 
non-specific binding and the detection of low molecular weight samples is still 
limited (Ahmed et al., 2010; Damborsky et al., 2016).  
SPR occurs when polarized light is applied to a glass prism-metal surface 
under total internal reflection (TIR) conditions. TIR is the point when all the incoming 
light reflects within the prism. This phenomenon will occur only at above a certain 
incidence angle. At the TIR condition, the reflected light produces an electrical field 
called an evanescent field on the surface. The wavelength of the evanescent wave is 
the same as that of the incident light but the amplitude decreases exponentially with 
increasing distance from the surface. When the prism is coated with a conducting 
material like gold, photons from the incident light interact with the outer shell or 
conduction band electrons of the gold and surface plasmons are generated, which 
are confined to the surface of the gold. These plasmons also produce an extended 
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evanescent wave across the gold surface and buffer solution. The conversion of 
photons to plasmons can occur when both momentum and energy of the process 
are maintained. The momentum can be referred to as a vector function with 
magnitude and direction of wave properties of both photons and plasmons. 
Resonance occurs when the momentum of incoming light is equal to the momentum 
of the plasmons. With this interaction, the photons convert to plasmons causing a 
dip in the reflected light intensity. At a specific angle where the maximum loss of the 
reflected light intensity occurs is called resonance angle, or SPR angle. To sustain this 
SPR phenomenon, the correct angle of incident light is required, but it is very 
sensitive to changes in refractive index at the surface. Therefore, any changes at the 
interface between the gold and the buffer, such as binding of molecule on the 
surface will alter the momentum of the surface plasmons and their associated 
evanescent wave. Regarding this, the SPR phenomenon no longer occurs at the same 
angle and leads to an SPR shift. The SPR configuration can be set up by detecting the 
SPR angle shifts at the sensor surface against time. The change corresponds to the 
biomolecule concentration. A schematic of the SPR principle is shown in Figure 1-2.  
 
Figure 1-2 Schematic of SPR principle. Ligands are immobilised on the sensor surface, 
while the analyte is flowed through the flow cell over the chip. The light source is 
fixed with incident angle and optical detection placed for SPR angle change. (A), 
when the analyte-ligand binding occurs, the plasmon generated absorbs light at a 
different angle (II) from when ligands present on the chip surface only (I), causing 
the point of minimum intensity shifts; (B), this change in shift is a resonance signal 
used for monitoring binding in real time.   
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Apart from SPR, there are other optical sensing platforms that have been 
commercialized. For examples, bio-layer interferometry (BLI) is another widely used 
technique commercialized under the Octet system by ForteBio (Cooper, 2006). The 
principle of BLI is shining the white light to the optical sensor surface and collect the 
reflected light. The thickness of the surface layers disturbs the reflected light. The 
waves of light travelling back to the detector can interact either constructively or 
destructively to each other causing a phase-shift of light wave pattern. This particular 
pattern correlates to the optical thickness and is directly measured in real time. 
Another interesting optical sensing platform is ellipsometry. It measures the 
polarization change of incident light when it is reflected from the sensor surface in 
the form of an amplitude ratio and a phase difference. This change is based on the 
surface properties e.g. refractive index, surface thickness. The technique is mostly 
used in non-destructive measurement of thickness and optical constants of optical 
layers at the interface. Data obtained from ellipsometry, however, requires an 
appropriate optical model fitting and calculations especially for biological molecules 
(Garipcan et al., 2011; Damborsky et al., 2016). In terms of biosensing applications, 
there have been several reports reporting the success of ellipsometry in detection 
of various analytes such as proteins (Bombarová et al., 2015), carbohydrate tumor 
markers (Zhang et al., 2011), toxins (Nabok et al., 2011) and viruses (Qi et al., 2010). 
In addition, it was used for a binding profile study of influenza virus and its glycan 
receptor in a microarray format (Fei et al., 2015).  
  
1.2.2 Labelled vs label-free sensing platform 
The trends in biosensing platforms have moved towards label-free sensing 
systems. The established platforms, i.e. enzyme-linked immunosorbent assay (ELISA) 
or radioimmuno assay (RIA), were introduced to the analytical field over 40 years 
ago and are currently using as gold standards for many applications, especially 
biomarkers detection or protein analysis (Johnson and Krauss, 2017).  
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The definitions of labelled and label-free techniques are diverse. Generally, 
label-free techniques exploit unique molecular properties of capture molecules 
(ligands), target molecules or sensor constructs. For examples, QCM based methods 
or mass spectrometry utilize molecular weight of target molecules, whilst SPR uses 
the refractive index changes of reflected light through a prism sensor chip coated 
with metal thin film. On the contrary, labelled techniques directly tag any foreign 
molecules to either a ligand or a target molecule in the system in which can disturb 
its intrinsic properties. For instance, almost all fluorescent-based sensing platforms 
are labelled-techniques as fluorophores are tagged onto a detection molecules e.g. 
IgG. Another example is ELISA because it involves tagging a secondary antibody (Ab) 
with reporter system such as the enzyme horseradish peroxidase (HRP). 
Nonetheless, the immobilization of ligand or target molecule onto an optical 
substrate, especially in nanoparticle sensors, is not considered as labelling as the 
measurement is made from the optical change of the AuNP probe as a result of a 
binding event. 
Though the use of labelled techniques have been established for a long time, 
there are many drawbacks. First, the tagging process is often complex and time-
consuming, which makes sensor fabrication more complicated and expensive. Also, 
having foreign molecules attached to either one of the component can compromise 
the assay results by interfering with the true binding interaction. In addition, some 
larger proteins might be tagged with more than one fluor molecules leading to 
overestimate in quantification and so fluor to detection molecule ratio must often 
be determined. Conversely, not every protein can be labeled well, especially smaller 
proteins (Ferrigno, 2016). Consequently, label-free systems have become 
increasingly preferred. With the emergence of nanotechnology, more opportunities 
to develop label-free assay systems have arisen, especially the use of nanoparticles 
(NPs). NPs are good candidate materials onto which to attach bioreceptors because 
of their exceptional physical, chemical properties and high surface to volume ratio. 
The number of publications via the literature search using key words ‘gold 
nanoparticle*’ and ‘sensing’ via ScienceDirect has increased from around 2000 
entries in 2009 to over 6000 entries in 2017 (Figure 1-3). 
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Figure 1-3 The number of publications derived via the Sciencedirect search engine, 
using the term “gold nanoparticle* and sensing” between the years 2009 to 2017. 
(Note “∗” allows nanoparticle and nanoparticles to be found)  
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1.3 Metal nanoparticles 
Metal nanoparticles, particularly gold, have been extensively studied 
because of their facile synthesis and modifiable surface chemistry. AuNP’s unique 
optical property is owing to the collective oscillation of electrons in the conduction 
band at the surface in resonance with a specific wavelength of incident 
electromagnetic radiation. This phenomenon is known as surface plasmon 
resonance (SPR) or localised SPR (LSPR). AuNPs have their oscillation resonance 
frequency in the near UV region so AuNPs are seen in the form of pink colloid 
solution. This LSPR phenomenon is very sensitive to AuNP size, shape, ligand, 
interparticle distance and surrounding environment, including the dielectric 
constant/refractive index of the medium, and temperature. Because AuNPs have a 
high surface area to volume ratio, changing these parameters directly affects the 
LSPR and leads to colour change in the solution (Wang and Ma, 2009; Ma et al., 2010; 
Dreaden et al., 2012). These tuneable optical properties of AuNPs enables many 
possibilities in creating new optical sensing platforms. AuNPs comprise of two main 
parts, which are the metal core and the surface layer. Biosensing applications can be 
designed to modify their surface coating or alter the core properties. Besides the 
optical properties mentioned, AuNPs also have high surface area, conductivity and 
catalytic properties. Again, these properties open up many opportunities in using 
AuNP to improve or generate new electrical and electrochemical sensing systems 
(Jans and Huo, 2012; Saha et al., 2012).  
  
1.3.1 Synthesis of gold nanoparticles 
The history of AuNP synthesis can be tracked back to 1857 when Michael 
Faraday gave a lecture about synthesis of gold solution. He described the reduction 
of gold chloride compounds (e.g. sodium chloroaurate, NaAuCl4) using phosphorus 
in carbon disulphide as a reducing agent (Faraday, 1857). The product solution had 
a beautiful ruby colour despite the yellow colour of the starting NaAuCl4 solution. He 
concluded that the ruby solution obtained was the dispersion of very fine gold 
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particles in the solution. Unfortunately, at that time the technology was not available 
to prove the idea.  
To date, there have been several methods of AuNP synthesis reported. The 
most common protocol and routinely used widespread is the citrate reduction 
method that uses citrate as a reducing and stabilizing agent at the same time. The 
process, developed by Turkevich et al., (1951), involves treating hydrogen 
tetrachloroaurate (HAuCl4) with boiling citric acid. The particle size can be controlled 
by adjusting the proportion of gold and citrate used in the protocol (Frens, 1973). 
Another well-known method was established by Brust et al. (1994) and is known as 
the Brust and Schriffin method. It was developed based on the fact that citrate-
stabilized AuNPs still tend to form irreversible aggregates when a functionalization 
process is required. Brust et al. (1994) introduced a two phase system that can 
produce AuNP with a capping ligand, such as alkane thiols, to further stabilise the 
AuNP dispersion.  
 
1.3.2 Functionalisation of AuNPs 
The modifiable surface chemistry of AuNPs is another reason why they 
attract a lot of attention as materials of choice in sensing applications. Various types 
of bioreceptor such as polymers, oligonucleotides or proteins can be conjugated 
onto AuNP surface by a wide range of chemistries. This section describes the method 
of functionalisation of AuNPs and how to confirm the functionalisation process. 
 
1.3.2.1 Functionalisation methods 
The functionalisation of AuNPs can be roughly divided into two main 
methods; physical adsorption and covalent interactions. Figure 1-4 shows a 
schematic representation of functionalisation on an AuNP surface. Regarding 
physical interactions, these rely on non-covalent processes. Proteins can directly 
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adsorb onto AuNPs surface via ionic interaction between the negatively charged 
surface of the AuNP and positively charged side chains of proteins at the optimum 
pH condition (Figure 1-4A). Also, AuNP surfaces are hydrophobic and can be used for 
conjugation via hydrophobic-hydrophobic interaction (Figure 1-4B). Despite the 
physical interaction method being simple to perform, the binding interactions may 
not be strong enough to maintain the functionalised molecules throughout the 
preparation process that contains multiple washing steps or high salt concentrations 
in the buffer. In addition, if the AuNP surface is not saturated with the bioreceptor 
or not blocked properly, there is a high chance of non-specific binding to occur, and 
the sensitivity of the assay might be decreased. Moreover, high concentrations of 
bioreceptor are required in the preparation and orientation of bioreceptors on the 
surface is not guaranteed, which might affect their binding response as well (Wang 
and Ma, 2009; Jazayeri et al., 2016). 
 
 
Figure 1-4 Schematic of functionalisation of AuNP probes. Representing physical (A-
B) and chemical (C-D) interaction; (A), ionic interaction between negatively charged 
AuNP surface and positively charged side chains of protein; (B), hydrophobic 
interaction; (C), dative binding between free conducting electrons of sulphur and 
gold surface; (D), specific recognition by an adapter (streptavidin-biotin interaction). 
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However, there have been a number of researchers using this method for 
conjugation. For examples, Wang and coworkers used physical adsorption method 
to prepare anti-hepatitis B antigen-antibody conjugated AuNPs (Wang et al., 2012) 
and Huang et al., (2015) prepared anti-Listeria monocytogenes mAb conjugated 
AuNP probes by the same method (Huang et al., 2015). It was suggested in both 
papers that the conditions used for physical adsorption must be optimal for the 
conjugated molecules.  
Chemical interaction, on the contrary, are more complicated and multiple 
steps are required, but the covalent bond formed possesses high stability to a range 
of conditions. In addition, using this functionalisation pathway the orientation of 
functionalised molecules can be controlled and this method requires less amount of 
the bioreceptor to be conjugated. A key aspect of chemical coupling methods lies in 
the use of self-assembled monolayers (SAMs) on gold via thiol interaction. SAMs 
show spontaneous assembly of an organic molecules onto a surface to form a well-
defined arrays of molecules (Bain et al., 1989). For example, the Nuzzo group (Bain 
et al., 1989; Love et al., 2005) showed formation of SAMs by alkanethiol molecules 
on planar gold. This well-ordered molecular array can serve as tethering layer for 
conjugation to the AuNP surface.  
Chemical coupling can be performed in several ways. For example, chemical 
adsorption of thiol containing proteins can occur via dative binding between free 
conducting electrons of sulphur atoms and the gold surface (Figure 1-4C). Normally, 
gold is an inert material but it can be oxidised in the presence of thiol group to form 
a thiolate-gold (RS-Au) bond, which is a covalent bond. The forming bond is very 
stable (~ 425 kJ/mol) and as strong as a gold-gold bond (Evans and Ulman, 1990; 
Häkkinen, 2012). Another approach to chemical coupling is using specific recognition 
between molecules as adapters on the surface such as protein A-antibody, 
streptavidin-biotin interactions (Figure 1-4D). By using these molecules as adapters 
not only provides strong interaction, but the molecule itself can act as a blocking 
agent to prevent non-specific binding to the AuNP surface too (Wang and Ma, 2009). 
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The high affinity interaction between biotin-avidin interaction are 
established and exploited for a long time (Wilchek and Bayer, 1990b). Biotin – also 
known as vitamin B7 or vitamin H – is a small molecule used extensively in biomedical 
applications as it is versatile for linking biomolecules via avidins as crosslinkers. There 
are various biotinylation reagents for different types of biomolecules i.e. biotin-N-
hydroxysuccinimide ester (biotin-NHS) for coupling to primary amine, biotin-
hydrazide for coupling to carbohydrate or biotin-maleimide for thiol coupling. This 
allows many approaches for conjugating AuNPs to biomolecules. Avidin is a hetero-
tetrameric glycoprotein derived from egg white. However, it has a high isoelectric 
point (pI), which can cause non-specific absorption of the molecule to negatively 
charge surfaces. As an alternative, streptavidin (derived from Streptomyces avidinii) 
and Neutravidin (deglycosylated avidin) can be used instead. The binding affinity still 
remains the same but their lower pIs mean they are negative at neutral pH. One 
molecule of avidin can theoretically bind to four molecules of biotin so it is possible 
to use a biotin tagged alkanethiol and use streptavidin to couple to biotin tagged 
bioreceptors. For example, Ahmed et al. (2013) constructed an impedance-based 
electrochemical immunosensors using neutravidin and biotin tagged whole 
antibodies for bacterial (Streptococus pyogenes) detection. 
The biotin-avidin interaction is non-covalent and with a very high affinity (KD 
= 10-15 M); this is comparable to covalent bonding (Hermanson, 2008). The 
advantage of the biotin-avidin system is its resistance to fairly harsh chemical and 
physical conditions (Wilchek and Bayer, 1990a). Regarding AuNP functionalisation, 
in work done by Gestwicki et al., (2000), streptavidin-coated 10 nm AuNPs were 
conjugated to the biotinylated target receptor, concanavalin A, to enhance contrast 
in transmission electron microscopy (TEM). Correspondingly, biotin-labeled mouse 
IgG antibody was added to streptavidin stabilised AuNPs for 1 h, followed by 
centrifugation to remove the excess biotinylated molecules. This method 
successfully conjugated the mouse IgG antibody to AuNPs as a sensing probe for 
detection of the mouse IgG (Liu and Huo, 2009). 
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 In addition, a crosslinker can also be used to link the proteins to AuNPs. For 
instance, Driskell et al., (2011) prepared anti-human influenza A virus antibody 
conjugated AuNPs by using 3,3’-dithiobis(sulfosuccinimidyl propionate) (DTSSP) as a 
bifunctional linker to link the antibodies to the gold surface. DTSSP contains an 
amine-reactive N-hydroxysulfosuccinimide (sulfo-NHS) groups at each end with a 
cleavable disulphide bridge in the middle (Figure 1-5). Therefore, a thiolate 
monolayer on gold surface could be formed via a thiol-gold bond, whilst the sulfo-
NHS end can react with a primary amine (-NH2) on antibody molecules and form a 
peptide bond. The conjugation was performed in two steps, which reflected the 
complexity of preparation.  
 
Figure 1-5 3,3’-dithobis(sulfosuccinimidyl propionate) (DTSSP) molecule. This 
crosslinking reagent contains cleavable disulphide bridge and primary amine 
reactive. 
 
1-ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC) is another linker used 
to conjugate proteins to AuNPs (Jazayeri et al., 2016). Carboxylic-AuNPs can be 
coupled to proteins using EDC via its carbodiimide reactive group, forming an 
unstable intermediate (o-acylisourea) as shown in Figure 1-6. The primary amine 
group of protein can then react with this intermediate and form a stable peptide 
bond (Hermanson, 2008). This was used by several groups. For instance, Di Pasqua 
et al., (2009) successfully demonstrated conjugation of anti-Escherichia coli O157:H7 
antibody to AuNPs pendant carboxylic acid groups. Also, Aslan (2004) conjugated (+)-
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biotinyl-3,6,9,-trioxaundecanediamine onto carboxyl-terminated alkanthiol 
adsorped AuNPs via EDC chemistry. The prepared AuNPs were used in an 
aggregation study in the presence of streptavidin. Other work involved dihydrolipoic 
acid (DHLA) capped AuNPs and Gαi1 subunit (of heterotrimeric G-proteins), (Singh et 
al., 2013). 
 
Figure 1-6 EDC crosslinking pathway. EDC can react with carboxylic group yielding an 
unstable intermediate. The presence of primary amine results in a stable amide bond 
formation.  
 
1.3.2.2 Confirmation of the functionalisation process 
There are various methods reported for confirmation of AuNP 
functionalisation. There includes UV-visible spectrophotometry, dynamic light 
scattering (DLS), differential centrifugal sedimentation (DCS), longitudinal SPR, 
atomic force microscopy (AFM) and TEM. Among those methods, UV-
spectrophotometry is one of the most common techniques as it is a fast, simple and 
instruments are found in most laboratories (Kumar et al., 2008; Zhang et al., 2015; 
D’Agata et al., 2017). Upon conjugation, the absorbance spectrum of the conjugated 
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AuNP will shift slightly to a longer wavelength because of the local refractive index 
shift resulting in changing LSPR properties of the particles (Pollitt et al., 2015; Filbrun 
and Driskell, 2016).  
In addition to UV-spectrophotometry, there were several studies using DLS 
as a tool confirming the conjugation of antibodies onto AuNPs. Jans et al., (2009) 
demonstrated the use of DLS in detection of bioconjugation by using protein A 
adsorption onto AuNPs as an example. The hydrodynamic diameter (DH) was 
measured and plotted against the concentration of protein A added to the AuNPs. A 
linear relationship was observed until the full coverage of AuNPs was reached and 
their size became stable. Although proteins have an intrinsic weak light scattering 
intensity, they cannot be detected by DLS unless a high concentration is used. 
However, when they fully adsorb onto the AuNP surface, the diameter of the AuNPs 
is expected to increase at least by twice the diameter of the protein molecule. 
Accordingly, Bell et al., (2013) demonstrated that DLS, nanoparticle tracking analysis 
(NTA) and DCS could be used to monitor IgG protein adsorption to AuNPs and gave 
comparable results to UV-visible spectrophotometry.  
The use of DLS and NTA for conjugation confirmation is exemplified in the 
work undertaken by James and Driskell (2013). They conducted a systemic 
experiment to investigate the use of NTA and DLS for monitoring AuNP conjugation. 
They found out that both DLS and NTA could provide information about the optimal 
amount of protein required for full coverage of AuNPs along with the optimal 
conditions suitable for the conjugation process. Moreover, Huang et al., (2015) 
investigated the amount of anti-Listeria monocytogenes monoclonal antibodies onto 
AuNPs by using DLS. They found out that when different concentrations of the 
antibodies were added, the mean DH linearly increased from 102 ± 2.5 nm to 112.7 
± 2.0 nm and levelled off when 10 µg/ml of the antibodies were reached. 
Additionally, DLS was also reported as a tool for surface interaction studies between 
DNA and AuNPs (Wang et al., 2014). 
All of the methods indicated above, nevertheless, cannot directly quantify 
the number of proteins attach per AuNP and only give a relative surface coverage 
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estimation. Previously, the quantitation of proteins bound on a AuNP surface was 
done by quantifying the excess proteins (i.e. not conjugated) recovered. This indirect 
method usually overestimates the amount of proteins bound to AuNPs, since some 
proteins might stick to the container used and is counted as conjugated material. 
Until recently, Filbrun and Driskell (2016) proposed a fluorescence-based method for 
quantification of immobilised antibodies on AuNPs. The method is based on the 
dissolution of AuNPs by potassium iodide (𝐾𝐼)/iodine (𝐼2) solution. Here, gold can be 
dissolved by the oxidant generated with the iodine-iodide system. The oxidant 
triiodide ion (𝐼3
−) could be produced via the reaction of 𝐼2 and 𝐼
− (Green, 2014). Once 
the AuNPs were fully dissolved, atomic absorption spectroscopy (AAS) was used to 
quantify the gold. At the same time, a fluorescent dye, called NanoOrange, was used 
to quantify antibodies released after the dissolution of the AuNPs. It should be noted 
that the protein solution was desalted to get rid of interferents. In comparison with 
indirect quantitation using excess antibodies in the supernatant during preparation 
process, this direct method gave significantly difference results but corresponded to 
the NTA size analysis of surface coverage of AuNPs. 
 
1.3.3 Gold nanoparticles as a biosensing system 
Initially, AuNPs were mostly used in the transduction process by acting as 
optical labels, electrochemical markers or signal amplifiers (Pissuwan et al., 2010; 
Kaittanis et al., 2010). However, in the past decades the trend has shifted to a 
biosensing assays using AuNPs as a platform not just a signal amplifier (Huang, 2007). 
Here are some examples of using AuNPs for biosensing. 
 
1.3.3.1 AuNPs in electrical and electrochemical sensing 
AuNPs have found applications in electrical and electorchemical sensing 
because of their exceptional conductivity and catalytic properties.  Also, AuNPs have 
a high surface area to volume ratio, which makes them even more reactive and 
applicable for sensing applications  (Saha et al., 2012). The development of an 
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electronic nose sensor is an example worth mentioning. Peng et al., (2010) 
successfully produced a nanosensor array for detection of volatile organic 
compounds (VOCs), which differentiates between healthy and cancer patients. The 
background of this valuable tool lies in various organic molecules used as capping 
monolayers on the AuNPs. The functionalised AuNPs were then dispersed on top of 
gold electrodes by drop casting methods. The data acquired from this new tool were 
comparable with the gold standard, gas chromatography-mass spectrometry (GC-
MS) for VOCs. 
Another applications of AuNPs in electrochemical sensing is their use as 
‘electron wires’. AuNPs enable electron transfer between redox proteins and the 
electrode surface, since most oxidoreductases used in electrochemical sensors are 
surrounded by protein in which becomes an insulating shells. As a result, the 
electrons cannot transfer to the electrode effectively, leading to reduced sensor 
performances (Li et al., 2010). Brown et al., (1996) was the first to demonstrate the 
use of AuNPs as electron wires. The untreated colloidal AuNPs were used with SnO2 
electrodes to detect horse heart cytochrome c (Cyt c). Direct electron transfer was 
proved to occur at uncoated submonolayers of colloidal AuNPs on SnO2 electrode 
when Cyt c electrostatically-bound to the AuNPs. They suggested that AuNPs could 
be used as mediators to protect direct contact between the protein and metal 
surface, which can lead to structural and functional changes. However, it was found 
out that aggregated AuNPs were not effective in electron transfer. 
 
1.3.3.2 AuNPs in QCM-based sensing 
QCM is a technique that measures binding events through a change of 
frequency that corresponds to a change in the mass of an oscillating crystal. The role 
of AuNPs in QCM-based sensing is mostly as a “mass enhancer” to intensify the 
frequency changes. In a study conducted by Kim et al., (2007), it was shown that 
AuNPs were effective as signal enhancers in a QCM biosensor. They used N-[6-
(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide or biotin-HPDP modified 
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AuNPs on a gold coated QCM electrode instead of using biotinylated bovine serum 
albumin (BSA) as a control to detect streptavidin. The detection limit was 50 ng/ml. 
There have been several reports of AuNP enhanced QCM-based sensing 
platforms.  For example, Chen et al., (2011) described using oligonucleotide 
functionalised-AuNP to amplify a QCM-D signal in the detection of mercury(II) ions 
(Hg2+). The sensor was able to detect the presence of Hg2+ in a drinking water source 
with detection limit of around 4 nM. Similarly, DNA-conjugated AuNPs were used to 
detect Bacillus anthracis, the anthrax causative agent (Hao et al., 2011). DNA 
complementary to the target DNA was immobilised on AuNPs and used as a signal 
amplifier for the QCM biosensor. Chu et al., (2012) successfully developed a sensor 
for gliadin, the protein responsible for causing food allergies, e.g. in coeliac disease, 
in food products by covering a QCM electrode with 25 nm AuNPs before 
immobilising anti-gliadin antibodies. With the high surface area of AuNPs, more 
antibodies could be conjugated and the sensitivity of the technique was improved. 
They reported that a 48% frequency shift could be observed with only 2 ppm of 
gliadin presented in commercial food products. 
 
1.3.3.3 AuNPs in optical sensing 
1.3.3.3.1 Fluorescence-based sensing 
AuNPs have a broad energy bandwidth and high molar extinction coefficient 
so they are an excellent materials for fluorescence-resonance energy transfer 
(FRET)-based assays. AuNPs can act as fluorescence quenchers; for example, a 
mercury(II) (Hg2+) sensing platform was successfully developed using rhodamine B 
(RB) fluorophore conjugated to AuNPs. RB exhibited a very weak fluorescent signal 
when adsorbed on AuNPs. With Hg2+ present, RB was freed from the surface and 
could re-establish its fluorescence.  The assay took only 10 min to perform and the 
limit of detection (LOD) was 2 ppb from a pond water sample (Huang and Chang, 
2006). Another interesting example of AuNPs in a fluorescence based assay is the 
chemical sensors developed by You et al., (2007). The main principle was to create a 
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fluorophore displacement protein sensor array. Six different non-covalent 
fluorescent polymer conjugates AuNPs were used. Before proteins were present, 
fluorescent property of the polymers was quenched by the AuNPs. By adding the 
proteins into the system, displacement of proteins triggered the fluorescent signal. 
They tested 52 unknown protein samples with seven different proteins using the 
sensor and the method showed an accuracy of 94.2%.  
 
1.3.3.3.2 Surface Enhanced Raman Scattering (SERS)-based sensing 
Raman spectroscopy uses an inelastic scattering process, known as Raman 
scattering or the Raman effect. It is a process where an incident photon interacts 
with a molecule and forces it into a higher vibrational state. Then, the photon is 
emitted upon relaxation to a lower vibrational state producing Raman scattered 
light. A spectrophotometer can separate the scattered light by wavelength and the 
results are presented as a graph between the Raman intensity vs wave-number 
giving a Raman shift, which is unique for each individual molecule. Therefore, these 
patterns can be used as a fingerprint to detect a target of interest (Saha et al., 2012). 
However, the use of Raman spectroscopy is limited because of its low scattered light 
intensity. By using plasmonic NPs or metal nanoparticles like AuNPs, the signal can 
be improved by up to 1011 order of magnitudes owing to their localised surface 
plasmons (LSRs). This method is called surface-enhanced Raman spectroscopy 
(SERS). When the frequencies of NPs’ LSP and Raman scattered light are in 
resonance, the increase in Raman intensity is obtained. This is via the extra energy 
put into the transition via coupling the LSPs to the change in vibrational states. Sun 
et al., (2007) tagged both ssDNA and nonfluorescent Raman tags (RTags) onto AuNPs 
forming detection probes, which successfully detected the target DNA. Also, it 
proved to be effective after the probes were kept for three months. 
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1.3.3.3.3 Detection based on the surface chemistry of AuNPs 
The DNA bio-bar-code is a well-known method that exemplifies the 
exploitation of the AuNP high surface area. Nam et al., (2003) discovered an 
ultrasensitive method for protein detection using AuNPs. Prostate-specific antigen 
(PSA) was used as model analyte to demonstrate the method. Two types of particles 
were used; anti-PSA monoclonal antibody conjugated magnetic microparticles 
(MMPs) and DNA encoded PSA-conjugated AuNPs together with anti-PSA polyclonal 
antibody (Figure 1-7A). Figure 1-7B shows the bio-barcode assay method. 
First, MMPs was used to capture free PSA from solution and the unbound 
PSA was removed by using a magnetic separator. Then, the modified AuNPs were 
added to form a sandwich format. The AuNPs reacted with the bound PSA on MMPs 
and provided DNA strands for signal amplification. Following this, dehybridization 
was performed to release oligonucleotides off the AuNP surface, quantitation was 
effected based on the amplified oligonucleotides. Because of the high surface area 
of AuNPs, the detection limit for PSA was in the aM range. Later, this method was 
also modified and used for DNA detection. The performance of the assay was 
comparable with conventional PCR-based techniques (Nam et al., 2004). 
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Figure 1-7 The bio-bar-code assay method. (A), two types of probes used in the 
assay: (i), anti-PSA monoclonal antibody conjugated magnetic microparticles 
(MMPs); and (ii), DNA encoded PSA- and anti-PSA polyclonal antibody-conjugated 
AuNPs. (B), PSA detection via bio-bar-code assay. First, free PSA was captured by 
MMPs then the complexes were sandwiched by DNA/pAb modified AuNPs. Magnetic 
separation was applied, following with dehybridization to release the bar-code DNA, 
which later used for quantitation. This figure was taken from Nam et al. (2003). 
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1.3.3.3.4 Detection based on LSPR 
With respect to LSPR, as stated earlier, AuNPs can strongly absorb and scatter 
light at their own SPR wavelength region and this property is dependent on NP size 
and shape. As a wide range of sizes and different shapes of AuNPs can be easily 
prepared, this makes the SPR wavelength tailorable from the visible region to near 
IR region. Not only the size and shape, but also modification of their surface 
chemistry or changing the inter-particle interactions can affect the SPR band of 
AuNPs. Mainly, this SPR shift of AuNPs can be detected either by measuring light 
absorption or light scattering (Jans and Huo, 2012). 
 
1.3.3.3.4.1 Detection based on light absorption 
For light absorption measurement, LSPR of AuNPs is used. When the analyte 
of interest binds or comes close to the surface of AuNPs, the LSPR spectrum will shift 
to a longer wavelength (red-shift), which can be detected by UV-visible 
spectrophotometry. Also, this property enables a colorimetric assay platform to be 
established. The disadvantages of this type of detection are its relatively low 
sensitivity and limitation to colorless samples only. Here are some examples of the 
AuNPs colorimetric sensing platform.  
A well-known application of AuNPs in optical sensing is the home-use 
pregnancy strip. Monoclonal anti-α-subunit of human chorionic gonadotropin (hCG) 
antibodies were conjugated onto AuNPs and used as probes of detection – hCG is a 
glycoprotein hormone found in pregnant woman. The strip is made mainly with 
nitrocellulose membrane to facilitate the transport of the urine sample to different 
components by capillary action. Figure 1-8 shows a schematic of main components 
of a pregnancy strip. At one end of the strip, there is a layer of sample addition pad 
and the probes embedded pad on top of the membrane. Another end contains an 
absorbent pad. Right before the absorbent pad, there are two lines; test and control 
line. The test line has immobilised antibodies against β-subunit of hCG, whereas the 
control line has immobilised antibodies against monoclonal anti-α-subunit of hCG 
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antibodies. Therefore, when urine sample is applied and transported pass the two 
lines, if there is hCG presented both lines will turn pink. But if there is no hCG, only 
the control line will produce colour (Marks, 2007; Lee, 2008). 
 
 
Figure 1-8 Schematic of main components of a lateral flow pregnancy strip. The strip 
is made of nitrocellulose membrane. At one end, it contains a sample pad with anti-
α-subunit hCG mAb conjugated AuNPs embedded pad on top. There are test and 
control lines near the other end of the strip comprising of anti-β-subunit hCG mAb 
and anti-IgG against anti-hCG mAb, respectively. When urine sample is applied to 
the sample pad and transported to the absorbent pad by capillary action, if hCG is 
present, test and control lines will appear red but without hCG only the control line 
will turn red. 
Mirkin et al., (1996) reported the use of this sensing technique for DNA 
detection. Two non-complementary DNAs were immobilised on AuNPs and acted as 
the probes of detection. The target DNA could bind to both DNAs and when added 
to the system, caused crosslinking between the particles. Quantitation could be 
performed by measuring the change in absorbance. Detection limits in the fM range 
could be obtained. In addition, with slight adaptation based on this technique, Aslan 
et al., (2004) published a paper describing glucose detection using competitive assay 
format. High molecular weight dextran-coated AuNPs were used as probes of 
detection. Aggregation of AuNPs was caused by adding concanavalin A (con A). By 
adding glucose to the system, it competed with the dextran-AuNPs for binding to 
con A, leading to deaggregation of AuNPs. The SPR shifted back to its near-red 
wavelength.  
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In addition to proteins, DNAs or small biomoelecules, this technique has been 
applied to detection of metal ions as well. Kim et al., (2001) developed a simple 
colorimetric technique for lead (Pb2+), cadmium (Cd2+) and mercury (Hg2+) trace 
detection in aqueous solution. 11-mercaptoundecanoic acid (MUA) were 
functionalised onto AuNPs, and in the presence of these ions, ion-templated 
chelation occurred and led to aggregation of AuNPs, which could be observed by the 
naked eye. Similarly, Si et al., (2007) reported the detection of Hg2+ using 
carboxylated peptide-functionalized AuNPs as probes. In the presence of Hg2+, the 
probes aggregated and SPR of AuNPs shifted to around 670 nm, which again could 
be observed by the naked eye. 
 
1.3.3.3.4.2 Detection based on light scattering 
In terms of detection based on light scattering properties of AuNPs, it can 
provide better sensitivity than light absorption based. According to the light 
scattering theory, the intensity of scattered light increases with increased particle 
size and the light scattering intensity is proportional to the 6th power of the radius of 
the particle for Rayleigh scattering (Yguerabide and Yguerabide, 1998). AuNPs are 
known to scatter light stronger than fluorescent molecules and even stronger as 
compared to polymer beads. Principally, this detection can be divided into two 
different categories; 
  
(i) Scattered light intensity/wavelength change-based methods 
For this category, similarly to the absorption based techniques, the 
chemical/biological binding event can be detected directly by measuring the 
intensity of scattered light or wavelength change. Mainly, the instrument involved is 
a spectrophotometer or sometimes the change can be observed by the naked eye. 
Complete quantification can be done by using the relationship of observed scattered 
light and concentration of analyte (Jans and Huo, 2012). Storhoff et al., (2004) 
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successfully developed a ‘spot-and-read’ technique for identifying nucleic acid 
sequences. Around 33 zmol of methicillin-resistant Staphylococcus aureus (MRSA) 
DNA in the 1-µl volume analysed on a glass slide could be detected without any signal 
amplification. Two oligonucleotide-conjugated AuNPs were used as probes and after 
the hybridization of the DNAs, the NP probes crosslinked and led to a SPR shift. The 
mixed samples were spotted onto a glass slide and illuminated with white light. The 
scattered yellow to orange light was observed if the complexes were formed due to 
a plasmon band red-shift.  
Another experiment by Xiang et al., (2009) developed a method investigating 
the interaction between glycogen and biomacromolecules. With the presence of 
glycogen and citrate-capped AuNPs, the NPs formed clusters. When a 
biomacromolecule that could interact with glycogen was added, the aggregation of 
the NPs was reduced. As a result, the light scattering intensity was also reduced. 
Spectrofluorimeter was used in this measurement. Correspondingly, Zhang et al., 
(2010) reported the detection of adenosine in human urine using modified AuNP 
with adenosine structure-switching aptamers. The LOD was 1.8 nM, which was 
comparable to high-performance liquid chromatography (HPLC). 
 
(ii) Size-shift based method 
With this type of optical sensing, the chemical/biological binding event is 
detected by the change in size of AuNP probes. Dynamic light scattering (DLS) is the 
main instrument used for this method (Jans and Huo, 2012). The principle of DLS and 
the assay will be discussed further in the following section.  
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1.4 AuNP size-shift based method 
DLS has become a common technique used routinely for determination of 
particle size and size distribution since it was first marketed in the 1970s. The 
measurement takes a short duration to perform and convenient to use. Also, it is a 
non-destructive measurement and samples in the submicron range can be 
measured; the amount of sample required is minimal (Hassan et al., 2015; Zheng, 
Bott, et al., 2016). In order to understand the assay better, the principles of DLS and 
the assay are described in the following sections, together with applications of the 
technique in various fields.  
  
1.4.1 Dynamic light scattering 
Scattering techniques for particle sizing rely on two characteristics of 
colloidal suspensions, which is the scattering effect of colloids known as the Tyndall 
effect and Brownian motion (Hassan et al., 2015). There are two types of scattering 
technique for sizing particle. The first one is static light scattering (SLS), which 
measures time averaged scattering intensity at different scattering angles. This type 
of measurement can only be done with particles of size at least greater than λ/20 so 
the range of detection is around 50 nm – 2000 µm (Hassan et al., 2015; Brar and 
Verma, 2011). Another type called dynamic light scattering (DLS) can be used with 
much smaller particles. DLS, which is sometimes known as photon correlation 
spectroscopy (PCS), measures the size of the particles related to Brownian motion 
(Brar and Verma, 2011; Hassan et al., 2015; Zheng, Bott, et al., 2016). Depending on 
the diffusion coefficient of these particles undergoing Brownian motion, as larger 
particles move slower than small particles, then scattering intensities fluctuate. So 
what exactly DLS measures is the fluctuation of scattering light intensity based upon 
time, triggered by particle movement. A schematic of a DLS instrument is shown in 
Figure 1-9.  
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Figure 1-9 Schematic of a DLS instrument. The DLS main components are (1), laser 
light source; (2), attenuator to adjust the power of laser beam passed to the sample; 
(3), sample holder for a cuvette; (4), detector used to detect the scattered light from 
the sample (both 90º and 173º angle of detection can be used) and (5), a correlator. 
 
There are five main components of DLS: (1) laser light source; (2) attenuator 
to adjust the power of laser beam passed to the sample; (3) sample holder for a 
cuvette; (4) detector used to detect the scattered light from the sample. It can be 
placed in two different positions, 90º and 173º angle of detection, depending on the 
model; and (5) correlator, which is a signal comparator. It calculates the fluctuation 
rate of the scattering intensity detected by the detector. It compares the intensity at 
sequential time intervals. More details will be discussed in the following paragraph. 
This information is passed onto the software to analyse and report as a particle size 
later. There are several companies selling DLS instruments, Malvern Instruments is 
the company dominating the DLS machine market in the UK. While, Beckman Coulter 
Inc., Microtrac, Micromeritics Instrument Corporation and Agilent Technologies are 
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major companies in the US market as well as Horiba, Ltd. – a global worldwide 
company from Japan – who dominates the Asian market. 
The most important component that allows the principle of DLS is called the 
correlator. It is a signal comparator that compare the degree of similarity between 
two different signals, or one signal with itself at varying time intervals. If the same 
signal is compared at a small difference in time interval, there will be a strong 
relationship between the two signals recorded. However, if the signal is compared 
at a much later time, we can predict that the two signals have little or no correlation 
at all. Based on this relationship in DLS measurements, a correlation compares 
scattering intensity signals detected from colloidal suspensions. The correlation is 
reported as a correlation coefficient. Perfect correlation is indicated as 1 whereas no 
correlation is represented with zero. A correlation graph (correlogram) is plotted 
between the correlation coefficient and time (Figure 1-10). With small particles in 
the sample, the decay of correlation function occurs more rapidly (Figure 1-10A) 
compared with large particles (Figure 1-10B). The information received from DLS is 
mainly derived from the correlogram plot, for example, the average size of sample 
is from the time at which the correlation starts to decay. The shape of the curve also 
gives the detail about sample polydispersity. The broader the line, the more 
polydispersity the sample is and vice versa. 
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Figure 1-10 Showing correlograms obtained from different sizes of particles. Decay 
of correlation function of small particles, (A); and large particles, (B). 
 
In terms of analysis, a correlation function (𝐺(𝜏)) is analysed to gain particle 
size information. For a monodisperse particle sample, 𝐺(𝜏) decays exponentially 
with the delay time 𝜏 and is given as  
 
𝐺(𝜏) = 𝐴(1 + 𝐵. 𝑒−2D𝑞
2𝜏)  (1-1) 
 
where 𝐴 and 𝐵 are baseline and intercept of the correlation function, respectively, 
𝐷 is the translational diffusion coefficient of the particles, and 𝑞 is the magnitude of 
the scattering vector, which can be calculated from the equation 1-2. Here, 𝑛 is a 
refractive index of the dispersant, while 𝜆 is a wavelength of the laser used and 𝜃 is 
the light scattering angle.  
 
𝑞 = (
4𝜋𝑛
𝜆
) sin(
𝜃
2
)   (1-2)  
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Whereas, for a polydisperse particle sample, sum of all exponential decays in 
the correlation function will be used instead. By using the translational diffusion 
coefficient (D) derived from these equations, the average particle size can be 
calculated via the Stokes-Einstein equation shown below. 
 
𝐷𝐻 =  
𝑘𝑇
6𝜋𝜂𝐷
   (1-3) 
where  𝑘 is the Boltzmann’s constant, 𝑇 is an absolute temperature and 𝜂 is solvent 
viscosity. The diameter obtained from DLS is called the hydrodynamic diameter (𝐷𝐻) 
because it is based on how the particles movement in fluid form. It is reported based 
on the diameter of a sphere that has the same 𝐷 (Hassan et al., 2015).  
Regarding practical data analysis, there are several methods to extract 
information from the raw data obtained from DLS. The most common technique 
used is called the method of cumulants. It is the method recommended in the 
international standard ISO 224112:2017. This method obtains the average size of the 
particles by fitting a single exponential to the correlation function (Hassan et al., 
2015). Other methods reported for DLS analysis are non-negative least squares 
(NNLS) (Morrison et al., 1985), CONTIN (Ju et al., 1992) and exponential sampling 
(Bertero and Pike, 1991). 
Normally, DLS reports both the average hydrodynamic diameter and the size 
distribution of the sample. The size distribution graph can be presented in three 
ways; intensity-, volume- or number-weighted distributions. The first one is obtained 
by plotting the size on the X-axis and relative intensity of the scattered light on the 
Y-axis. This is the best representative of sample population data as it is generated 
from the measured data directly. The volume-weighted distribution is converted 
from intensity distribution via Mie theory, which is later used in calculating number-
weighted distributions.  
One of the shortcomings of DLS is that the average hydrodynamic diameter 
or mean DH of NP is reported based on the scattered light intensity of the particle. 
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Therefore, particles with a larger size scatter to a larger extent. Accordingly, with 
polydispersed sample, the average size will be susceptible to the large sized particles 
within the population. However, DLS is still preferable for designing an NP 
aggregation assay because it means that only a small change in size can be detected 
by DLS by observing the average size. In other words, if only a small portion of 
aggregates form in the system, DLS is still able to report that. This was verified by 
Zheng et al. (2016). In the experiment, citrate-stabilised AuNPs with diameter of 20 
and 100 nm were used to represent dispersed and aggregated populations 
respectively. It was reported that even with only 0.001% of 100 nm AuNPs presence 
in the system, the average size of well-dispersed 20 nm AuNPs increased from 23 to 
27 nm.  
In addition, there are several factors affecting the efficacy of DLS in terms of 
particle sizing. Temperature is a very important factor as it directly affects  the 
viscosity of the samples, which can cause a non-random movement and eventually 
lead to misinterpretation of the NP size (Brar and Verma, 2011). Another factor 
needed to be considered is the saturation of detector, which is a systemic error issue. 
Too strongly scattered light can saturate the detector and leads to miscounting of 
photons by the detector. It is strongly recommended by the Malvern’s user manual 
that the photon count rate should be in a few hundred kilo counts per second (kcps). 
This can be easily prevented by attenuating the laser power in the system. Besides 
systemic errors that can be prevented, multiple scattering processes give another 
error that might occur and lead to a dramatic error in particle sizing by DLS. Multiple 
scattering occurs when photon of scattered light is re-scattered again by another 
particles before reaching the detector. This re-scattered photon will affect the 
intensity fluctuation compared by the correlator and lead to miscalculation of 
particle size, which normally undervalues the actual size of the particles.  
The photon mean free path (MFP) is one of the factors regulating the extent 
of multiple scattering. The MFP basically represents the average distance travelled 
by scattered photons from the scattering volume before re-scattering occurs. The 
term scattering volume refers to the actual volume within the sample from which 
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photons are directly detected by the photomultiplier. To avoiding multiple 
scattering, back scattering angle detection can be introduced. As shown in Figure 1-
9, the detector can be arranged at two different angle. At 173º, the backscattering 
angle, the scattered light path length is shorter, or in other words, scattered photons 
have to travel further to reach the detector when it is placed at 90º and the further 
the photon travels the more chances are that it will be re-scattered. Nevertheless, it 
was reported that back scattering angle detection did not greatly reduce multiple 
scattering effects better than 90º detection (Zheng et al., 2016). To this end, it was 
explained that there were other factors affecting this process such as concentration 
of NPs and laser power. 
In the same paper by Zheng et al., (2016), the NP concentration was found to 
be another factor associated with multiple scattering. The concentration analysis 
was performed using 100 nm citrate-capped AuNPs. The results indicated that a 
linear relationship between scattering light intensity and concentration was 
observed until a certain concentration (the peak point). Above this peak point, the 
intensity dropped with further increase in NP concentration. It was explained by 
Zheng et al., (2016) that this might be due to the reduction in laser power by 
absorption/scattering effects of AuNPs before and after the scattering volume. 
Subsequently, the intensity of scattered light at the detector was reduced. In order 
to observe multiple scattering, the graph between mean DH and NP concentrations 
was plotted. The concentration where the average size started to drop indicated the 
possible beginning of multiple scattering. It was strongly suggested that the best 
concentration of NP used should be the one that give strongest scattering light 
intensity but shows no multiple scattering. 
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1.4.2 Principle of nanoparticle-coupled dynamic light scattering assay 
 In terms of chemical and biological sensing, DLS was first proposed as a tool 
in an aggregation assay in 1975. Cohen and Benedek (1975) used polymer beads 
coated with BSA to detect anti-BSA Ab in the serum. When the antibodies bound to 
BSA, agglutination occurred and could be detected by DLS. The DLS could report the 
change in the average size of the polymer beads and this could be used to quantify 
the amount of antibody presented in the solution. However, this technique was 
abandoned because it could not be used as a practical application. One of the main 
obstacles at that time was the low scattering intensity of polymer beads. Therefore, 
background scattering, e.g. from proteins in blood, interfered with the actual 
scattering from the sample and quantification was not possible. Nevertheless, the 
arrival of AuNPs led to a renewed interest in using DLS for agglutination or 
aggregation assays, as AuNPs have a thousand time stronger scattering as compared 
with similar size polymer beads. This distinctive property is due to the SPR signal 
mentioned earlier.  
For any particle aggregation assay, it is very important to understand control 
of the NP aggregation process, because aggregation should only occur in the 
presence of analytes and random cluster formation should be avoided. AuNPs are in 
a colloidal dispersion; thus stabilization relies on the balance between interparticle 
attractive (e.g. van der Waal force) and repulsive forces, known as colloidal 
stabilization effects. There are three stabilization mechanisms (Figure 1-11), which 
are electrostatic, steric and electrosteric stabilization. Electrostatic stabilization 
utilizes the charge of molecules on the NP surface to maintain the repulsive forces, 
whilst, steric stabilization uses grafted macromolecules (i.e. proteins, polymers) on 
the surfaces to act as barriers in order to prevent the particles moving closer 
together when van der Waals attractive forces become a dominant factor. For 
electrosteric stabilization, the first two mechanisms are combined by using 
macromolecules with charges, like DNA (negatively charged polymers) (Dunn, 1986; 
Zhao et al., 2008). 
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Figure 1-11 The stabilization mechanisms of colloidal AuNP dispersion. There are 
three different mechanisms: (A), electrostatic stabilization; (B), steric stabilization 
using macromolecules; (C), electrosteric stabilization.  
 
In general, to control the aggregation of NPs, there are two main approaches, 
which are non-crosslinking aggregation or interparticle crosslinking aggregation 
mechanisms. The first can be caused without the formation of interparticle bond but 
by removal of colloidal stabilization effects. For examples, the loss of charge surfaces 
(Figure 1-12A) or removal of polymer molecules on the surfaces (Figure 1-12B). 
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Figure 1-12 Schematic of non-crosslinking aggregation mechanisms; A), via loss of 
charge surfaces; B), via removal of polymers on nanoparticle surfaces. 
 
In contrast, the latter mechanism focuses on the formation of interparticle 
bonding to crosslink the particles, which leads to complex formation and aggregation 
(Zhao et al., 2008). There are several ways to bring about interparticle crosslinking 
(Figure 1-13). For example, via direct interaction between different modified 
receptors on NP surfaces such as DNA complementary base pairs, or via using other 
molecules to crosslink the nanoparticles together, known as crosslinker molecules. 
Regarding this mechanism, multiple binding sites for crosslinker molecules are 
required and the binding and the aggregation rate depends on crosslinking reaction, 
which is often slower than with a non-crosslinking mechanism. Still, it is a common 
method selected by researchers in designing aggregation assays (Sato et al., 2003). 
Various aggregation assay platforms can be designed based on controlling NP 
aggregation, either with or without crosslinking molecules. Principally, the platforms 
can be divided into two categories; direct and indirect assays. Regarding the direct 
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assay, it is more straightforward than the latter as it measures the shift to a larger 
size NP. In contrast, the indirect assay’s biorecognition process is based on the 
removal of the aggregation and measures the shift to a smaller size of NP.  
In the case of interparticle crosslinking aggregation mechanism, there are 
several platforms designed. Two different modified NPs can be used for cluster 
forming (Figure 1-13A, Pathway A). One of the NP probes are modified with 
bioreceptors, whereas another NPs are modified with complementary molecules, for 
examples, two complementary DNAs that can hybrid the target analyte at the same 
time. Another platform is using multiple binding sites crosslinking molecules like 
polyclonal antibody (pAb) (Liu and Huo, 2009) or multiple NP modified with different 
binding molecules to the same target (Figure 1-13B, Pathway C) (Dai et al., 2008; Liu 
et al., 2008). This is the most common methods used in numerous studies. In 
addition, the target analyte with multi-binding sites such as multimeric molecules or 
large molecule with high number of antigen epitopes can be detected with one type 
of bioreceptor-conjugated NPs as shown in Figure 1-13C, Pathway E (Driskell et al., 
2011; Nietzold and Lisdat, 2012; Huang et al., 2015). It should be noted that the 
aggregation process of NPs is reversible in every platform. This mean that indirect 
assay can be designed. By removing the crosslinking molecules or breaking the 
binding interaction, it is possible to quantify the analyte as well (Figure 1-13A-C, 
Pathway B, D and F). This type of assay favours the quantitation of small molecules 
that have restrict area for crosslinking molecule to bind. By tagging the small analytes 
on NP surface and couples with its specific bioreceptors-modified NPs, the aggregate 
can be formed. With the presence of the free analytes, there will be a competitive 
binding to the receptor NPs in which leads to deaggregation and smaller size 
observed. That is why sometimes indirect assay is called competitive assay. 
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Figure 1-13 Schematic of interparticle crosslinking aggregation mechanism. (A), two 
different complementary molecules modified AuNPs are used as detection probes; 
(B), two different binding molecules to the same target are modified on AuNPs and 
used as detection probes; (C), target analyte with multiple binding sites can be 
detected with one type of modified AuNPs; pathway A, C and D represents the direct 
assay format, whereas pathway B, D and F represents the indirect assay format.  
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 Similarly, for non-crosslinking aggregation mechanism, the direct assay can 
be performed by destabilization process of the colloidal AuNP dispersion. Basically, 
by adding the analytes, the stabilization of probes is destroyed, leading to an 
aggregate formation and can be detected using DLS (Figure 1-12A) like most of metal 
ions detection (Kalluri et al., 2009; Beqa et al., 2011; Durgadas et al., 2011). Whereas, 
in the indirect/competitive assay format, NP probes are aggregated prior the 
presence of the analyte. By adding the analytes, the analyte itself might act as a 
stabilizer for the NPs as seen in experiment done by (Wang et al., 2010). 
In summary, NP-enable DLS assay principle is fundamentally all about the 
controlling aggregation of NPs. The specific aggregation/deaggregation of the NP 
probes can be detected with DLS. For complete quantitation, calibration curve can 
be obtained using standard solutions. The combination of NP distinctive light 
scattering property and DLS potential to detect a small change in size provides a 
great opportunity to establish new assay.  
 
1.4.3 Applications of nanoparticle-coupled DLS assay 
There are several papers reported the use of DLS in chemical and biological 
sensing, including other applications. Table 1-1, 1-2 and 1-3 summarize some of DLS 
sensor examples in recent years categorized by target analytes. The next section 
describes NP coupled DLS sensing platform applications in the literature. 
 
1.4.3.1 Chemical sensing  
Relevant chemical sensing papers are summarized in Table 1-1.  
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1.4.3.1.1 Metal ions 
Heavy metal ions are a major public health problem, especially in drinking or 
ground water. Detection of these metal ions is extremely important for the 
prevention of a metal ion poisonings. There were reports of using DLS based sensing 
platform in detection of arsenic (As3+) (Kalluri et al., 2009), lead (II)(Pb2+) (Beqa et al., 
2011; Miao et al., 2011), copper (II)(Cu2+) (Miao et al., 2012), and mercury(II)(Hg2+) 
(Xiong and Ling, 2012; Ma et al., 2014).  
In 2009, Kalluri and a group of scientists in Bangladesh successfully developed 
an AuNP-DLS based assay for As3+ detection (Kalluri et al., 2009). They modified 
AuNPs with three different thiol containing compounds via the Au-S interaction, 
which were glutathione (GSH), dithiothreitol (DTT) and cysteine (Cys). The 
crosslinking between modified AuNPs was based on the binding of As3+ to DTT via 
the As-S bond, whilst for GSH and Cys, there is no free thiol group left after 
conjugation with the AuNPs so the binding of As3+ occurred via the As-O bond 
instead. The DLS intensity was increased after the presence of As3+. They also 
suggested that bigger AuNPs have more surface area per individual NP compared 
with smaller ones so that is reason why the sensitivity could be improved with 
increasing AuNP size. The detection limit of the assay was reported at 3 ppt when 
110 nm of AuNPs were used. The reported data were comparable with the data 
obtained from inductively coupled plasma mass spectrometry (ICP-MS). They 
concluded that their DLS technique had a three orders of magnitude better detection 
than the WHO limit guidelines for detection of As3+. 
Pb2+ is another metal ions heavily investigated by researchers as it is a 
compound found in common objects, i.e. paints or plastic toys, or army related 
materials like ammunition. Beqa et al., (2011) successfully demonstrated that GSH 
coated AuNPs could be used to detect Pb2+ via DLS as low as 100 ppt from plastic 
toys, paints and water samples within 20 min. The DLS could be used with gold 
nanorods (AuNRs) and silver nanoparticles (AgNPs) in quantitative assays for Pb2+ 
(Durgadas et al., 2011). The detection limits for both techniques were as low as 25 
nM and 0.25 pM, respectively. Another DLS based method developed for Pb2+ 
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detection was developed by Miao et al., (2011). They utilized Pb2+-specific DNAzymes 
to disaggregate of two different oligonucleotide-conjugated AuNPs. Using a similar 
principle, the Miao group later developed an assay for Cu2+ ions, but this time 
unmodified AuNPs were used instead (Miao et al., 2012). The principle of the assay 
was based on the ability of Cu2+ to cleave the DNAzyme from double-stranded (ds) 
to single-stranded DNA (ssDNA). The ssDNA fragment’s was able to coat bare AuNPs, 
which protecting them from aggregate with the presence of sodium chloride (NaCl) 
salt, and the extent of aggregation proportionally to the concentration of Cu2+ was 
reported via DLS measurement mean hydrodynamic diameter (DH) of the AuNPs. 
 Recently after, Hg2+ is another metal ions that has been detected using a DLS-
based assay. Oligonucleotide- and Hg2+ aptamer conjugated AuNPs were used as 
probes for detection of Hg2+ (Xiong and Ling, 2012; Ma et al., 2014). Both reports 
used the same principle, where DLS was used to recover the average DH of modified-
AuNPs in the presence of Hg2+. The mean DH increased after NaCl salt was added to 
the system, as Hg2+ disrupted the structure of the oligonucleotide and aptamer 
resulting in lack of protection of the AuNP surface and aggregation. These methods 
gave detection limits in the nanomolar range. 
 
1.4.3.1.2 Small chemicals and biomolecules 
When it comes to small biomolecules, glucose is one of the most common 
targets for developing a sensing platform. There have been various types of glucose 
sensors established including DLS based sensors. Recently, Miao et al., (2013) proved 
that by conjugating two different pre-designed oligonucleotides onto AuNPs, the 
glucose level could be measured with DLS. By crosslinking the two modified AuNPs 
with another specific oligonucleotides (named Oligo-3), the AuNPs formed an 
aggregate. In the presence of glucose, glucose oxidase (GOx) and Fe2+, Oligo-3 was 
cleaved and could not hybridized the two AuNPs. This eventually led to a 
proportional decrease in the mean size of AuNPs detected by DLS with detection 
limit of 38 pM. The selectivity of the assay was tested against five other sugars and 
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it showed good selectivity for glucose. In another work by Miao et al. (2014), 8.3 pM 
of glucose was determined by DLS and AuNPs in human serum. This time ssDNA 
coated AuNPs were used as probes. By adding glucose to the system, the ssDNAs 
were cleaved and could not be adsorbed onto AuNPs. Therefore, when NaCl was 
added, AuNPs aggregated and DLS was again used as signal transducer. The 
aggregation assay format coupled with DLS measurement has proved to be useful 
for detection of other molecules. Yang et al., (2011) demonstrated a one-step 
sandwich-format for adenosine detection. An adenosine binding aptamer was split 
into two fragments and conjugated onto AuNPs (mean DH = 31 nm). Upon binding 
adenosine, crosslinking of AuNPs could occur because an adenosine aptamer 
complex had been formed and DH increased substantially. This method improved the 
limit of detection (LOD) to around 7 nM. Also, the change in mean DH was selective 
to adenosine as there was no response observed in the presence of its analogues 
such as uridine, cytidine and guanosine.  
Applications of the AuNP-DLS sensing platform have extended to security 
uses as well, and an interesting target analyte worth mentioning is 2,4,6-
trinitrotoluene (TNT), a well-known explosive. Dasary et al., (2010) successfully 
established AuNP probes coupled with DLS for TNT detection with a detection limit 
of 100 pM. Para-aminothiophenol (p-ATP) was conjugated onto AuNPs because of 
its ability to form strong 𝜋-donor-acceptor interactions with TNT, which led to 
aggregation. In this work, they compared the DLS assay with a colorimetric assay and 
found that the LOD could be lowered using DLS. They also pointed out that with low 
levels of TNT in the solution, only dimers were formed, not larger aggregates. The 
colorimetric assay could not differentiate between monomers and dimers but DLS 
could do so, because it is sensitive in small changes in particle size. Similar to this 
experiment, the same principle was applied by Lin et al., (2012) but 1,2-
ethylenediamine (EDA) was coated onto AuNPs instead and 0.4 pM of TNT could be 
determined.  
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1.4.3.1.3 Toxins 
The AuNP-coupled DLS sensing assay has found applications in measuring 
environmental, agricultural and food contaminants. Here are some examples: 
In 2010, Wang et.al. demonstrated the use of antibody-modified gold 
nanorods (AuNRs) in detection of microcystin-LR (MC-LR), a water contaminant from 
cyanobacteria that can cause liver cancer if exposed for a long time (Wang et al., 
2010). A competitive assay format was used in this experiment. First, either side-by-
side or end-to-end nanorod (NR) assemblies were formed via crosslinking of anti-
MC-LR antibody modified AuNRs and MC-LR-OVA antigen modified AuNRs. The 
addition of toxin analyte competed with the antigen AuNRs and disrupted the 
assemblies resulting in reduction of mean DH. The acquisition time of the assay was 
faster than ELISA, which was the established method to which the DLS assay 
compared. 
Regarding food toxins, aflatoxins (AFs) are common mycotoxins produced 
from Aspergillus, and are well-known as carcinogens mainly affecting the liver. The 
established methods for AFs detection are time-consuming and labour intensive. In 
2013, Xu et al. demonstrated that a gold nanorod (AuNR) coupled DLS based system 
could quantify the amount of AFB1, which is the most toxic type of AF, in peanut 
samples. Again, a competitive format was applied, but this time the AFB1-BSA 
antigen were immobilised onto AuNR surfaces protecting the rods from aggregation. 
Next, anti-AFB1 antibodies were added to the system and crosslinked the AuNRs 
causing aggregation. Competition occurred when AFB1 in the sample was added to 
the system. Free AFB1 competed with AFB1-conjugated AuNRs and prevented the 
rods from aggregating and consequently DH changed from 776 nm to 80 nm with the 
20 ng/ml of AFB1. This technique proved to quantify as low as 0.16 ng/ml of AFB1 
and took only 45 min to perform. With the same principle, a competitive assay was 
applied by Zhang et al., (2013) for aflatoxin M1 (AFM) determination. Yet, this time 
there were two different probes, which were anti-AFM modified magnetic beads and 
AFM-BSA conjugated AuNPs. The AFM analyte competed with AFM-BSA AuNPs for 
binding to antibody-magnetic beads. The unbound AuNPs were separated and 
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measured by DLS. A linear relationship between the average size of the AuNPs and 
AFM concentrations was found with a LOD of 27.5 ng/L in milk samples.  
In addition, melamine is a contaminant substance used in food containers 
that can migrate into food and cause health issues. It is also an illegal additive used 
to increase protein level in milk products. Ma et al. was the first group utilizing DLS 
in melamine sensing. Using citrate-stabilised AuNPs as probes Ma et al., (2014), 
crosslinking between AuNPs were based on the binding of melamine directly to the 
AuNPs. It was reported that the change in mean DH could be observed with only 0.05 
ppm of melamine from milk sample. The effect of pH was also tested and showed no 
effect on the DLS measurement. Whereas, another group from China used thymine 
containing DNA coated AuNPs to detect melamine monomer’s migratory quantity 
(MMMQ) (Wu et al., 2014). They exploited the hydrogen bonding between 
melamine and the thymine base and showed a detection limit of 2 µg/L. In addition, 
there was a reported AuNP-based DLS assay for the food contaminant cholera toxin, 
a protein enterotoxin from Vibrio cholera, which is a major cause of epidemic 
outbreak in developing countries (Khan et al., 2015). Anti-cholera antibodies were 
immobilised on AuNPs and acted as detection agents. The presence of cholera toxin 
caused aggregation of the particles and led to a shift in size, which was later detected 
by DLS. 
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Table 1-1 Chemical sensing application 
Analyte Probe Detection limit Source of sample References 
Metal ions 
Arsenic (As3+) Glutathione (GSH)-dithiothreitol (DTT)-cysteine 
(CYS) modified AuNPs 
3 ppt Ground water (Kalluri et al., 2009) 
Lead(II) (Pb2+) 
GSH-conjugated AuNPs 100 ppt Paints 
Plastics 
Water samples 
(Beqa et al., 2011) 
Aza-crown-ether-modified silver nanoparticles 
(AgNPs) 
0.20 pM 
0.22 pM 
0.25 pM 
Yangtze water 
East Lake water 
Drinking water 
(Zhang et al., 2011) 
Oligonucleotide-conjugated AuNPs coupled with 
Pb2+-dependent DNAzyme 
35 pM Drinking water (Miao et al., 2011) 
GSH modified gold nanorods (AuNRs) 0.025 mM Deionized water (Durgadas et al., 2011) 
Copper(II) (Cu2+) Unmodified AuNPs 60 pM River water (Miao et al., 2012) 
Mercury(II) (Hg2+) Oligonucleotide-conjugated AuNPs 0.43 nM River/Pond water (Xiong and Ling, 2012) 
Mercury(II) (Hg2+) Hg2+ aptamer-DNA AuNPs 0.1 nM Lake water (Ma et al., 2014) 
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Table 1-1: Chemical sensing application (continue) 
Analyte Probe Detection limit Source of sample References 
Small chemicals 
2,4,6-Trinitrotoluene 
(TNT) 
Para-aminothiophenol conjugated AuNPs 100 pM 4:1 
Ethanol/Acetonitrile 
(Dasary et al., 2010) 
Adenosine ssDNA-conjugated AuNPs 7 nM 10 mM PBS buffer 
(pH 7.3) 
(Yang et al., 2011) 
2,4,6-Trinitrotoluene 
(TNT) 
1,2-ethylenediamine (EDA) capped AuNPs 0.4 pM Tap water (Lin et al., 2012) 
Glucose Oligonucleotide conjugated AuNPs 38 pM Human serums (Miao et al., 2013) 
Glucose ssDNA adsorbed AuNPs 8.3 pM Human serums (Miao et al., 2014) 
Toxins 
Microcystin-LR (MC-
LR) 
AuNRs assemblies side-by-side/ene-to-end by anti-
MC-LR antibody modified and MC-LR-OVA antigen 
modified AuNRs  
Side-by-side: 
0.45 ng/ml 
End-to-end: 
5 pg/ml 
Water spike with  
MC-LR standards 
(Wang et al., 2010) 
Aflatoxin B1 (AFB) AFB1-BSA conjugated AuNRs 0.16 ng/ml Peanut samples (Xu et al., 2013) 
Aflatoxin M1 (AFM) AFM-BSA conjugated AuNPs 
Anti-AFM modified magnetic beads 
27.5 ng/L Milk samples (Zhang et al., 2013) 
Melamine Citrate-stabilised AuNPs 0.05 pM Milk product (Ma et al., 2014) 
Melamine Thymine containing DNA coated AuNPs 2 µg/L Food simulants (Wu et al., 2014) 
Cholera toxin Ab-conjugated AuNPs 10 nM Tap/Lake water (Khan et al., 2015) 
 50 
 
1.4.3.2 Biological sensing 
Relevant biological sensing papers are summarized in Table 1-2. 
 
1.4.3.2.1 Proteins and biomarker 
Liu and Huo (2009) conducted a systemic study of AuNP-DLS based methods 
using mouse IgG antibody as an analyte. The binding kinetics were investigated by 
measuring DH as a function of time when mixing goat anti-mouse IgG Ab- and mouse 
IgG-conjugated AuNPs together in a 1:1 ratio. A linear response was observed and 
this suggested that the antibody-antigen interaction could crosslink the AuNPs 
leading to cluster formation, which is the key feature of the immunoaffinity NP 
aggregation assay. In addition to kinetics being tested, the temperature effect was 
also investigated. It was determined that at higher temperature (37 ºC), aggregation 
occurred faster than at lower temperatures. For mouse IgG assay in solution, goat-
anti mouse IgG was used as the bioreceptors and DH was measured after incubation 
for 2 h at 37 ºC. There was a linear response between the mean DH and concentration 
of the IgG upto 5 µg/ml. After this point, the size dropped substantially forming a 
curve similarly to the Heidelberger-Kendall curve reported for immunoprecipitation 
assays. This phenomenon was explained as the ‘hook effect’. It is a common situation 
observed in particle aggregation assays. This might be due to the large amount of 
antigen added to the system occupying all of the bioreceptors on the surface of 
AuNPs and thereby preventing crosslinking between AuNPs. This limits the upper 
range of detection of the assay.  
To avoid this effect, it was suggested in the paper to adjust the NP 
concentration, dilute the analyte concentration or use a competitive assay format 
instead. The competitive platform was accomplished by forming an aggregate 
between goat anti-mouse IgG Ab- and mouse-IgG-conjugated AuNPs. Adding mouse 
IgG in solution competed with the mouse-IgG AuNPs in binding to the anti-mouse Ab 
conjugated AuNPs. A reduction in mean DH was observed and the concentration of 
analyte could be quantified. Despite avoiding the hook effect, it should be noted that 
using competitive format provided a less sensitive assay system. 
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There is a large volume of published work describing the role of AuNP 
coupled with DLS in terms of molecular biomarker detection. The Qun Huo group 
was the first to demonstrate that the quantification of free prostate specific antigen 
(f-PSA) could be performed with this platform (Liu et al., 2008). The free to total PSA 
ratio is different in cancer patients and benign prostate hyperplasia patients. 
However, the range of PSA presented in blood is in ng/ml so very sensitive assays are 
required. The established methods are either time consuming, involve labelling or 
have low sensitivity. With the DLS method, the detection limit was 0.1 ng/ml. Ab 
conjugated AuNPs were used for detection while Ab conjugated AuNRs was used for 
analyte capture in this method. In the presence of f-PSA, there were two different 
sizes observed in the DLS size distribution; 20 – 60 nm representing the free AuNPs 
and AuNRs and 60 – 500 nm representing dimers/trimers/oligomers formed via 
antibody-antigen interaction. The ratio between the two size populations were 
plotted and a linear response proportional to the concentration of f-PSA added to 
the system was found. The selectivity was tested using a different cancer marker, 
CA125 and the technique showed no response. 
There were reports of another cancer biomarker (alpha-fetoprotein - AFP), 
which significantly increases in liver cancer patients. Nietzold and Lisdat (2012) 
utilized anti-AFP monoclonal Ab (mAb)-conjugated AuNPs and were able to detect 
0.1 – 0.4 µg/ml of AFP in serum samples with the direct assay format. They suggested 
that the bigger the particles, the larger the change in mean DH would occur. In 
addition, small change in temperature, ionic strength and pH did not disturb the 
assay. Another study conducted by Chun et al., (2011) confirmed the principle of NP 
coupled DLS assay in detection of AFP. Anti-AFP IgG conjugated with gold-coated 
magnetic NPs were used as probes. Magnetic NPs were incorporated in the assay to 
ease AuNP functionalisation and orientation of anti-AFP IgG on the surface. Using 
this method an LOD of 0.01 ng/ml could be obtained. With regard to the detection 
probes, not only AuNPs were used in the DLS based assay, AuNRs or magnetic NPs 
were also used. In another paper published recently, silver NPs (AgNPs) were used 
as detection agents for carcinoembryonic antigen (CEA) – a tumour marker related 
to colorectal cancer (Miao et al., 2014). Anti-CEA IgG were conjugated to Ag-core Au-
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shell nanoparticles (Ag@Au CSNPs) and used as probes. A linear response between 
mean DH and concentration of CEA was observed. The incubation time was optimised 
to maximise the Ab-antigen interaction and 15 min was the optimum time reported. 
Also, pH effect was investigated and it was found out that at pH above pH 7.5, there 
was a decrease in mean DH. It was concluded that this method provided a fast, 
convenient and sensitive (LOD = 35.6 pg/ml) method of detecting CEA with the 
volume of sample required for the assay being only 20 µl. 
In addition, there was a report regarding polypeptide detection. Qin et al., 
(2017) described a sandwich-type DLS assay for pancreatic polypeptide (PP). Two 
different aptamers that could bind to PP were immobilised on AuNPs. Crosslinking 
of the AuNPs followed addition of PP to the system as the two aptamers could bind 
to the PP at the same time, leading to cluster formation detected by DLS. The LOD 
was reported to be 56 pM. 
  
1.4.3.2.2 Oligonucleotides 
Various approaches established for quantifying DNA mainly involve 
fluorescent optical labelling. There are drawbacks apart from the process being time-
consuming. With low DNA concentrations, the signal may not be strong enough to 
detect and fluorophores can photobleach or degrade with time, which results in 
inconsistent results. Thus, there are several studies conducted in searching for an 
alternative method for oligonucleotide detection and quantification. 
Dai et al., (2008) was the first team to publish a paper in which they described 
the use of AuNPs coupled with DLS technique in detection of DNA sequences. 
Specific DNA sequences were detected via AuNPs conjugated to two different 
complementary DNAs. In the presence of target DNA, crosslinking between AuNPs 
occurred due to hybridization of the DNA and aggregation of the AuNPs was 
identified by DLS. The detection limit was approximated to be around 1 pM. 
Moreover, when the single base pair mismatched target DNA was added instead, 
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there was no AuNPs size shift, reflecting the possible application in differentiating 
intact and damaged or mutant DNA.  
Consistently, Pylaev et al., (2011) reported a similar assay to detect cDNA 
sequences. They described the use of cetytrimethylammonium bromide (CTAB)-
coated positively charged AuNPs to detect a 21-mer single stranded DNA (ssDNA) 
from the human immunodeficiency virus type 1 (HIV-1 U5), a 23-mer ssDNA from 
the Bacillus anthracis cryptic protein and protective antigen precursor (pagA) genes. 
The results corresponded to the previous study in that the DLS method could 
discriminate single and three base pair mismatched sequences from the native 
sequence. Also, they compared the use of AuNRs as probes and suggested that 
AuNPs were more feasible for genome sensing. This concept was applied to double-
stranded DNA and  microRNA (miRNA) (Miao et al., 2011; Seow et al., 2014). Another 
paper reported by Zhang et al., (2012) confirmed the success of this technique for 
DNA detection. The paper described a slightly different method from that of Pylaev 
et al., (2011). Here, AuNPs were aggregated previously in the presence of 
dithiothreitol (DTT). By adding monothiol DNAs to the system, they could prevent 
the aggregation of the AuNPs, which led to the decrease in mean DH proportionally. 
The technique was not only reported for DNA or RNA detection, but also 
found application for transgenic product detection. In a paper published by Gao et 
al., (2011), sequence-specific nopaline synthase (NOS) gene produced in transgenic 
plants could be detected. Citrate-stabilised AuNPs were used to detect the 
transcripts in the presence of NaCl solution. The AuNPs were stabilised by the 
adsorption of NOS genes on the surface when the salt solution was added. However, 
in the presence of target sequence (sample), NOS genes were hybridized so the 
AuNPs were destabilized and aggregated when the salt solution was added. A linear 
relationship between the mean DH and the target sequence concentrations was 
obtained with a detection limit of 0.3 fM. 
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1.4.3.2.3 Bacteria, viruses and viral antigens 
There are a few reports applying AuNP-DLS based sensing platforms for large 
analytes such as viruses and bacteria.  
Driskell et al., (2011) demonstrated that the technique could quantify human 
influenza A virus strain H1N1:PR8 by using mAb clone IC5-4F8 modified AuNPs as 
probes. The DLS assay successfully quantified the viruses with a LOD of 8.6 x 101 
TCID50/ml. The hook effect was observed similar to most DLS assays. The effect of NP 
concentration was also investigated and the data suggested that below the hook 
point, a greater DH was observed at lower AuNP concentrations. So the dynamic 
range of assay could be adjusted by diluting or concentrating the AuNPs. However, 
it is worth noting that too dilute NP concentrations might result in too low scattering 
intensity signals, which would affect the signal to noise ratio.  
 In comparison to DLS assays for protein detection, the relationship of size-
shift and concentration of the analyte was sigmoidal for virus detection. The possible 
explanation given by Driskell et al., (2011) was that the viruses are larger than 
proteins and a single virus could bind to more than one AuNP probes leading to a 
substantial change in size, in contrast, one molecule of a small protein would allow 
only a dimer to form and dimer would affect the DH less than complexes-formed by 
larger analytes. Moreover, the effect of NP size was investigated and was expected 
to boost the sensitivity of the assay as seen in several studies already mentioned. 
Overall, a 30 nm core size of AuNPs provided the best detection limit compared with 
60 and 80 nm. Steric hindrance could be the key explanation to this contradiction, as 
a virus is a large analyte and at low level of virus the 30 nm NPs could occupy the 
surface of viruses more than 60 and 80 nm NPs. This led to fewer unbound probes 
left over in the solution and resulted in larger mean DH reported. In addition, the 
effect of AuNP concentration could be another reason as to why the effect of size 
contradicted the hypothesis and previous studies, because the DLS assay performed 
was based on the supplied concentration of each NP sizes, which had different 
number of particles/ml. Another point worth mentioning from this report by Driskell 
et al., (2011) is that AuNP stability was investigated. The functionalised AuNPs were 
 55 
 
prepared and used in the DLS assay for four consecutive days and were stored at 4 
ºC between each assay. The results showed no reduction in performance.  
 Regarding virus detection, Wang et al., (2012) described a DLS assay for 
hepatitis B antigen (HBsAg). In this study, they used anti-HBsAg mAb-conjugated to 
50 nm AuNPs as the detection agents coupled with anti-HBsAg polyclonal Ab (pAb)-
conjugated to either 10 nm or 100 nm AuNPs. The ratio between those two probes 
were optimised. The system with AuNP100-AuNP50 particles showed considerably 
better response, with LOD at 0.005 IU/ml, as compared to the LOD at 0.01 IU/ml 
obtained from the AuNP10-AuNP50 system. This again corresponded to most studies 
in terms of AuNP size since 100 nm AuNPs scatter light more strongly than 10 nm 
AuNPs. The linear response between the mean DH and concentration of analyte, 
conversely, was not observed in this experiment like in other DLS assay studies. The 
explanation given in the paper assumed that the clusters formed between two 
different sizes of AuNPs were not spherical in shape in which affects Brownian 
motion and the translational diffusion coefficient (𝐷). This was confirmed with TEM 
images showing various shapes of aggregates. However, the assay was 
demonstrated to be selective against HBsAg, with a much faster data acquisition 
time and sensitivity compared with conventional ELISA method. 
More recently, an AuNP-based DLS immunoassay has proved to be effective 
in detection of pathogenic bacteria. Huang et al., (2015) demonstrated the 
application of the assay for Listeria monocytogenes, a Gram positive bacteria causing 
food poisoning. The established method for this bacteria is culture-based, which 
takes approximately 7 days. The bacteria were extracted from lettuces using anti-
Listeria monocytogens monoclonal antibodies coated onto magnetic NPs (mAbs-
MNPs). The quantitative assay was conducted by using anti-Listeria monocytogens 
monoclonal antibodies coated onto AuNPs (mAbs-AuNPs) as detection agents 
similarly to most DLS-based methods. The mean DH increased proportionally with 
increasing concentration of analyte. The reaction time between the mAbs-AuNPs 
and analytes was investigated and 30 min was reported to be optimum. They also 
tested the effect of antibody concentration coated onto the AuNPs and found out 
that 10 µg/ml of the antibodies gave a maximum response. The assay proved to be 
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selective to Listeria monocytogenes strains only and showed no significant response 
with 15 other bacterial strains. In addition, they revealed that the LOD of the assay 
could be enhanced by increasing of AuNP size, when optimal NP concentration was 
used. However, they suggested that the oversized NPs could block the antibody-
antigen interaction because of steric hindrance. 
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Table 1-2 Biological sensing applications 
Analyte Probe Detection limit Source of sample References 
Proteins 
Free prostate specific 
antigen (f-PSA) 
Detection Ab-conjugated AuNPs  
Capture Ab-conjugated AuNRs 
0.1 ng/ml Nanopure water (Liu et al., 2008) 
Mouse IgG Ab 
Direct assay: 
Goat anit-mouse IgG Ab conjugated AuNPs 
Competitive assay 
The direct assay’s probe and mouse IgG conjugated 
AuNPs 
Direct: 
0.5 ng/ml 
Competitive: 
100 ng/ml 
PBS buffer (Liu and Huo, 2009) 
Alpha-fetoprotein 
(AFP) 
Anti-AFP conjugated gold-coated iron oxide 
magnetic NPs 
0.01 ng/ml Buffer solution (Chun et al., 2011) 
Alpha-fetoprotein 
(AFP) 
Anti-AFP Ab-conjugated AuNPs 0.1 – 0.4 µg/ml Serum sample (Nietzold and Lisdat, 2012) 
Carcinoembryonic 
antigen (CEA) 
Anti-CEA Ab-conjugated silver core gold shell NPs 
(Ag@Au CSNPs) 
35.6 pg/ml Serum sample (Miao et al., 2014) 
Pancreatic 
polypeptide (PP) 
Dual-aptamer immobilised AuNPs 56 pM Buffer solution (Qin et al., 2017) 
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Table 1-2: Biological sensing applications (continue) 
Analyte Probe Detection limit Source of sample References 
Oligonucleotides 
Target DNA Single stranded DNA (ssDNA)-conjugated AuNPs 
(citrate-stabilised AuNPs) 
1 pM Buffer solution (Dai et al., 2008) 
Complementary DNA 
(cDNA) of  
ssDNA-conjugated AuNPs 
ssDNA-conjugated AuNRs 
AuNPs: 
10 pM 
Buffer solution (Pylaev et al., 2011) 
Double-stranded DNA 
(dsDNA) 
dsDNA modified AuNPs 593 fM Buffer solution (Miao et al., 2011) 
Nopaline synthase 
(NOS) gene 
Citrate-stabilised AuNPs 3.0 x 10-14 M Buffer solution (Gao et al., 2011) 
Let7 family microRNA 
(miRNA) 
ssDNA-conjugated AuNPs 100 fmol Buffer solution (Seow et al., 2014) 
Bacteria, Viruses and Virus antigens 
Human influenza A 
virus (H1N1:PR8) 
mAb clone IC5-4F8 modified AuNPs 8.6 x 101 TCID50/ml 
PBS buffer  
(pH 7.4) 
(Driskell et al., 2011) 
Hepatitis B antigen 
(HBsAg) 
Anti-HBsAg mAb-conjugated 50 nm AuNPs coupled 
with either anti-HBsAg polyclonal Ab (pAb)-
conjugated 10 or 100 nm AuNPs 
AuNP10-AuNP50: 
0.01 IU/ml 
AuNP100-AuNP50: 
0.005 IU/ml 
Tris-HCl buffer 
(pH 7.4) 
(Wang et al., 2012) 
Listeria 
Monocytogenes 
Anti-Listeria monocytogenes mAb conjugated 
AuNPs 
3.5 x 101 CFU/ml 
2.2 x 101 CFU/ml 
PBS (pH 7.4) 
Lettuce sample 
(Huang et al., 2015) 
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1.4.3.3 Other applications 
There was a report by Zheng et al., (2015) on the potential of the NP-DLS 
coupled assay as a universal cancer screening test. The principle is based on the 
knowledge of tumour antigen-specific autoantibodies. It is a response of human 
body to tumour cells. Auto-antibodies are produced and secreted into our serum 
relatively early and before diagnosis of the disease. Therefore, they become one of 
the best biomarkers for cancer screening. The assay proposed utilized citrate-
stabilised AuNPs as probes and contained two steps. The first involved mixing human 
serum sample with the AuNPs, which led to the adsorption of serum proteins on the 
AuNP surface, forming a complex with a ‘protein corona’. After 5-20 min incubation, 
the mean DH of AuNPs was measured (D1). Following this, rabbit anti-human IgG Ab 
were added to the mixture and bound to the IgG present on the corona leading to 
NP crosslinking and cluster formation. Again, the mean DH of AuNPs was measured 
(D2). The ratio between D2/D1 were reported as a test score. So far, two pilot studies 
were conducted. The first study used prostate cancer versus non-cancer patient 
samples, whilst the second looked at prostate cancer versus benign prostate 
hyperplasia (BPH – a non-cancerous condition) samples. The specificities for both 
studies were 95% and 91%, respectively. It was concluded that this assay could be a 
fast, simple and reliable cancer screening test. 
Another interesting applications of an NP aggregation assay coupled with DLS 
was to study protein-protein interaction. Conventional methods are mainly labelled 
techniques and true binding might be affected by fluorescence labels. Also, these 
assays are time-consuming and labour intensive. Recently, label-free techniques like 
SPR have become an option for protein-protein interaction monitoring. However, 
SPR requires a complex equipment and an expert to operate it. Furthermore, large 
protein aggregates cannot be studied with SPR. Bogdanovic et al., (2010) reported 
using DLS to examine the aggregation of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Anti-GAPDH Ab-conjugated AuNPs were used as detection 
probes. Previously, it was not possible to directly measure aggregation extent of 
GAPDH at low concentrations (<100 µg/ml), which are likely to be found under 
physiological conditions. Using the AbAuNP probes and DLS, it was revealed that 
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GAPDH tended to aggregate over a concentration range of 10 – 25 µg/ml. The study 
was conducted by measuring the average size of the AbAuNP probes and GAPDH 
complexes. Moreover, size distribution plots from DLS provided the characteristics 
of the aggregates formed too. It was reported that GADPH aggregates were not 
uniform. 
A different paper published by Qun Huo (2010) correspondingly revealed that 
this NP-DLS aggregation assay could be used for protein complex/aggregate 
detection. This potential to reveal the level of protein aggregation could be used to 
differentiate between normal and cancer patients. The study was focused on four 
different cancer biomarkers: CA125 (ovarian cancer), CEA (ovarian and colon 
cancer), CA19-9 (colon cancer) and prostatic acid phosphatase (PAP) (prostate 
cancer). Antibodies specific to each biomarker were conjugated to AuNPs. The assay 
was performed by comparing change in the average size of healthy and cancer 
assayed samples. It was shown that the levels of aggregated proteins in cancer 
patients samples were higher in healthy ones. The authors suggested that for cancer 
patients, the pattern of protein expression is different from normal cell function and 
when secreted out of the cells, the behaviour of proteins will be changed. Huo (2010) 
concluded that this might be an alternative method for cancer diagnosis. 
Correspondingly, it was also demonstrated recently that DLS assays could be used to 
screen antigen-antibody binding activity (Lai et al., 2015). Influenza virus (H1N1) was 
selected as an antigen of interest and four different mAbs (InA4, InA16, InA88 and 
InA97) were screened with the proposed technique. Data was compared to a gold 
standard ELISA. The results from the DLS assay was comparable to the results from 
ELISA but with only 30 min processing time. 
 A final application of a NP-coupled DLS technique is a tool for studying 
protein structure. Actually, DLS on itself can be used in protein size analysis, but 
there are some limitations. Small proteins (MW < 50 KDa) do not have enough 
scattering intensity and so the concentration of proteins has to be high (> 1 mg/ml) 
to be measured. In the paper published by Zheng et al., (2016), AuNPs were used in 
conjunction with DLS to determine the hydrodynamic size of protein disulphide 
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isomerase (PDI). The mean DH of citrate-stabilised AuNPs was measured and 
compared with the average size after PDI was added to the AuNPs. Once more, the 
ability to form a protein corona on the AuNP surface was exploited. The difference 
in size before and after the corona formation could be calculated and reported as 
PDI hydrodynamic protein size. The study also compared the sizes of reduced and 
oxidised forms of PDI. The results were similar to X-ray diffraction analysis, which 
showed that the reduced form had a smaller hydrodynamic diameter. Relevant 
papers for other applications of NP-DLS based assay are summarised in Table 1-3.  
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Table 1-3 Other applications 
Analytes Probes Proposed applications References 
Glyceraldehyde 
3-phosphate 
dehydrogenase 
(GAPDH) 
Anti-GAPDH Ab-conjugated AuNPs Protein-protein interaction study (Bogdanovic et al., 2010) 
Cancer 
biomarkers 
Ab-conjugated AuNPs Cancer biomarker determination (Huo, 2010) 
Influenza virus 
(H1N1) 
Ab-conjugated AuNPs Antigen-antibody binding activity (Lai et al., 2015) 
Prostate cancer 
biomarker 
Citrate-stabilised AuNPs Cancer screening test (Zheng et al., 2015) 
Protein 
disulphide 
isomerase (PDI) 
Citrate-stabilised AuNPs Determine hydrodynamic size of protein (Zheng et al., 2016) 
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1.4.4 Challenges in the development of nanoparticle-coupled dynamic 
light scattering detection 
Initially, DLS was not an option for quantitative analysis for chemical and 
biological sensing because prior to the arrival of AuNPs it could not differentiate the 
light scattering from the polymer beads and background matrices so it could not 
meet the practical application at that time. However, it is now well-established from 
a variety of studies that NP-coupled DLS assays are capable of quantitative analysis 
for target analytes ranging from metal ions to proteins. Alternatively, the assay can 
be used in biomolecular interaction studies.  
The main advantages of the size-shift assay over other methods is that it is a 
label-free technique with no labelling of the target or ligand needed. Therefore, true 
interactions can be obtained. Without labelling, the complexity of the technique is 
also reduced, removing the need for an expert to operate the DLS equipment and 
making the technique more available. In addition, homogeneous assays can be 
performed with this technique as there is no need to separate the NP probes and 
analytes before measurement takes place. DLS has a fast operation time and the 
assay results could be obtained within minutes. Furthermore, DLS has been 
commercialised in the form of plate reader. This opens up an opportunity to design 
high-throughput systems for screening or studying molecular interaction. In fact, 
there is the company Nano Discovery Inc. commercialises nanoparticle-coupled DLS 
technology as its core business. Their assays are sold in the form of AuNP ready-to-
use conjugate kit; bioreceptors are provided by the customer.  
To date, all applications of nanoparticle-coupled DLS assay have been 
established at the experimental stage and have not yet been widely accepted for 
industrial or field use. The remaining challenges for this technology are how to use 
the assay with various background matrices and how to maintain the stability of the 
nanoparticle reagents prepared for the assay. Regarding background matrices; it is 
necessary to make sure that the aggregation of AuNPs is specific to the target analyte 
and is not interfered with the background signal. In real world applications, there is 
a limited chance that the samples arrive in a pure solution and a complex matrix like 
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serum is more likely. Another challenge is the stability of the probes. This issue is 
critical to the technique because it is the key part of the aggregation control. The 
quality of AuNPs themselves should be maintained in order to avoid random 
aggregation. Moreover, the binding activity between the bioreceptor and target 
analyte is even more important to ensure the qualitative and quantitative efficacy of 
the assay.  
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1.5 Bioreceptors 
The bioreceptor is an important element in any biosensing platform since the 
binding event between the target analyte and bioreceptor leads to generation of the 
signal, no matter which type of sensing application is concerned. Ideally, the 
receptor should bind specifically to the interested analyte, and the binding activity 
should produce a strong enough signal enable the development of a sensitive 
sensing system. In terms of NP-coupled DLS assays, several types of bioreceptor have 
been reported previously, especially oligonucleotides and antibodies. This section 
provides a brief summary of the bioreceptors used in optical sensing, together with 
the possible molecules that can be used to improve detection in NP- coupled DLS 
assays.  
 
1.5.1 Oligonucleotides and aptamers 
Oligonucleotides are commonly used coupled to AuNPs for DNA detection. 
The base paring between complementary DNA has been exploited in sensing 
applications for a long time. The analytes for this type of bioreceptor are mainly DNA, 
RNA or their analogues (Luong et al., 2008; Jolly et al., 2016). Nevertheless, the 
stability of DNA is still a major problem as in some conditions (e.g. in acid solution) 
it can be depurinated (Brandt and Hoheisel, 2004). Hence, there has been an attempt 
to use an artificially synthesized nucleic acid or peptide nucleic acid (PNA) instead 
because it has the same characteristics as DNA or RNA but is far more stable at 
different temperatures or pHs. Also, it tolerates various enzymes (i.e.nuclease) 
(Demidov et al., 1994). 
In recent time, protein-binding oligonucleotides, aptamers, have emerged. 
They are produced using the systematic evolution of ligands by exponential 
enrichment – known as SELEX and automated chemical solid-phase synthesis is used 
for production. The aptamers are single-stranded DNA (ssDNA) or RNA (ssRNA) 
sequences that can be produced to have a high specificity and affinity towards the 
target molecules. The binding mechanism of aptamers is based on conformational 
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change and not complementary base pairing. They are considered as antibody 
alternatives (Nimjee et al., 2005; Jolly et al., 2016).  
Aptamers exhibit a reversible denaturation property with fully recovery of 
function which can be controlled by changing conditions such as pH, temperature, 
ionic strength. A variety of target analytes have been screened including proteins, 
small molecules, viruses, but the greatest advantage of aptamers is their ability to 
bind to small molecules. Although, the structure of theophylline and caffeine are 
almost identical (Figure 1-14), apart from one methyl group, aptamers against 
theophylline could specifically bind to the target with no cross reactivity. This was 
shown by Jiang et al., (2015). In the same way as oligonucleotides, aptamers are 
charged, which makes the binding responsive to solution they are in. This may 
restrict the use of aptamers in complex buffer solution like blood or biological 
samples (McKeague and DeRosa, 2012; Lakhin et al., 2013). 
 
 
 Figure 1-14 Structures of theophylline and caffeine. The red circle indicates a 
position of methyl group within caffeine structure that different from theophylline. 
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1.5.2 Antibodies and their alternatives 
1.5.2.1 Antibodies 
For decades, antibodies have been exploited by researchers in biological 
science. They have become one of the most frequently used tools in both 
therapeutic and diagnostic applications. Antibodies are used extensively in ELISA, 
protein blotting, immunohistochemistry, immunoprecipitation and flow cytometry 
analysis.  Not only for research fields, antibodies are also used as therapeutic agents 
in treatment of cancer, autoimmune or inflammatory diseases. As bioreceptors, the 
specific interaction between antigen and the antibody is exploited in affinity based 
biosensors (Vo-Dinh and Cullum, 2000; Morrison et al., 2007). 
Antibodies or immunoglobulins (Igs) are proteins produced by B cells to 
protect the body from invasion by foreign molecules. It is a very important element 
in the human immune system. Figure 1-15 shows a schematic of an antibody 
molecule. It has Y-shaped structure comprising of four polypeptide chains linked 
together with multiple disulphide bonds. Antibody basic structure comprises two 
identical 25 kDa light chains and two 50 kDa heavy chains. Both light and heavy 
chains contain variable regions at their N-termini whereas their C-termini are 
constant. The antigen binding site (Fab) is located at the N-terminus of each heavy 
chain and its adjacent light chain. There are three complementarity determining 
regions (CDRs) in the binding site that are actually involved in antigen binding. 
However, the remaining domains of both chains support the CDRs to aid binding 
specificity. Identical C-terminal parts of the two heavy chains form a region called Fc. 
It contains an effector site, which enables the antigen downstream destruction 
process. 
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Figure 1-15 Antibody (IgG) molecular structure. (A), schematic of IgG structure 
comprising of two identical light chains and two identical heavy chains. Both light 
and heavy chains contain variable regions at their N-termini (VL and VH, respectively) 
whereas their C-termini are constant (CL and CH, respectively). The antigen binding 
site (Fab) is located at the N-terminus of each heavy chain and its adjacent light 
chain. There are three complementarity determining regions (CDRs) in the binding 
site that are actually involved in antigen binding. Identical C-terminal parts of the 
two heavy chains forms a region called Fc; (B), 3D structure of Ab from PDB file: 1IGY. 
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Antibodies are produced by immunizing animals such as mice, rabbits, 
chickens with the analyte of interest. Antibodies against the target are produced by 
the B cells, which can be isolated and utilized for monoclonal antibody production. 
However, antibodies produced in response to simple immunization are called 
‘polyclonal antibodies’ and are made by multiple B cells. So essentially, they are a 
pool of antibodies that bind to the specific antigen at multiple epitopes. Monoclonal 
antibodies that bind to a single epitope are produced by isolating single antibody 
producing B cells from the animal, fusing the isolated cells with myeloma cells to 
produce hybridomas, and growing the hybridomas in the media that only allows the 
hybridomas to survive. 
Antibodies have proven to be really useful tools for many applications. Yet, 
there are a number of disadvantages regarding antibodies. The production of 
antibodies involves animals, is time-comsuming, requires expert labour and is 
expensive. Also, some target molecules antibody production is difficult. For example, 
toxic proteins in some cases cannot be injected to the animals as they may be 
harmful or even kill the animal. Also antibodies are large multimeric molecular 
structure containing multiple disulphide bonds and show limited stability.   
Another major issue concerning antibody use is a batch-to-batch 
heterogeneity. This is a common problem with commercial antibodies. There was a 
report on this issue in 2015 (Baker, 2015; Bradbury and Plückthun, 2015) suggesting 
that antibody variation is a major cause of reproducibility problems in life sciences 
research because of batch-to-batch variability and poor characterisation. It was also 
reported that around 50% of globally invested funds on protein-binding reagents 
were wasted due to poorly characterised antibodies (Baker, 2015; Bradbury and 
Plückthun, 2015; O’Kennedy et al., 2017). With this downside, it is hard for diagnostic 
fields to rely on antibodies as it is difficult to maintain the quality on long-term 
supplies for assay.  This drawback of antibodies can be solved by using monoclonal 
antibodies as they have no batch variability. However, monoclonal antibody 
production is complicated, time-consuming and very expensive. Therefore, several 
alternatives have been proposed to replace antibodies. 
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Antibody fragments have become a replacements for whole antibodies in 
solving the problems mentioned. It is the active fraction of the antibody, such as Fv, 
Fab and multivalent fragments, which participate in binding that are used. The 
fabrication of these fragments is fairly easy, including the removal the Fc region that 
sometimes provides unpleasant side effects for biopharmaceutical applications 
(Plückthun and Pack, 1997). By using synthetic or recombinant libraries from B cells, 
the specificity can be more controlled and production is also cheaper (Vaughan et 
al., 1996; Knappik et al., 2000). Nevertheless, the use of antibody fragments is not 
widespread because of their stability (Binz and Plückthun, 2005). For example, in the 
absence of the Fc region, some immobilization processes are not possible and thus 
several applications are restricted. A lot of attention has turned to non-antibody 
binding proteins and these will be discussed in the next section. 
  
1.5.2.2 Non-antibody binding proteins 
Non-antibody binding proteins are based on the concept of protein scaffold 
engineering. This refers to introduction of additional affinity function into a stable 
folded protein (Nygren and Skerra, 2004). The properties that protein scaffolds 
should have are to be strong, stable, compact and have a monomeric structure. 
These make for easy genetic engineering and expression in prokaryotic systems, 
which is inexpensive. In addition, their most significant property is their structurally 
rigid area, which means a region where the replacements, insertions or deletions of 
amino acids can take place at a primary structure level without disturbing overall 
protein structure, in order to generate new binding sites similar in those the 
antibody hypervariable loop (Skerra, 2003; Skerra, 2007). 
With advancements in protein engineering and the latest library selection 
technologies, proteins that can replicate antibody function are already available. The 
procedure of generating synthetic non-antibody binding proteins usually starts with 
building a combinatorial library onto a preferred protein scaffold. The library is built 
by selective random mutagenesis of unprotected surface residues of the scaffold, 
typically unstructured loops. After this, a range of binding affinities are produced by 
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careful selection of variants using phage display. The degree of mutagenesis and the 
selection conditions are the two most important factors for determining 
biomolecular properties of the binding molecules. Ideally, the binding protein should 
have sufficient affinity and specificity to a target. Also, it should exhibit 
thermodynamic, chemical and enzymatic stabilities (Skerra, 2007; Hamzeh-
Mivehroud et al., 2013). 
In comparison with antibodies, non-antibody binding proteins possess better 
stability and their production is much cheaper. Most of them lack disulphide bonds, 
except where engineered in. This allow cysteine reduction to facilitate the 
orientation bioreceptor coupling and their use in intracellular assays and structural 
biology application (Helma et al., 2015). Additionally, without batch-to-batch 
variability, reproducibility is usually much higher. So far, there are more than 50 
different non-antibody binding proteins reported. Broadly speaking, they can be 
classified into two groups. The first group is constrained peptides (2 – 4 kDa), while 
the second group comprises domain-sized scaffolds with ~ 6 – 20 kDa molecular 
weight. If we investigate further the mechanism of binding, they also can be divided 
into two subgroups (Table 1-4 and 1-5). The first binding mechanism is via surface-
exposed side chains of secondary structural elements whilst the other is via the 
binding loop(s) on a protein scaffold. The latter mechanism mimics the binding by an 
antibody (Nygren and Skerra, 2004; Weidle et al., 2013). 
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Table 1-4 Examples of secondary structure based binding mechanism non-antibody (Ab) binding proteins. The list is intended to show a variety of 
non-Ab binding proteins that have been developed. PDB files were obtained from RCSB protein data bank (http://www.rcsb.org/pdb/home/). 
Name Protein scaffolds Species origin Randomization Structure PDB Ref 
Darpin Ankyrin repeat proteins Human 7 residues in each n-
repeat 
 
4J7W (Plückthun, 2015) 
Affibody Protein A Bacteria 
(Staphylococcus 
aureus) 
13 residues in 2 helices 
 
1LP1 (Shishido et al., 2010) 
Affilins (1) 𝛾-B-crystallin Human 8 residues 
 
2JDG (Ebersbach et al., 
2007) 
Affilins (2) Ubiquitin Human 6 residues in the β-
sheet 
 
1UBI (Hoffmann et al., 
2012) 
Armadillo 
repeats 
Armadillo (homologous to 
b-catenin) 
Consensus 
protein 
6 residues in each 
internal repeat 
 
4DB6 (Parmeggiani et al., 
2008) 
Repebody Leucine-rich repeat (LRR) 
modules 
Consensus 
protein 
5 residues in each LRR 
 
4J4L (Lee et al., 2012) 
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Table 1-5 Examples of loop based binding mechanism non-antibody binding proteins. The list is intended to show a variety of non-Ab binding 
proteins that have been developed. PDB files were obtained from RCSB protein data bank (http://www.rcsb.org/pdb/home/). 
Name Protein scaffolds Species origin Randomization Structure PDB Ref 
Adnectin 10th domain of fibronectin 
type 3 (10Fn3) 
Human 
extracelluar 
matrix protein 
fibronectin 
3 CDR regions total 
20-25 residues 
 
1TTG (Lipovsek, 2011) 
Anticalin Lipocalins Human body 
fluids 
16-18 residues 
 
1LNM (Skerra, 2008) 
Kunitz domain 
scaffold 
Protease inhibitors Human 1-2 loops 
 
1KTH (Dennis et al., 1995) 
Avimer Low-density lipoprotein 
receptor A domain 
Human 28 residues 
 
1AJJ (Silverman et al., 
2005) 
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Table 1-5 Examples of loop based binding mechanism non-antibody binding proteins (continue) 
Name Protein scaffolds Species origin Randomization Structure PDB Ref 
Knottin Toxins Spiders 
Scorpions 
Marine cone 
snails 
3 disulfide bridges, the 
so-called cystine knot 
 
2LZX (Moore et al., 2012) 
Fynomer SH3 domain of human Fyn 
tyrosine kinase 
Human 6 residues in 2 loops 
 
4AFQ (Schlatter et al., 2012) 
Atrimer Tetranectin Human 6 – 9 amino acids 
between 5 loops 
 
1TN3 (Zelensky and Gready, 
2005) 
Affimer Protease inhibitor stefin 
A/phytocyststatin protein 
Human/Plant 18 residues between 2 
loops 
 
4N6T (Tiede et al., 2014) 
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In the field of non-antibody binding proteins, most research has focused on 
therapeutic applications to replace and overcome the drawbacks of monoclonal 
antibodies that have been used as therapeutic agents. However, some non-antibody 
binding proteins have been used in biosensing application too. Thioredoxins, 
Affibodies and Affimers are among the binding proteins that have been used in 
biosensing platforms (Ferrigno, 2016). Thioredoxin (TrxA), sometimes called a 
peptide aptamer, is an enzyme involving in the cytosolic thiol/disulfide equilibrium 
of bacteria Escherichia coli (E.coli). It is small, soluble and stable enzyme with short 
active site sequence forming accessible binding loops (LaVallie et al., 1993; Skerra, 
2007). Regarding biosensing applications, Thioredoxin-based peptide aptamer 
microarrays were developed by Laurenson et al. (2011) for detection of endogenous 
cellular proteins; cyclin-dependent kinases 2 and 4 (CDK2 and CDK4) and virally 
encoded E6/E7 proteins from human papilloma virus (HPV) infected cells. 
The Affibody is a non-antibody binding protein based on the protein A 
scaffold at the immunoglobulin G binding domain, called the Z domain. It consists of 
58 amino acids with a binding loop mechanism. In 2005, Affibodies were successfully 
used in two different biosensing platforms. There were a real-time SPR biosensor 
and a microarray system (Renberg et al., 2005). It is interesting that the orientated 
Affibodies on the SPR sensor proved to significantly increase the sensitivity of the 
technique. However, it was not the case for the microarray system. In other work 
conducted by the same group, Affibody recognition ability was tested against IgA-, 
IgE-, IgG-antibodies, TNF-α, insulin and Taq DNA polymerase by using fluorescent-
labeled analytes when the Affibodies were immobilized on microarray slides 
(Renberg et al., 2007). In addition, Affibody specific to human epidermal growth 
factor receptor type 2 (HER2) was used in combination with quantum dots (QDs) and 
iron oxide (IO) NPs for molecular imaging and diagnosis (Gao et al., 2011). Recently, 
Ravalli et al., (2015) reported the development of impedimetric biosensors using 
anti-HER2 Affibody as the bioreceptor. The limit of detection (LOD) of HER2 was 
around 6 µg/L. 
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1.5.2.3 Affimer (Adhiron) 
Affimers are engineered protein scaffolds derived from the cystatin family 
commercialized under collaboration between the University of Leeds, the Leeds 
BioScreening Technology Group (BSTG) and Avacta Life Sciences Ltd. There are two 
scaffolds developed based around the human protease inhibitor stefin A and the 
plant phytocyststatin protein, respectively.  
In 2014, Tiede et al. successfully developed an engineered binding protein 
called the ‘Adhiron’, which now referred to as the Affimer. Its molecular weight is 
around 12-13 kDa and it contains 92 amino acids. The structure consists of four anti-
parallel β-strands and one α-helix (Figure 1-16). The scaffold also contains two 
variable regions forming binding loops, similar to the CDR loops of antibodies. 
Randomization takes place within nine residues of each loop in generating the 
Affimer library. The generation of the Affimer library commenced with the 
preparation and modification of a consensus sequence derived from plant 
phytocystatins from many species. The coding region of the Affimer scaffold was 
cloned between NheI and NotI restriction sites in phagemid vector pBSTG1 to 
produce the Affimer/truncated pIII fusion protein in the ER2738 suppressor cells for 
phage display. Randomization was done by randomly introducing three base pairs at 
a time as a single codon for each of the 19 amino acids (excluding cysteine and stop 
codons). A high quality recombinant protein library could be generated with 3x1010 
clones and 86% complexity.  
The advantage of using non-antibody binding proteins in a biosensing 
platform is that a uniform protein can be produced by a cheaper and less 
complicated process, which enables long-term availability. In addition, because of 
their compact size, they can be packed on to the surface of biosensor more densely 
as compared to larger antibodies, which may enhance the sensitivity of the sensing 
platform. Due to their small size, the bioreceptors are immobilized closer to the 
surface of sensors than larger antibodies. Again, for some types of application this 
can help improve platform sensitivity (Tiede et al., 2014; Ferrigno, 2016).  
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So far, Affimers have proved to be as effective as antibodies in standard 
techniques such as Western blotting and ELISA (Tiede et al., 2014). In addition, Tiede 
et al., (2017) demonstrated further the use of Affimers in molecular and cell biology 
applications. For example, Affimers were used for in vivo imaging of the colorectal 
cancer marker Tenascin C. Affimers against Tenascin C were screened, characterised 
and used for tumour imaging compared to anti-Tenascin C antibody. The results 
were similar between the Affimer and antibody staining patterns. Moreover, 
Affimers have been used for super resolution microscopy, Affinity histochemistry, 
inhibiting extracellular receptor function and modulating ion channel activity (Tiede 
et al., 2017).  
In terms of biosensing applications, Raina et al., (2015) successfully 
developed an Affimer-based impedimetric biosensor for detection of the anti-myc 
tag IgG. In this work, 34 Affimers against anti-myc tag IgG were screened from a 
phage library: 20 Affimers were selected via their affinities obtained by bio-layer 
interferometry (BLI). After ELISA was performed, anti-myc IgG Affimer clones 2 and 
13 showed the highest responses, but clone 13 aggregated and therefore Affimer 
clone 2 was used in the sensor system. In addition, the thermal stability of the 
Affimer clone 2 was investigated using differential scanning calorimetry (DSC). No 
Binding 
loop 1
Binding 
loop 2
C-terminal
N-terminal
Figure 1-16 Molecular structure of an 
Affimer (PDB file 4N6T). Four anti-
parallel β strands and one α helix strand 
are shown in yellow and pink, 
respectively. The two binding loops at 
the N-terminal are shown in grey. 
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degradation observed at temperature below 85 ºC. The impedimetric biosensor was 
constructed via EDC/NHS amine coupling chemistry between amines of the Affimer 
and carboxylic group of monothiol-alkane-PEG-acid self-assembled monolayer 
(SAM) on a gold electrode. The sensor could detect 6.7 – 330 pM of anti-myc tag 
antibodies.  
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1.6 Project aims and impact statement: potential applications 
The main objective of this project is to develop a NP size-shift assay coupling 
with DLS by using a non-antibody binding proteins, Affimers, as bioreceptors, Figure 
1-17 shows a schematic of a proposed NP-coupled DLS assay. The Affimers are 
immobilized on AuNPs forming nanobiosensors. When the target analytes are added 
to the system, specific binding between the Affimers and the analytes will lead to 
crosslinking of the NPs and aggregates will form. Without needing separation of the 
excess AuNPs, the mean AuNP probe/aggregate size is determined via DLS. For 
complete quantitation, calibration curves can be obtained using standard solutions. 
Affimers will be screened and specifically characterized for use in the size-shift assay. 
In addition, the Affimer conjugated AuNPs will be investigated in terms of optimum 
concentration required for nanobiosensor preparation, the kinetics of the system as 
well as other related factors affecting the assay such as NP concentration or size. 
Finally, the reproducibility and stability of nanobiosensors are also examined. 
As mentioned in section 1.4.4, the challenge remaining in the field of NP-
coupled DLS assays is to produce bioreceptors-modified AuNPs with good stability, 
especially the maintenance of binding activity, because the binding event is the key 
in controlled aggregation and directly affects the sensitivity of the assay. Therefore, 
by replacing antibodies with more stable bioreceptors such as Affimers, the AuNPs 
obtained should give reproducible assay results and be stable for long term use. In 
comparison, antibodies used in the size shift assay are polyclonal and there have 
been several reports about the batch-to-batch variations of pAb. Hence, the binding 
activity should remain the same with the Affimers as they will not have the 
inhomogeneity problem. Additionally, there are also numerous reports using 
monoclonal antibodies for the size shift assay. However, at least two mAbs are 
required to crosslink AuNPs, which can restrict assay development in terms of 
production cost, so Affimers might be a solution to this problem as it is much cheaper 
to produce.  
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Figure 1-17 Schematic of NP-coupled DLS size shift assay. (A), Affimers for specific 
analyte are conjugated onto AuNPs and act as nanobiosensors. With the presence of 
analytes in the system, specific binding between the Affimer and analyte will lead to 
crosslinking and aggregation of the AuNPs. (B), DLS is used in detection of 
crosslinking and aggregation by measuring: (i), size shift of AuNPs before and after 
adding analytes to the system. The complete quantitation can be performed by 
generating a calibration curve, (ii). 
 
The size shift assay using DLS is a label-free technique for which a wide variety 
of applications have been reported.  By using a novel bioreceptor, the Affimer, the 
proposed assay could be an alternative technique with consistency of reagent quality 
and no interference from tagging molecules such as chromophores or fluorophores. 
A future aim is to develop a novel size-shift assay platform for screening purposes. 
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This would be useful for industries such as pharmaceuticals, food or agriculture. With 
more stable bioreceptors, there is potential to produce a ready-to-use kit for people 
in the field work to operate with only one instrument and one-step homogeneous 
assay. This particular assay will benefit developing countries particularly in terms of 
cost reduction, since DLS instruments are fairly common and not too expensive. In 
addition, if we can reduce the price of bioreceptors, the assay will be more accessible 
to most laboratories. Finally, a DLS plate readers are commercially available so there 
is an opportunity to develop a high-throughput system for detection and to study 
protein-protein interactions. 
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Inorganic materials 
Potassium iodide (KI), sodium chloride (NaCl) and sodium phosphate monobasic 
(NaH2PO4) were obtained from BDH laboratories and Fisher Scientific, respectively. 
Iodine (I2) and sodium periodate (NaIO4) were purchased from Sigma-Aldrich. 
  
2.1.2 Organic materials 
Myoglobin from equine heart, biotin maleimide, dimethyl sulfoxide (DMSO), 
imidazole and bovine serum albumin (BSA) were obtained from Sigma-Aldrich. 
Pierce® immobilized tris(2-carboxyethyl)phosphine (TCEP) gel, glycerol, EZ-linkTM N-
hydroxysuccinimide (NHS)-biotin, EZ-linkTM hydrazide-biotin, high sensitivity 
streptavidin conjugated horseradish peroxidase (HRP), enhanced chemiluminescent 
(ECL) western blotting substrate and GlycolinkTM coupling catalyst (containing 
GlycoLink coupling buffer; 0.1 M sodium acetate, 0.15 M NaCl, pH 5.5 and aniline) 
were purchased from Thermo Fisher Scientific. 3,3’,5,5’-tetramethylbenzidine (TMB) 
substrate (Seramun® fast) was purchased from Seramun Diagnostica GmbH. 
Clostridium difficile toxin B and anti-Closridium difficile toxin B Affimers (Clone 18C 
and 45C) were provided by the Leeds BioScreening Technology Group (BSTG). 
 
2.1.3 Antibodies 
All antibodies used in this project are summarised in Table 2-1. 
Table 2-1 Summary of all antibodies used in this project 
Antibody Origin Source 
Anti-myoglobin Rabbit polyclonal IgG GenScript Ltd. 
Anti-rabbit IgG-HRP Goat polyclonal IgG GenScript Ltd. 
Anti-His6-HRP Rabbit polyclonal IgG AbCam Plc. 
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2.1.4 Buffers and solutions 
10X phosphate buffer saline (PBS) was purchased from Cambridge Bioscience and 
diluted with deionised water to 1X before used. 10X Tris-glycine SDS-PAGE running 
buffer and quick Coomassie stain were obtained from Bio-Rad Laboratories and 
Generon Ltd, respectively. Bradford dye reagent ready-to-use solution was 
purchased from Alfa Aesar. 10X blocking buffer and Tris were purchased from Sigma 
and Bio Basic Canada Inc, respectively. Glycine and acetic acid were purchased from 
BDH laboratory supplies. Tween-20® was obtained from Sigma-Aldrich. All other 
buffers were prepared in the laboratory and the summary of buffers used in this 
project is shown in Table 2-2.  
 
Table 2-2 Summary of buffers used in this project 
Name Ingredients pH Application 
1X PBS 
137 mM NaCl; 10 mM phosphate; 2.7 
mM KCl 
7.4 General use 
TE 10 mM Tris; 1 mM EDTA 8.0 Phage display 
Glycine 0.2 M glycine 2.2 Phage display 
Tris 1 M Tris-HCl 
7.0 
9.1 
Phage display 
1X TGS 
25 mM Tris; 192 mM glycine; 0.1% 
(w/v) SDS 
8.3 
 
SDS-PAGE gel 
PBS-T 1X PBS + 0.1% (v/v) Tween-20 7.4 
Phage display 
ELISA 
TAE 
40 mM Tris; 20 mM acetate; 1 mM 
EDTA 
8.6 
Electrophoresis 
gel 
Lysis buffer 
50 mM NaH2PO4; 300 mM NaCl;  
30 mM imidazole; 10% (v/v) glycerol 
7.4 
Extraction and 
purification of 
Affimer 
Wash buffer 
50 mM NaH2PO4; 500 mM NaCl;  
30 mM imidazole; 10% (v/v) glycerol 
7.4 
Elution buffer 
50 mM NaH2PO4; 500 mM NaCl;  
300 mM imidazole; 20% (v/v) glycerol 
7.4 
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2.1.5 Kits and consumables 
QIAGEN® Miniprep and plasmid Maxi kits were obtained from QIAGEN. NucleoSpin® 
Gel and PCR clean-up kit and 14 ml round-bottom polypropylene tubes were 
purchased from Macherey-Nagel and BD FalconTM, respectively. Millex®-GP filter 
unit (0.22 µm) and Mini-protein TGX precast protein gels (4-15% w/v, 12-well) for 
SDS-PAGE were purchased from Merck and Bio-rad laboratories, respectively. Nunc-
ImmunoTM MaxisorpTM 96-well solid plates and Eppendorf® protein LoBIND 
microcentrifuge tubes (1.5 ml) were purchased from Sigma-Aldrich. ZepaTM spin 
desalting columns (0.5 and 2 ml), small volume disposable cuvettes and 
NanoOrangeTM protein quantitation kit were purchased from ThermoFisher 
Scientific. Corning® 15 and 50 ml centrifuge tubes and Pur-A-LyzerTM Mini 6000 
dialysing units were purchased from Sigma.  
 
2.1.6 Growth media for bacteria and antibiotics 
Carbenicillin disodium salt and kanamycin were obtained from Alfa Aesar in powder 
form and the stock solutions were prepared in sterile deionised water at 50 mg/ml 
and 25 mg/ml, respectively. Tryptone and agar were obtained from Sigma-Aldrich, 
whilst glucose and yeast extract were purchased from BDH laboratories and Oxoid 
respectively. All media used in this project are summarised in Table 2-3. 
Table 2-3 Summary of all growth media for bacteria used in this project 
Media Ingredients 
Luria-Bertani (LB) 
Per 1 L: 
10 g tryptone; 5 g yeast extract; 10 g NaCI 
LB agar plate 
Per 1 L: 
LB media + 15 g agar  
2TY 
Per 1 L: 
16 g tryptone; 10 g yeast extract; 5 g NaCl 
Super optimum broth 
(SOB) 
Per 1 L: 
20 g tryptone; 5 g yeast extract; 0.5 g NaCl;  
10 ml of each 1 M MgCl2 and MgSO4  
SOB with catabolite 
repression (SOC) 
Per 100 ml: 
2 ml of 20% (w/v) glucose + 98 ml of SOB media 
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2.1.7 Phage display and phage ELISA related materials 
Nunc-ImmunoTM MaxisorpTM strips, streptavidin coated (HBC) 8 –well strips, deep 
well 96 plate, KingFisher (200 µl) 96 plate, Neutravidin coated (HBC) 8-well strips 
were purchased from Thermo Scientific. Streptavidin beads (Dynabeads® MyOne™ 
Streptavidin T1, 10 mg/ml) were purchase from Invitrogen. Triethylamine and 
glycerol were purchased from Sigma-Aldrich. Anti-Fd-bacteriophage-HRP was 
obtained from Seramun Diagnostica GmbH. Tetracylcine hydrochloride (1000x stock: 
12 mg/ml in 70% (v/v) ethanol), ER2738 E.coli cells, M13K07 helper phage (titre ca. 
1014/ml) and PEG-NaCl precipitation solution (20% (w/v) PEG 8000, 2.5 M NaCl) were 
prepared in the laboratory.  
 
2.1.8 Subcloning Affimer DNA related materials 
pET11a vector was provided by the BSTG. NotI-HFTM (20,000 units/ml), NheI-HFTM 
(20,000 units/ml), CutSmartTM buffer, 10X Antarctic phosphatase reaction buffer, 
Antarctic phosphatase (5,000 units/ml), DpnI, T4 DNA ligase (400,000 units/ml), 10X 
T4 DNA ligase reaction buffer and 6X orange G loading dye were purchased from 
New England Biolab® Inc. Phusion high-fidelity DNA polymerase containing phusion 
DNA polymerase (2 units/µl), 5X phusion HF buffer and DMSO were purchased from 
Thermo Scienctific. dNTPs mix 25 mM was obtained from MB Biomedicals. XL1 blue 
supercompetent cells and agarose were obtained from Agilent technologies and 
Melford Laboratories Ltd, respectively. PCR primers; forward primer (Affimer short 
5’ – ATGGCTAGCGGTAACGAAAACTCCCTG) and reverse primer (pDHis-C-rev 5’ – 
TTACTAATGCGGCCGCACAAGCGTCACCAACCGGTTTG) were purchased from Sigma. 
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2.1.9 Expression and purification of Affimer related materials 
BL21-Gold(DE3) competent cells  and isopropyl β-D-1-thiogalactopyronoside (IPTG) 
were obtained from Agilent technologies and Promega, respectively. Pierce 
disposable column 2 ml and Halt protease inhibitor cocktail (100X) were purchased 
from Thermo Scientific. Bugbuster® 10X protein extraction reagent and Benzonase® 
nuclease, purity >99% were purchased from Novagen®. Amintra nickel-
nitrilotriacetic acid (Ni2+-NTA) resin was obtained from Expedeon. Lysis, wash and 
elution buffers were prepared in the laboratory using the ingredients summarised in 
Table 2-2. 
 
2.1.10 Gold nanoparticles (AuNPs) 
Streptavidin coated AuNPs (strep-AuNPs) with core diameter of 20 and 40 nm were 
purchased from BBITM Solutions; whilst strep-AuNPs with core diameter of 60, 80 
and 100 nm were obtained from Cytodiagnostics Inc. 
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2.2 Methods 
2.2.1 Affimer production 
2.2.1.1 Phage display 
Biotinylation of target molecule; myoglobin (Mb) was biotinylated using biotin N-
hydroxysuccinimide (NHS). First, Mb was dissolved in 1X PBS buffer (pH 7.4) at a 
concentration of 1 mg/ml, whereas biotin NHS was dissolved in DMSO (5 mg/ml). 
Next, 10 µl of 1 mg/ml Mb solution was added to 0.8 µl of biotin NHS and the total 
volume was adjusted to 100 µl using the PBS buffer. The mixture was incubated for 
1 h at RT. Free biotin was removed by using a Zeba Spin Desalting Columns (7K 
MWCO). Then, 100 µl of 80% (v/v) glycerol was added to the mixture. The solution 
was stored at -20 ˚C.  
ELISA was performed to check the success of biotinylation. Nunc-ImmunoTM 
MaxiSorpTM strip was used for the ELISA. First, 50 µl of 1X PBS buffer (pH 7.4) were 
added to each well of the strip (four wells). The volumes of 1, 0.1 and 0.01 µl of 
biotinylated target were added to first three wells. After the strip was incubated 
overnight at 4 ˚C, 300 µl of 1X PBS (pH 7.4) + 0.1% (v/v) Tween-20 (PBS-T) were used 
to wash each well three times. Then, each well was blocked with 250 µl of 10x 
blocking buffer and incubated 3 h at 37 ˚C. PBS-T was used to wash three times 
before 50 µl of diluted high sensitivity streptavidin-HRP (1:1000 in 2x blocking buffer) 
were added to each well. The strip was incubated on a vibrating platform shaker for 
1 h at RT and washed with PBS-T six times using the plate washer. Next, 50 µl of 
3,3’,5,5’-tetramethylbenzidine (TMB) substrate (SeramunBlau®) were aliquoted per 
well and colour allowed to develop for 3 min before measuring the absorbance at 
620 nm. 
Phage display screening; four panning rounds of phage display were performed in 
this experiment. For the first panning round, biotinylated Mb was bound to 
streptavidin-coated well for 2 h in the panning well, and then 5 µl of pre-panned 
phage library was added. The mixture was incubated for 2 h at RT on a vibrating 
platform shaker. After that, the panning well was washed 27 times with 300 µl of 
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PBS-T using a plate washer and eluted with 100 µl of 0.2 M glycine (pH 2.2) for 10 
min. Then, neutralisation was performed by adding 15 µl of 1 M Tris-HCl (pH 9.1). 
The eluted phage was transferred immediately to an 8 ml aliquot of the ER2738 cells 
in a 50 ml Falcon tube. Second elution was performed by adding 100 µl of the diluted 
triethlyamine (14 µl of triethylamine in 986 µl of 1X PBS) and incubated for 6 min at 
RT. The neutralisation was done by adding 50 µl of 1 M Tris-HCl (pH 7). The second 
eluted phage was transferred immediately to the ER2748 cells tube. The tube filled 
with ER2738 cells and eluted phage was incubated for 1 h at 37 ˚C without shaking 
and then plated onto LB agar plate with 100 µg/ml carbenicillin (LB carb plate) and 
grown overnight (1 µl of the phage-infected ER2738 cells was plated separately, to 
determine roughly the total number of cells per 8 ml). Colonies were scraped into 5 
ml of 2TY media containing 100 µg/ml carbenicillin and transferred to a 50 ml falcon 
tube. A further 2 ml of the 2TY media was added to scrape off any remaining cells. 
The cells were diluted to an 8 ml culture to obtain the absorbance at 600 nm around 
0.2. The diluted cells were incubated for 1 h at 37 ˚C at 230 rpm. Then, they were 
infected with 0.32 µl of M13K07 helper phage and incubated for 30 min at 37 ˚C at 
90 rpm. Following this, 16 µl of kanamycin (25 mg/ml) was added. The mixture was 
incubated overnight in an orbital incubator at 25 ˚C at 170 rpm. Next, the phage-
infected cultures were centrifuged at 3500 xg for 10 min and the phage-containing 
supernatant was transferred to a fresh tube. Then, 2 ml of PEG-NaCl precipitation 
solution (20% (w/v) PEG 8000, 2.5 M NaCl) was added to the supernatant and the 
mixture was incubated overnight. The phage was centrifuged at 4,800 xg for 30 min 
to pellet the phage. This time the supernatant was removed and the pellet was 
resuspended with 320 µl of buffer containing 10 mM Tris and 1 mM EDTA (TE buffer 
– pH 8) and transferred to a microcentrifuge tube to be centrifuged at 16,000 xg for 
10 min. The phage-containing supernatant was recovered and stored at 4 ˚C. 
For the second panning round of selection, streptavidin magnetic beads were used 
instead of the plate. Biotinylated Mb 15 µl was added to 200 µl of 2x blocking buffer 
with 50 µl of the pre-blocked streptavidin beads and incubated for 1 h on a rotator. 
Meanwhile, 125 µl aliquot of phage suspension from the first panning round was 
pre-panned by using pre-blocked streptavidin beads. Following this, the suspension 
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containing biotinylated Mb and the pre-panned phage suspension were centrifuged 
at 800 xg for 1 min and both tubes were placed on a magnet. The beads containing 
biotinylated Mb were washed three times with 500 µl of 2x blocking buffer and 
added to the supernatant containing the pre-panned phage. The beads were 
resuspended and transferred to the pre-blocked 96-deep-well plate. The plate was 
then put in the KingFisher Flex machine, which was set to run 
“Phage_display_pH_elution” protocol (Appendix 1). Similar to the first panning 
round, the bound phages were eluted and amplified in the same conditions.   
For the third and fourth panning rounds, the method was exactly the same as the 
first panning round but using Neutravidin high binding capacity (HBC) and 
streptavidin coated plates instead, respectively. Also, 200 µl of phage-containing 
supernatant from the second and third panning rounds were used in the pre-panning 
steps, correspondingly.  In the final panning round, the negative control with no Mb 
was also performed. Both panning and negative wells were washed three times with 
PBS-T, added with 100 µl of phage from the pre-pan well and incubated for 30 – 45 
min at RT on a vibrating platform. After that, both wells were washed 27 times with 
300 µl of PBS-T using a plate washer. The phage were eluted and amplified as 
mentioned above in the first panning round. But, this time the phage were plated 
with a range of volumes (0.1, 1, 10 and 100 µl) onto LB carb plates. For the negative 
controls, only 10 µl was plated in order to compare the result. 
 
2.2.1.2 Phage ELISA 
First, 48 individual ER2738 colonies from last panning round of phage display were 
picked and grown overnight in 200 µl 2TY media with 100 µg/ml carbenicillin in a 96-
well V-bottom deep well plate at 37 ˚C with shaking 1050 rpm. A 25 µl of the 
overnight culture was transferred to new plate containing 200 µl of the 2TY and 
grown at 37 ˚C for 1 h at 1050 rpm in the incubating microplate shaker. After this, 10 
µl of diluted M13K07 helper phage (titre ca. 1014/ml) (1/1000) was added per well to 
a freshly grown culture using a multichannel pipette and incubated for 30 min at RT 
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in an incubating microplate shaker at 450 rpm. Following this, 10 µl of 1/20 diluted 
kanamycin stock (25 mg/ml) was added per well to the phage-infected cultures and 
incubated overnight at RT in the shaker at 750 rpm. Next, the phage infected-culture 
were centrifuged at 3500 xg for 10 min. The supernatant containing the phage was 
transferred to the ELISA plate to test for the binding to Mb. 
A 50 µl aliquot of 5 mg/ml streptavidin was added into each well of a Nunc-
ImmunoTM MaxisorpTM 96-well plate and incubated overnight at 4 ˚ C. After that, each 
well was blocked with 200 µl of 2x blocking buffer and incubated overnight at 37 ˚C. 
The plate was washed three times with 300 µl per well of PBS-T on a plate washer. 
Then, 50 µl per well of diluted biotinylated Mb (1/1000) were added into the first six 
columns of the streptavidin-coated 96-well plate. For the last six columns, 50 µl per 
well of 2x blocking buffer were added as negative control wells. The plate was 
incubated for 1 h at RT on a vibrating platform shaker. After that, it was washed three 
times with 300 µl per well of PBS-T and added with 10 µl per well of 10x blocking 
buffer. A 40 µl per well of phage-containing supernatant was added, each one was 
tested against the target and a negative control well (e.g. binder A1 was added to 
wells A1 and A7), and incubated for 1 h at RT on the shaker. The plate was washed 
six times with 300 µl per well of PBS-T before 50 µl per well of diluted anti-Fd-
bacteriophage-HRP (1/1000) were added, incubated for 1 h at RT and washed ten 
times with PBS-T. Following washing, phage were visualised using TMB substrates 
with 3 min reaction time and the absorbance at 620 nm was measured. 
 
2.2.1.3 DNA sequencing 
Positive wells from the phage ELISA were selected for sequencing. 10 µl of the 
overnight culture plate from phage ELISA was grown in 3 ml of 2TY with 100 µg/ml 
of carbenicillin in the round bottom tube per well at 37 ºC with 230 rpm in a shaking 
incubator. A QIAGEN® miniprep kit was used according to the instructions provided 
to extract the phagemid DNA. DNA concentrations were determined by measuring 
absorbance at 260 nm using a Nanodrop spectrometer. Then, 15 µl of each selected 
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phagemid DNAs were sent out to Beckman Coulter Genomics for sequencing at a 
DNA concentration < 100 ng/µl. 
 
2.2.1.4 Subcloning Affimer DNA 
Digestion of pET11a vector: initially, transformation of pET11a vector was carried out 
into XL-1 supercompetent cells. The competent cells were slowly thawed on ice; 
whilst 1 µl of pET11a DNA was aliquoted into a 1.5 ml low protein binding Eppendorf 
tube and pre-chilled on ice. Then, 10 µl of the competent cells were added to the 
pre-chilled DNA and incubated on ice for 30 min. The cells were heat shocked in a 42 
ºC water bath for 45 s before incubating on ice again for 2 min. Next, 180 µl of SOC 
media was added to the cells and incubated for 1 h at 37 ºC with shaking at 230 rpm. 
The cells (100 µl) were then spread onto a LB carb plate and grown overnight at 37 
ºC. The vector was then multiplied using a QIAGEN® plasmid Maxi kit by following 
the instructions for low-copy plasmids and vector DNA was eluted in 400 µl sterile 
deionised water. The concentration of digested vector DNA was measured using a 
Nanodrop spectrometer at 260 nm. 
Next, 5 µg of pET11a plasmid was digested with NheI and NotI restriction enzymes 
overnight at 37 ºC. The following day, Antarctic phosphatase enzyme was added and 
incubated for 15 min at 37 ºC. After that, it was inactivated by heating at 65 ºC for 5 
min. Then, 20 µl of 6X orange G loading dye was added and the digested vector was 
separated on a 0.7% (w/v) agarose gel. The gel was run in 1X TAE buffer at 100 V for 
1 h. The digested vector was extracted from the gel using a NucleoSpin gel and PCR 
clean-up kit according to the manufacturer’s instructions and eluted in 50 µl of sterile 
deionised water. The concentration of digested vector DNA was measured using a 
Nanodrop spectrometer and stored at -20 ºC until ready for ligation process. 
PCR amplification of the Affimer DNA sequences from the phagemid vector: the 
sequences of forward and reverse primers were provided by the BSTG. The C-
terminal cysteine was added in this step by using the pDHis-C-rev reverse primer. A 
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25 µl PCR reaction was set up in a 0.2 ml PCR tube according to the following formula 
provided in Table 2-4.  
Table 2-4 Summary of PCR 25 µl reaction set up for Affimer DNA amplification 
Component 25 µl Reaction Final Concentration 
Sterile deionised water 13.8 µl  
5X Phusion HF buffer 5 µl 1X 
dNTPs mix, 25 mM 0.2 µl 200 µM each 
DMSO 0.75 µl 3% 
Forward primer, 10 µM 2 µl 0.8 µM 
Reverse primer, 10 µM 2 µl 0.8 µM 
Phusion DNA polymerase 0.25 µl 0.02 units/µl 
Template DNA (phagemid vector) 1 µl  
 
The PCR tube was transferred to a PCR machine thermocycled under conditions 
shown in Table 2-5. After that, the PCR product was cleaned up by using a NucleoSpin 
gel and PCR clean-up kit according to the manufacturer’s instructions and eluted in 
50 µl of sterile deionised water. Then, 50 µl of PCR product was digested with NheI 
and NotI restriction enzymes by incubating at 37 ºC overnight. Finally, 0.5 µl of DpnI 
enzyme was added to remove methylated template DNA. Again, the product was 
purified using a NucleoSpin gel and PCR clean-up kit similar to previously performed. 
The concentration was measured using a Nanodrop spectrometer. 
 
Table 2-5 Thermocycling conditions used for Affimer DNA amplification via PCR 
Cycle Step Temperature Time Cycles 
Initial denaturation 98°C 30 seconds 1 
Denaturation 
Annealing 
Extension 
98°C 
54°C 
72°C 
20 seconds 
20 seconds 
20 seconds 
 
30 
Final Extension 
Hold 
72°C 
4°C 
10 minutes 
Hold 
1 
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Ligation of the NheI-NotI digested insert into the pET11a vector: ligation was carried 
out by mixing 40 ng of digested pET11a vector with 10 ng of insert DNA with the 
presence of DNA ligase (0.5 µl of T4 DNA ligase + 0.5 µl of 10X T4 DNA ligase buffer 
+ sterile deionised water to make a total volume of 5 µl). The mixed solution was 
incubated overnight at RT. The negative control was also set up using the pET11a 
vector only. The ligation mix was transformed into XL-1 supercompetent cells by heat 
shock method as described earlier. The negative control plate should show no 
colonies. 
Colonies from ligation mix plate were picked and grown in 3 ml of LB media 
containing carbenicillin (100 µg/ml) overnight at 37 ºC with shaking 230 rpm. The 
plasmid DNA was extracted using a QIAGEN® miniprep kit according to the 
manufacturer’s instruction but eluted in 50 µl sterile deionised water and sent out 
for sequencing to confirm the success of the subcloning process. 
 
2.2.1.5 Expression of Affimer 
Expression of Affimers was performed using the isopropyl β-D-1-
thiogalactopyronoside (IPTG) induced expression method. First, the Affimer-pET11a 
plasmid was transformed into BL21-Gold (DE3) competent cells by using a heat shock 
protocol previously described in section 2.2.1.4. The start-up culture was prepared 
the following day by selecting and growing colonies overnight in 2 ml of 2TY 
containing carbenicillin (100 µg/ml) and 1% (w/v) glucose at 37 ºC with shaking 230 
rpm. Meanwhile, 50 ml of LB media was placed at 37 ºC in a 250 ml flask overnight 
to warm the media. Next day, 100 µl of 50 mg/ml carbenicillin was added to the pre-
warmed media, following by 625 µl of the overnight culture. The culture was grown 
until its optical density (OD) at 600 nm reached around 0.8 before adding IPTG to a 
final concentration of 0.1 mM. Then, the culture was incubated for an additional 18 
h at 25 ºC with shaking 150 rpm. The cells were harvested by centrifugation at 3,220 
xg for 30 min using an Eppendorf centrifuge, model 5810R. The supernatant was 
removed and the cell pellet was stored at -20 ºC until ready for purification. 
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2.2.1.6 Extraction and purification of Affimer 
First, the cell pellet was thawed and resuspended in 1 ml of lysis buffer 
supplemented with Bugbuster® protein extraction reagent, Benzonase® nuclease 
and protease inhibitor cocktail (Table 2-6). The solution was transferred to a 2 ml 
microcentrifuge tube and incubated for 20 min on a rotator at RT. Next, the pellet 
was incubated at 50 ºC in a water bath for 20 min to denature non-specific proteins 
(this step was optional for some Affimers). The solution was then centrifuged at 
16,000 xg for 20 min to pellet the cell debris and insoluble proteins. Meanwhile, 300 
µl of Ni2+-nitrilotriacetic acid (Ni2+-NTA) resin was resuspended in 1 ml lysis buffer in 
a 2 ml tube and washed one time by centrifugation at 1,000 xg for 1 min to sediment 
the resin and the buffer was carefully removed using a pipette. 
 
Table 2-6 Showing the volume of supplement reagents in lysis buffer used for 
Affimer extraction 
Reagents 
Volume for 
50 ml culture cell pellet 
Bugbuster® 10X protein extraction reagent 100 l (1X) 
Benzonase® nuclease, purity > 99% (25 U/l) 0.4 l (10 U/ml) 
Halt protease inhibitor cocktail (100X) 10 l (1X) 
Lysis buffer to a total volume of 1 ml 
 
The supernatant above the cell pellet containing soluble proteins was transferred to 
the washed resin and incubated for 2 h on a rotator at RT. After incubation, the 
mixed solution was centrifuged at 1,000 xg for 1 min to sediment the Affimer-bound 
resin. The supernatant was transferred to a fresh tube and kept at -20 ºC to check 
whether there were unbound Affimers left or not. A Pierce disposable 2 ml column 
was used to facilitate the purification. The Affimer-bound resin was resuspended in 
1 ml wash buffer and moved to the equilibrated column. The resin was washed with 
wash buffer several times until the absorbance at 280 nm of the wash buffer was 
consistently lower than 0.09. The Affimers were eluted with 500 µl of elution buffer. 
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The concentration of Affimers were determined using a Nanodrop spectrometer and 
biotinylation was performed immediately.  
  
2.2.1.7 Biotinylation of Affimer 
Affimers were biotinylated via maleimide coupling chemistry to the thiol group (-SH) 
of theirs C-terminal cysteine. Before starting the biotinylation process, immobilized 
TCEP reducing gel was used to reduce Affimer disulphide bonds to make sure that all 
-SH were available for labelling. First, 150 µl of TCEP gel was washed with PBS 
containing 1 mM EDTA three times. Then, 4 µl of PBS containing 50 mM EDTA, 
followed by adding of 150 µl of 0.5 mg/ml Affimer. The mixture was incubated for 1 
h at RT on a rotator (20 rpm) to keep the gel in suspension. After that, the mixture 
was centrifuged (1,000 xg, 1 min) and the supernatant containing the reduced 
Affimer was recovered.  
For biotin labelling, 5 mg biotin maleimide was dissolved in 1 ml of DMSO. Then, a 6 
µl aliquot was immediately added to the reduced Affimer. This was incubated at RT 
for 2 h. After that the free biotin maleimide was removed by using a Zepa spin 
desalting column (7K MWCO). The biotinylation was confirmed by ELISA (described 
in 2.2.1.1) and the samples were sent out to the Mass Spectrometry Facility (Faculty 
of Biological Science, University of Leeds) to confirm the success of biotinylation.   
 
2.2.2 Characterisation of Affimers 
2.2.2.1 Immunoprecipitation (pull-down assay) 
All selected anti-Mb Affimers and Mb were dialysed in 1X PBS (pH 7.4) prior to the 
pull-down assay. First, 40 µl of Ni2+-NTA resin was washed three times with wash 
buffer by centrifugation and resuspended in 40 µl wash buffer. Then, 200 µg of 
Affimer was added to the washed resin and incubated at 4 ºC on a rotator for 90 min. 
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Next, the Affimer-loaded resin was centrifuged at 1,000 xg to remove unbound 
Affimers, following by a single wash with wash buffer. The same amount of Mb was 
added to the loaded resin and incubated overnight at 4 ºC on a rotator. After that, 
the unbound Mb was removed by centrifugation at 1,000 xg, following by three 
washes with 1 ml wash buffer. After the final wash, the resin was resuspended in 60 
µl of wash buffer and ready for confirmation. An SDS-PAGE gel was run with all 
fractions collected from the pull-down assay, which were unbound Affimer, washed 
Affimer, unbound Mb, all three washes to remove free Mb and the lysate.  
First, 10 µl of each fraction was mixed with 10 µl of reducing dye and boiled at 95 ºC 
for 5 min. Then, the mixed solutions were centrifuged at 16,000 xg for 5 min to 
sediment the resin. After that, 10 µl of the supernatants were loaded into the precast 
gel (4-15% (w/v)) along with 5 µl of protein ladder. The gel was run at 100V for 75 
min with 1X Tris-glycine running buffer and developed with quick Coomassie stain 
dye for 1 h at RT. 
 
2.2.2.2 Direct ELISA 
First, Neutravidin-coated 96-well plate was prepared from Neutravidin in lyophilized 
form. The Neutravidin stock of 1 mg/ml was prepared using 100 mM PBS (store at -
20 ºC). Neutravidin at a concentration of 5 µg/ml in 100 mM PBS was added (50 
µl/well) into a Nunc-ImmunoTM MaxisorpTM 96-well plate. The plates were incubated 
overnight at 4 ºC before used. The plate was blocked with 200 µl of 2x blocking buffer 
per well, overnight at 37 ºC. The plate was then washed one time with PBS-T. 
Biotinylated Mb 1 mg/ml (prepared as mentioned in section 2.2.1.1) was diluted 
1:1000 in 2x blocking buffer and aliquoted 50 µl per well and incubated at RT for 1 h 
on a plate shaker (400 rpm). Then, the plates were washed three times with PBS-T. 
Next, 10 µl of 10x blocking buffer was added into each well together with 40 µl of 0 
– 100 µg/ml Affimers. Incubation was carried out at RT for 1 h on a shaking platform 
at 400 rpm. After three washing steps with PBS-T, 50 µl of anti-His6-HRP (1:1000) in 
2x blocking buffer were added as a secondary antibody and incubated at RT for 1 h 
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on a plate shaker (400 rpm). The washing was performed six times with PBS-T and 
TMB substrate was added 50 µl per well and colour allowed to develop for 5 min 
before measuring absorbance at 620 nm.   
 
2.2.2.3 Surface plasmon resonance (SPR) 
All Affimers were dialysed in filtered sterile 1X PBS containing 0.01% (v/v) Tween-20 
(pH 7.4) before characterised with SPR. 
Calibration free concentration analysis (CFCA): CFCA was carried out to quantify the 
active concentration of Affimers by using anti-His6 Ab immobilised onto a 
carboxymethylated dextran (CM5) chip. The immobilisation was performed via 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide (EDC/NHS) 
linking of the functional group –COOH of the chip surface to the amine groups of the 
Ab. After this, ethanolamine was added to block the free –COOH groups on the 
surface. Next, an estimated 1 mg/ml of Affimer was diluted 1/5000 and injected to 
the flow cell with two different rates, 5 µl/min and 100 µl/min. The response was 
plotted against time and linear fitting was carried out. The concentration of Affimer 
could be calculated based on the diffusion coefficient and the differences in binding 
rates when injected at different rates. 
Kinetics study: once the active concentration of Affimers was obtained, a 
streptavidin chip was used in kinetics analysis. Biotinylated Mb was first immobilised 
to the chip surface only on flow cell 2 and acted as the ‘receptor’; whilst flow cell 1 
was used as a non-specific control cell (no Mb present). Next, Affimers (0 – 1000 nM) 
were flowed over both cells and acted as the ‘ligand’. Regeneration was 
implemented between each concentration of the Affimer using 10 mM glycine, pH 3 
as regeneration buffer. Here, buffer only was used in the experiment as well to 
eliminate a non-specific binding on Mb immobilised surface. The sensorgram 
between response units and time was plotted using adjusted values by subtracting 
 99 
 
both non-specific binding values obtained. The data were analysed using GraphPad 
Prism 7. 
 
2.2.2.4 Affimer pair selection 
To find a binding pair, five selected anti-Mb Affimers were screened by using a 
modified sandwich ELISA method. First, 50 µg/ml of Affimer was immobilised on a 
Nunc-ImmunoTM MaxisorpTM 96-well plate 50 µl per well and incubated for 16 h at 4 
ºC. Wells were blocked with 250 µl of 10x blocking buffer for 3 h at 37 ºC. Then, wells 
were washed with 200 µl of PBS-T three times and 50 µl of 50 µg/ml Mb was added 
per well and incubated 4 h on a plate shaker (400 rpm) at RT. After this the wells 
were washed six times with 200 µl of PBS-T to remove unbound Mb. The five selected 
biotinylated Affimers in 2x blocking buffer were added to the wells and left to 
incubate for 2 h on a shaking platform at RT, following by a ten washing steps with 
200 µl of PBS-T. Biotinylated anti-Mb Ab and 1X PBS were used as positive and 
negative control, respectively. Finally, 1:1000 of streptavidin-HRP in 2x blocking 
buffer was added to the wells as a secondary antibody to detect biotinylated Affimer. 
The incubation was carried out for 1 h at RT on a shaker. Finally, the washing was 
performed ten times with PBS-T and TMB substrate was added 50 µl per well and 
allowed to develop for 25 min before measuring absorbance at 620 nm.   
 
2.2.3 Preparation of nanobiosensors 
2.2.3.1 Biotinylation of bioreceptors 
Biotin maleimide was used to biotinylate Affimers as described in section 2.2.1.7; 
whilst anti-Mb IgGs were biotinylated using biotin hydrazide via the carbohydrate on 
the Fc region. First, 1 ml of 4.2 mg/ml sodium periodate was mixed with 2 mg/ml 
anti-Mb IgG in Glycolink coupling buffer and incubated for 30 min at RT protected 
from light. The excess sodium periodate was removed from the solution using a Zepa 
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spin desalting column (7K MWCO). Next, 200 µl of 5 mM biotin hydrazide was added 
to 1.8 ml of the oxidized and purified solution. After this, 18 µl of aniline was added 
to the mixture under a fume hood and incubated for 1 h at RT. Lastly, a new Zepa 
spin desalting column (7K MWCO) was used to remove the excess biotin hydrazide 
and aniline. The success of biotinylatation for both IgGs and Affimers were confirmed 
by ELISA (see section 2.2.1.1). In addition, biotinylated Affimers were sent out for 
mass spectrometry at a concentration of 10 µM.  
 
2.2.3.2 Streptavidin-biotin coupling 
To functionalise gold nanoparticles (AuNPs) via streptavidin-biotin coupling, 25 µg of 
biotinylated bioreceptors were added to 1 ml of 40 nm core diameter streptavidin 
coated AuNPs (strep-AuNPs) (Optical density (OD) at 529 nm = 1) in a total volume 
of 1.5 ml. In terms of AuNPs, OD is often used as it is directly proportional to the 
concentration and is always given at the wavelength that shows peak absorbance. 
The ODs of 20, 40, 60, 80 and 100 nm core diameter streptavidin coated AuNPs were 
measured at 520, 529, 540, 553 and 572 nm, respectively. 
Next, the mixed solutions were incubated for 2 h at RT on a rotator protected from 
light. After this, the mixture was centrifuged to remove unreacted biotinylated 
proteins. Table 2-7 shows the appropriate g forces used for different core diameter 
AuNPs. Following this, washing step was carried out by centrifugation, removal of 
supernatant and resuspending the AuNPs in PBS buffer. This step was repeated twice 
before the AuNPs were resuspended in 1 ml of the PBS buffer. The nanobiosensors 
were kept in a container protected from light at 4 ºC. 
Table 2-7 Appropriate g forces used for AuNPs with different core diameter 
Core diameter of AuNPs (nm) Speed (g) Time (min) 
20 6,500 30 
40 4,500 30 
60 1,200 30 
80 600 30 
100 400 30 
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2.2.4 Characterisation of nanobiosensors 
2.2.4.1 Dot blotting 
A 3 x 2 cm piece of nitrocellulose membrane was divided into two different areas for 
negative control and experiment. For both anti-Mb IgG and Affimers, strep-AuNPs 
was used as negative control. First, 6 µl of each sample was spotted onto the 
membranes (by applying 2 µl at a time, air-drying for 15 min and repeated again). 
The membranes were then blocked with a 3 ml blocking buffer comprising 5% (w/v) 
BSA in PBS-T for 1 h on a plate shaker to prevent non-specific binding. After that, the 
membranes were washed once with PBS-T and incubated with primary antibodies 
specific for each bioreceptor. For anti-Mb IgG, goat anti-rabbit HRP-conjugated IgG 
was used; while anti-His6-HRP conjugated IgG was used for Affimer detection. Both 
secondary reagents were used at 1:1000 dilution in PBS-T. The incubation was 
performed for 1 h at RT on a shaker. Then, the membranes were washed by 
incubating in 5 ml of PBS-T for 5 min and this process was repeated two times. For 
the last washing step, PBS buffer was used instead of PBS-T as Tween-20 could 
interfere with the enhanced chemiluminescence (ECL) substrate. In the final step, 
ECL was applied for signal generation. 
 
2.2.4.2 UV-spectrophotometry  
The prepared anti-Mb IgG and Affimer conjugated AuNPs were diluted 1:1 with 1X 
PBS buffer (pH 7.4) then transferred to a 96-well plate (200 µl) and scanned across 
the wavelength of 400 – 700 nm to obtain their UV spectra using a FLUOstar Omega 
plate reader.  
 
2.2.4.3 Dynamic light scattering (DLS) 
The DLS measurement on all sample solutions were made using a Zetasizer Nano 
series, Nano-ZS DLS system (Malvern Instruments Ltd). The instrument was equipped 
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with a red (633 nm) laser. The data were analysed using DTS Applications 5.10 
software. For each sample, 10 measurement runs with 10 s/run were performed and 
the average value was reported. All measurements were performed at RT and a small 
volume disposable cuvette was used. For characterisation of functionalised AuNPs, 
100 µl of each nanobiosensor was used in the measurement. 
 
2.2.4.4 Quantification of bioreceptors on AuNP surface 
First, 50 µg of anti-Mb IgG and Affimer were coupled to 2 ml of AuNPs with 40 nm 
core diameter (OD529 = 1) and incubated for 2 h at RT on a rotator. Following this, 
the mixtures were centrifuged at 4,500 xg for 30 min and the supernatants were 
transferred to low protein binding tubes for the indirect quantification method, 
whilst, the prepared AuNPs were used in the direct method. Then, multiple washing 
steps were carried out as previously described in section 2.2.3.2 and finally the 
functionalised AuNPs were resuspended in 2 ml of 1X PBS buffer (pH 7.4).  
Indirect method: the Bradford assay was used to quantify the amount of biotinylated 
IgG and Affimer left in the supernatant after functionalisation. Standard solutions of 
IgG and Affimer (0 – 25 µg) were prepared in 1X PBS buffer (pH 7.4) to a final volume 
of 50 µl. The supernatants obtained from the preparation of anti-Mb IgG- and 
Affimer conjugated AuNPs (IgG-AuNPs and Affimer-AuNPs) were concentrated to 
500 µl using Amicon 50K and 3K filters, respectively and 50 µl of the concentrated 
samples were used for quantification.  
Next, 50 µl of standard and sample solution was mixed with 450 µl of Bradford dye 
reagent in 1.5 ml low protein binding tubes and incubated at RT for 5 min. Then, 200 
µl of each solution was transferred to a 96-well plate, the absorbance was measured 
at 595 nm with a ThermoScientific Varioskan Flash 6.45 plate reader. The absorbance 
values of the standards and samples were subtracted from the value of reagent 
blank. The corrected values were used in generating calibration curves using 
OriginPro and linear fitting was performed. 
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Direct method: here, 1 ml of the prepared anti-Mb IgG- and Affimer-AuNPs were 
centrifuged at 4,500 xg for 30 min and the supernatants were transferred to fresh 
tubes. Both the sedimented AuNP pellets and supernatants were dissolved in 50 µl 
of KI/I2 solution containing 333 mM KI and 50 mM I2 for 15 min. After this, all 
dissolved AuNPs and supernatants were diluted to a 10 ml volume with 1X PBS buffer 
(pH 7.4) and sent for quantification of gold by inductively coupled plasma-mass 
spectrometry (ICP-MS). 
Another 1 ml of the IgG-AuNPs and Affimer-AuNPs were also centrifuged at 4,500 xg 
for 30 min. The supernatants were discarded; whilst the sedimented AuNP pellets 
were dissolved using KI/I2 solution as above. The dissolved AuNPs were desalted 
using a Zepa spin desalting column (7K MWCO) to remove KI/I2 that might interfere 
with a fluorescent dye (NanoOrange®). The released IgGs and Affimers were 
quantified using a NanoOrange® protein quantitation kit.  
Standard solutions of IgG and Affimer (0 – 2.5 µg) were prepared in 1X NanoOrange® 
reagent working solution from 10 µg/ml stock solutions. For sample analysis, 10 µl 
of each desalted solution was mixed with 240 µl of 1X NanoOrange® working 
solution. All standard and sample solutions were prepared in 500 µl tubes and 
incubated at 95 ºC in a water bath for 10 min. All processes were carried out 
protected from light. The samples were allowed to cool down at RT for 20 min before 
200 µl of each solution was transferred to a 96-well plate for fluorescence intensity 
measurement as in the indirect method. The measurement was carried out with 
excitation and emission wavelengths of 485 nm and 590 nm, respectively. The 
fluorescence values of the standards and samples were subtracted from the value of 
reagent blank. The corrected values were used in generating calibration curves using 
OriginPro and linear fitting was performed. 
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2.2.5 Nanoparticle (NP)-coupled dynamic light scattering (DLS) size 
shift assay 
All DLS measurement were performed as described in section 2.2.4.3. 
 
2.2.5.1 Kinetics study 
For kinetics study, four different functionalised AuNPs were used; myoglobin 
conjugated AuNPs (Mb-AuNPs), anti-myoglobin Affimer conjugated AuNPs (Affimer-
AuNPs), anti-myoglobin IgG conjugated AuNPs (IgG-AuNPs) and strep-AuNPs. The 
functionalised AuNPs were prepared using methods described in section 2.2.3.2. 
Then, 100 µl of Mb-AuNPs were mixed with 100 µl Affimer-AuNPs and incubated at 
RT for 24 h. The average hydrodynamic diameters (DH) were measured intermittently 
during this time. Positive and negative controls were performed by changing 
Affimer-AuNPs with IgG-AuNPs and strep-AuNPs, respectively. Triplicate 
experiments were carried out for each AuNP.  
 
2.2.5.2 NP-coupled DLS size shift assay for myoglobin and Clostidium difficile toxin 
B detections 
Mb stock solution with a concentration of 5 mg/ml was used to prepare Mb solutions 
at concentrations of 10 fM to 10 µM by serial dilution using 1X PBS buffer (pH 7.4). 
Initially, 10 µl of nanobiosensors was mixed thoroughly with 90 µl of each Mb 
solution and incubated for 30 min at RT in a low binding protein tube prior to the 
measurements. Then, 80 µl of the mixed solution was transferred to a small volume 
disposable cuvette for DLS measurements. For Clostridium difficile toxin B, similar 
process was carried out. 
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2.2.5.3 TEM 
TEM images were captured using a JEM1400 model eletron microscope (JEOL Ltd.). 
A beam voltage of 120 kV was used with a tungsten filament. Copper grids (3.05 mm 
diameter, 300 square meshes) coated with Formvar resin and carbon were used. For 
sample preparation, 5 µl of each solution was dropped onto a grid and left to dry at 
RT for at least 30 min. Excess sample was removed using filter paper.  
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Chapter 3 Affimer production and characterisation 
3.1 Introduction 
This chapter focuses on anti-myoglobin Affimer production and 
characterisation. Myoglobin (Mb) is a small globular protein with Mr 17 kDa (Figure 
3-1). Its presence in blood indicates muscle injury and renal failure can also be 
indicated by detection of Mb in renal excretion. Formerly, Mb was an important 
cardiac marker for acute myocardial infarction (MI), but has been superseded by 
cardiac troponin, which is now the gold standard marker. Despite Mb appearing 
rapidly after acute MI, it is not specific to cardiac muscle like troponin as it can be 
released after injury of any muscle. Mb from equine heart was selected as a model 
analyte because it is an inexpensive protein with good availability. In addition, there 
are a lot of information regarding myoglobin structure or properties reported, which 
benefits laboratory investigations. 
 
  
Affimers are synthetic binding proteins that replicate antibody function. 
Previous work by Tiede et al. (2014) successfully generated a high quality Affimer 
based library. The size of the library was 3x1010 clones and 86% complexity after 
phage production (see Chapter 1). Phage display was used to select specific Affimers 
for analytes of interest.   
Figure 3-1 Molecular structure of 
myoglobin. This figure was 
derived from PDB file: 1WLA 
 108 
 
3.2 Affimer production 
3.2.1 Phage display screening 
Phage display screening was performed to select anti-myoglobin Affimers 
from the library. Myoglobin was biotinylated via biotin NHS (see section 2.2.1.1) and 
used as a screening sample. ELISA was used to confirm the biotinylation process. 
Figure 3-2 shows that biotinylation of myoglobin was successful. Four panning 
rounds of screening were performed by immobilised biotinylated myoglobin onto a 
streptavidin plate, streptavidin magnetic beads, Neutravidin plate and streptavidin 
plate, respectively. After the final panning round, the phage and negative control, 
which were the phage underwent panning but without biotinylated Mb immobilised 
on the streptavidin plate, were plated and 48 clones were randomly selected for 
phage ELISA.                                                                                                                                                                                      
 
Figure 3-2 ELISA to validate biotinylation of myoglobin for phage display screening. 
(A), showing ELISA strip for three different dilutions of biotinylated myoglobin 1 
mg/ml (1, 1/10 and 1/100) and negative control (PBS buffer) from top to bottom; 
(B), showing the absorbance at 620 nm of each tested sample. 
 
 
 
 109 
 
3.2.2 Phage ELISA 
Phage ELISA was conducted to confirm the binding of 48 selected clones to 
myoglobin. Biotinylated myoglobin was immobilised onto a streptavidin coated 96-
well plate and then phage-containing supernatant was added to each well. Figure 3-
3 shows the ELISA plate. As mentioned in Chapter 2, phage-containing supernatant 
was tested against the target in the first six columns (1 - 6), whereas 2x blocking 
buffer was used as a negative control in another six columns (7 - 12). For example, 
binder A1 was added to wells A1 and A7, therefore, the results were compared in 
the same manner.  3,3’,5,5’-tetramethylbenzidine (TMB) substrate was used as 
detecting agent for HRP-conjugated anti-phage antibody by allowing 3 min reaction 
time. The absorbance at 620 nm for each well was measured and plotted as a 
histogram in Figure 3-4. It was observed that out of 48 clones, only 4 samples - E4, 
E5, F2 and G5 - showed no binding compared to their compared negative controls. 
Positive clones were designated by well number and sent for sequencing. 
  
Figure 3-3 Phage ELISA to show binding of myoglobin Affimer binders. This ELISA 
plates was performed using randomly selected 48 Affimer clones, after four panning 
rounds of phage display screening. In column 1 to 6, the clones were tested against 
immobilised myoglobin via streptavidin-biotin reaction. Whereas, 2x blocking buffer 
were used as corresponding negative control in column 6 to 12 (e.g. A1 was 
compared with A7). The binder in wells E4, E5, F2 and G5 show no positive binding 
to myoglobin compared with their relative controls. 
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Figure 3-4 Phage ELISA histogram for anti-myoglobin Affimers. The histogram shows the comparison of absorbance at 620 nm of the tested wells 
with their corresponding negative wells. The binder in E4, E5, F2 and G5 show no significant absorbance difference. 
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3.2.3 DNA sequencing 
DNA sequencing results for 44 binders is shown in Figure 3-5. To enable 
myoglobin-mediated inter-nanoparticle crosslinking, the nanoparticle size-shift 
assay requires at least two different binders that bind to different epitopes of the 
target in order to crosslink between the particles. Therefore, six binders were chosen 
based on the difference of binding loop sequences for this project.  
 
 
 
 
Figure 3-5 DNA sequencing results for anti-myoglobin Affimers. (A), showing Affimer 
scaffold sequence consisting of two insertion sites (9 amino acids in each site); (B), 
showing insertion sequences of each anti-Mb Affimer selected from a phage display 
library.   
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Table 3-1 shows six unique binders and their binding loop sequences (B5, C2, 
D1, E3, F5 and H1) from all 44 positive Affimer clones. Among all selected binders, 
the C2 sequence represents the majority; there were 36 clones with the same 
binding loops as C2, followed by D1 with four identical clones. The other binders are 
only present as one clone. 
 
Table 3-1 Affimer insert sequences for six unique anti-myoglobin Affimers. 
Name Insertion site 1 Insertion site 2 
B5 QVSEVFHWY AKWHINDEV 
C2 QEQYYKPWI HPKTAFAHA 
D1 VPGWWASWD EWLNMRKLE 
E3 WDETFNWYM NYNEYMHVK 
F5 KITPVFTPG LYEIFNHRH 
H1 YPFGHHFVW TVPRFTWLQ 
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3.2.4 Subcloning 
Selected coding sequence of phagemids containing anti-myoglobin Affimers 
were cloned into pET11a vector in order to increase their expression. According to 
the protocol optimized by the BSTG, PCR was used to amplify the DNA coding 
sequence. At this stage, a cysteine residue was inserted at the C-terminal region by 
incorporating the codon sequence in the reverse primer. PCR gel purification kit was 
used to purify the product prior to digestion with DpnI to get rid of the methylated 
template plasmid DNA according to the manufacturer’s protocol. Figure 3-6 shows 
the bands of the purified PCR product after the digestion of DpnI on 1% (w/v) agarose 
gel. The purified product’s size was around 300 base pairs, which corresponds to the 
theoretical size of Affimer clone. However, when using the concentrated DNA 
templates, the PCR products after the second clean-up show that there was some 
original template DNA left in the samples (Figure 3-6A). Compared to the 1/30 
dilution DNA templates in Figure 3-6B, the obtained PCR products were cleaner. 
Therefore, these suggested that the phagemid DNA templates should be diluted 
down to minimize the amount of original template DNA left in the purified product.  
 
Figure 3-6 Gel electrophoresis for anti-myoglobin Affimer inserts. The 1% (w/v) 
agarose gel shows the bands migrated at around 300 base pairs. (A), concentrated 
DNA templates were used and there were some original template fragment left 
(shown in red box area); (B), 1/30 dilution of DNA templates were used and much 
cleaner products were observed.  
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The purified PCR products were then digested with NHeI and NotI restriction 
enzymes and cloned into pET11a vector containing the Affimer scaffold similarly 
digested. The schematic of incorporating Affimers into pET11a vector is shown in 
Figure 3-7 and Figure 3-8 shows the map of pET11a vector used in the experiment. 
The vector was provided by the BSTG.  
 
 
 
 
 
 
 
Figure 3-7 Schematic of incorporating Affimers into pET11a vector. The vector and 
PCR amplified fragment containing anti-myoglobin Affimer coding sequence are cut 
with the same restriction enzymes. The ligation process is done using T7 ligase 
enzyme. 
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The linearised pET11a fragment was run on 1% (w/v) agarose gel, shown in 
Figure 3-9 and a gel extraction kit was used to extract the linear pET11a. Ligation was 
performed overnight by mixing the PCR and pET11a fragments together and then 
the mixture binder was transformed into XL-1 competent cells using the heat shock 
technique. The negative control was carried out by transformation of only pET11a 
fragment with no PCR products. Plasmid DNA of each binder was extracted from 
positive colonies by miniprep kit. Those DNAs were sent out for sequencing again to 
confirm the success of the subcloning process. The sequences are shown in Figure 3-
10. All plasmids with the right sequences were used for expression and purification.  
 
 
Figure 3-9 Gel electrophoresis for linearised pETT11a vector. The 1% (w/v) agarose 
gel showing the linearised pET11a vector migrated at a slower rate compared to 
uncut pET11a vector that moves much faster as it is in supercoiled form. 
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Figure 3-10 Subcloned DNA sequences of anti-myoglobin Affimer subclones. All six binders were subcloned successfully with the same insertion 
loops. Also, the cysteine residue was successfully added to each binder located close to the histidine tag region.
 
 Insertion       
Loop 1 
Insertion       
Loop 2 
Cysteine 
residue 
* 
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3.2.5 Expression and purification 
A protocol for expression of Affimers was established previously using an 
IPTG induction method by BSTG. The expression was based on the pET expression 
system for recombinant protein. Some optimization was carried out in order to 
increase the yield for each Affimer, after plasmid DNA containing anti-Mb Affimers 
were transformed into BL21-Gold (DE3) competent cells. Originally, single colonies 
from each binder were picked and a start-up culture was inoculated in 2 ml LB media 
+ 1% (w/v) glucose. However, it was found out that using 2TY media as a start-up 
culture instead could increase the yield by 0.5 - 1 mg/50 ml culture. Also, a final IPTG 
concentration of 0.1 mM with a longer incubation time (16 h) provided a better yield 
when compared with 0.5 mM incubated for 6 h was used. The optimisation was 
effective for three binders (B5, C2 and F5 with a yield of 3-4 mg/50 ml culture), 
whilst, the other binders’ yields were limited to around 0.1 mg/50 ml culture. 
Purification of Affimer was performed using Ni2+-NTA resin as the Affimer 
structure contained a His8 tag, after the 50 ml culture of transformed BL21-Gold 
(DE3) had been harvested. The cells were lysed using lysis buffer and heated at 50 
C for 20 min. The cell lysates were subsequently centrifuged to remove insoluble 
protein. Only the soluble fraction was transferred to the tubes containing the Ni2+-
NTA resin and incubated for 2 h. After that, the mixture was applied to the 
equilibrated column and the flow-through fractions were collected (section 2.2.1.6). 
The resins were centrifuged and supernatants were kept to check if there were 
Affimers left. The bound-resin was washed with wash buffer to eliminate unbound 
proteins before the elution buffer containing 300 mM imidazole was added. Then, 
4-15% (w/v) gradient SDS-PAGE gels were used to confirm the expression of Affimer 
(Figure 3-11). All six elutions of each binder were run on the gels alongside with the 
lysate, insoluble and soluble fractions, as well as the supernatants from the bound-
resin. For all six anti-Mb Affimer (B5, C2, D1, E3, F5 and H1), the elution bands 
migrated in the range between 10 and 15 kDa, which is around the theoretical Mr of 
Affimers (12 – 13 kDa). It is clear that the Affimer D1, E3 and H1 showed a limited 
protein expression compared with B5, C2 and F5 despite using the same volume of 
eluant. 
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Figure 3-11 SDS-PAGE gel of purified anti-Mb Affimers. (A) – (F) showing gels of Affimers B5, C2, D1, E3, F5 and H1, respectively. The 4-15% (w/v) 
gradient gel was used to confirm the expression of the binders. The lanes denote: (M), protein ladder (kDa); (L), lysate fraction; (I), insoluble protein 
fraction; (S), soluble protein fraction; (SN), supernatant fraction for unbound Affimers; (E), imidazole eluted fractions 1 – 6. The Affimers were 
eluted using elution buffer containing 50 mM NaH2PO4, 500 mM NaCl; 300 mM imidazole; 20% (v/v) glycerol; pH 7.4. 10 µl of sample was loaded in 
each well.  
B A 
D E F 
C 
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In a typical protein purification process, there is no heating at 50 ºC step, 
which was used in the original protocol provided by the BSTG. The heating was 
introduced in order to remove non-specific proteins based on the property of 
Affimers that they are stable at higher temperature compared to other proteins. 
However, not all of the anti-Mb Affimers could tolerate temperatures over 50 ºC and 
so processing the lysates without the 50 ºC heating step was tested. The SDS-PAGE 
gels in Figure 3-12 show gels of non-heated lysate expression batch. In Figure 3-11, 
the supernatant containing soluble proteins after the centrifugation to remove 
insoluble protein (Lane S) of D1, E3 and H1 gels show a limited amount of Affimers 
at the bands migrating between 10 – 15 kDa. Whereas in the gels of non-heated 
lysates in Figure 3-12, there were intense bands at the same position in Lane S. 
Optimisation of the purification method increased the expression yield of D1, E3 and 
H1 substantially to around 2 – 2.5 mg/50 ml  culture but the yield of B5, C2 and F5 
only showed slight increase. This suggested that anti-Mb Affimers with different loop 
sequences have unique properties.  
The purified Affimers were biotinylated using biotin malemide at the C-
terminal cysteine immediately after the purification process to avoid aggregation, 
which was experienced with all binders at high concentrations. This may due to 
disulphide bond formation from the thiol groups of cysteine residue. Also, some 
Affimers were kept in elution buffer by snap freezing in liquid nitrogen. 
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Figure 3-12 SDS-PAGE gel of purified anti-Mb Affimers without heating step to the cell lysates. (A) – (F) showing gels of Affimers B5, C2, D1, E3, F5 
and H1, respectively. The 4-15% (w/v) gradient gel was used to confirm the expression of the binders. The lanes denote: (M), protein ladder (kDa); 
(I), insoluble protein fraction; (S), soluble protein fraction; (SN), supernatant fraction for unbound Affimers; (E), imidazole eluted fractions 1 – 8. 
The Affimers were eluted in elution buffer containing 50 mM NaH2PO4, 500 mM NaCl; 300 mM imidazole; 20% (v/v) glycerol; pH 7.4. 10 µl of sample 
was loaded in each well.  
A B C 
D E F 
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3.3 Affimer characterisations 
As anti-myoglobin Affimers were selected from phage display screening, the 
binding of each occurred when protein was expressed on the phage’s surface. 
Therefore, it is very important to confirm the binding properties of Affimers selected 
from the phage library and check they can still adequately bind the target when 
independent from the phage. 
 
3.3.1 Immunoprecipitation (pull-down assay) 
The immunoprecipitation or pull-down assay is a well-known technique used 
to isolate a particular protein out of solution by relying on antigen-antibody binding 
activity. In this experiment, anti-Mb Affimers were used instead of antibody to pull 
down the analyte. Figure 3-13A – F shows the SDS-PAGE gels resulting for anti-Mb 
Affimers B5, C2, D1, E3, F5 and H1, respectively. The Affimers were immobilised onto 
Ni2+-NTA resin via their His6-tag residues and excess Affimers were removed by 
centrifugation. The supernatant was kept and run on an SDS-PAGE gel. In the lane of 
unbound Affimer (UB AF), there were bands migrating between 10 – 15 kDa, 
suggesting the Affimers were in this fraction. This confirmed that the resins were 
saturated with the binders before moving to the next step. The Affimer loaded resins 
were then incubated with myoglobin solution overnight and the supernatants 
containing unbound myoglobin were kept to run on an SDS-PAGE gel. Unbound Mb 
was removed by several washing steps; after three washes, no Mb was observed in 
the flow-through fractions.  
The lysates of each Affimer were then boiled for 5 min at 95 C to break the 
binding and centrifuged down to sediment the resin. The supernatants were loaded 
on 4-15% (w/v) SDS-PAGE gel (section 2.2.2.1). However, western blotting was not 
performed as in usual immunoprecipitations because Mb used was a recombinant 
purified protein. All Affimers showed that they bound specifically to myoglobin and 
removed it from solution. As seen in the last lane, the bands migrated to two 
different components, Mb (~ 17 kDa) and the Affimer (12-13 kDa). Also, the washing 
steps 1 – 3 showed no proteins in the flow-through fractions, which means there 
were no non-specifically bound proteins to the resins as well as other contaminants.
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Figure 3-13 SDS-PAGE gel for pull-down Mb using Affimers. (A) – (F) showing gels of Affimers B5, C2, D1, E3, F5 and H1, respectively. The lanes 
denote: (M), Mr marker protein ladder (10 – 260 kDa); (UB AF) and (UB Mb), unbound fractions of Affimer and Mb, respectively; (W), washed 
fraction 1 - 3; (P), mixture pull down lysate.  All Affimers pulled Mb from solution as the bands in Lane P show both Affimer (12 – 13 kDa) and Mb 
(17 kDa).
A B C 
D E F 
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3.3.2 ELISA analysis with purified Affimers 
To evaluate the binding characteristics of Affimers as proteins, the anti-
myoglobin Affimers were used in an ELISA (Figure 3-14). Myoglobin was biotinylated 
and immobilized onto streptavidin coated Nunc-ImmunoTM MaxisorpTM 96-well plate 
and each Affimer was used as a primary detection agent at varying concentrations. 
Anti-His6-HRP was used as secondary antibody at 1:1000 dilution.  
 
Figure 3-14 Direct ELISA results for six anti-Mb Affimers together with negative 
controls. Anti-His6-HRP conjugate was used as the secondary reagent at 1/1000 and 
TMB was used as substrate by allowing 5 min reaction time. ( ), anit-Mb Affimer 
B5; ( ), anti-Mb Affimer C2; ( ), anti-Mb Affimer D1; ( ), anti-Mb Affimer E3;      
( ), anti-Mb Affimer F5; ( ), anti-Mb Affimer H1 and the negative controls ( ), 
anti-yeast SUMO Affimer, ( ), anti-calprotectin Affimer 4 and ( ), anti-
calprotectin Affimer 15.  
 
All six anti-Mb Affimers showed binding to Mb in proportion to the 
concentration of Affimers. Among selected binders, D1 and E3 showed the least 
response compared with the other four binders that had similar levels of binding. To 
prevent non-specific binding of secondary antibody to the Affimers, one anti-yeast-
SUMO and two anti-calprotection Affimers (4 and 15) were used as negative controls 
in the experiment. They showed minimum response suggesting that the binding of 
anti-Mb Affimers was genuine.   
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3.3.3  Binding kinetics 
To investigate the binding parameters (Ka, Kb) of selected anti-Mb Affimers 
that have been expressed, SPR was used. Biotinylated Mb was immobilised onto a 
streptavidin (SA) chip and acted as a receptor in this context. Conventionally, the 
immobilized component is the ‘receptor’ and the flowing component is the ‘ligand’. 
The Affimers were used as analyte flowing in solution over surface. With this design, 
accurate concentration of analyte is very important for determining the binding 
parameters. Therefore, calibration free concentration analysis (CFCA) was used to 
measure the active concentration of each Affimer prior to the kinetics study using a 
carboxymethylated dextran (CM5) chip onto which anti-His6-antibodies were 
immobilised. 
The SPR experiment was set up by using two flow cells (cell 1 and 2) on an SA 
chip. The first cell (flow cell 1) was used to eliminate non-specific binding by flowing 
the Affimers over the sensor surface without any Mb immobilised. So the real 
binding data could be corrected non-specific binding of Affimers to the chip itself by 
subtraction. Another control to prevent non-specific binding was to flow buffer only 
over flow cell 2, onto which had previously immobilised biotinylated Mb. This again 
was used to subtract from the binding data. A multicycle kinetic study was 
performed with concentration of Affimers ranging from 0 – 1000 nM with 120 and 
480 seconds of association and dissociation time, respectively. Anti-yeast-SUMO was 
used as a negative control and 10 mM glycine pH 3 was selected as the regeneration 
buffer after each concentration cycle ended. Real time binding data from the 
experiment is shown in Figure 3-15.  
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Figure 3-15 Real time binding data of SPR experiment on anti-Mb Affimers and its 
negative control. The graphs (A-G) show real time binding data of anti-Mb B5, C2, 
D1, E3, F5, H1 and anti-yeast SUMO Affimer systems, respectively. All Affimers 
except E3 and anti-yeast-SUMO showed binding activity to Mb immobilised on a 
streptavidin (SA) chip. Concentrations of Affimer used were: ( ), 3.91 nM; ( ), 7.81 
nM; ( ), 15.62 nM; ( ), 31.25 nM; ( ), 62.5 nM; ( ), 125 nM; ( ), 250 nM; ( ), 
500 nM; ( ), 1 µM. 
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From these data, we can see the binding responses with all anti-Mb Affimers 
except E3. All response binding curve showed the steep association characteristic 
and followed by a much shallower dissociation curve, which could not be seen in 
Affimer E3 (Figure 3-15D). Similar to the negative control, there was no binding 
responses of anti-yeast-SUMO Affimer to Mb at any of concentrations used (Figure 
3-15G). Despite Affimer E3 being successfully used in ELISA and pull down assay, it 
showed no response in the SPR system. A possible explanation could be that it 
aggregated during the experiment as we can see a slight increase of a noisy line in 
the association curve (Figure 3-16A) compared with anti-yeast-SUMO that showed 
no binding at all (Figure 3-16B). This could mean that some Affimer E3 could bind to 
Mb but insufficient to generate a proper binding curve as seen in others. As a result, 
Affimer E3 was excluded from subsequent analyses as the other Affimers proved to 
be better in terms of binding kinetics. 
 
 
 
Figure 3-16 Real time binding data of anti-Mb Affimer E3 and anti-yeast-SUMO 
Affimer on an expanded scale. (A), Affimer E3 binding data with some degree of 
binding, but binding curves were non-smooth indicating aggregation problems; (B), 
anti-yeast-SUMO Affimer binding data with no binding activity at all. 
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To compare the remaining five anti-Mb Affimers, the association and 
dissociation half-time of the highest concentration (1000 nM) of each Affimer were 
plotted (Figure 3-17). If we draw an arbitrary line to divide the graph in Figure 3-17 
into four sections representing four different characteristics of bioreceptor, the ideal 
binder should fall into the bottom right section, which means it takes less time to 
reach 50% maximum responses and take long time to half dissociate to a plateau 
phase as known as “fast on – slow off” binders. However, there was no anti-Mb 
Affimers that met the criteria of an ideal binder. The best Affimers from this graph 
would be B5 and D1 that both fell into “slow on – slow off” binders, although it must 
be admitted that the designation ‘fast’ and ‘slow’ are somewhat arbitrary. As well as 
C2 and F5 that fell in the “fast on – fast off” binder segment.  In addition, if we look 
deeply into the size of maximum response, represented by the size of the circles, B5 
might be a better binder as compared to D1 at the same concentration as it gave 
more SPR response units. H1 gave the largest maximum response compared to 
others but with its “slow on – fast off” property made it less desirable. 
 
Figure 3-17 Comparison graph of five anti-Mb Affimers SPR binding data. The graph 
was plotted using the real time binding data of the maximum concentration of each 
Affimer (1000 µM). The X-axis represents how fast the dissociation happened. Y-axis 
is how fast the association happened. Area of circle is the total association maximum 
(Bmax). The ideal binders should be on the bottom-right of the graph. 
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Figure 3-18 shows typical SPR binding curve containing association and 
dissociation phases. 
  
Figure 3-18 Typical SPR binding curve containing association and dissociation 
phases. 
 
The time-dependent rate equations for association phase is described as: 
   
𝑑𝑛
𝑑𝑡
=  𝑘𝑜𝑛 (𝑁 − 𝑛)𝐶 −  𝑘𝑜𝑓𝑓  ∙  𝑛 (3-1) 
where 𝑛 is concentration of analyte-ligand complex, 𝑁 is concentration of immobilised 
ligands, 𝑘𝑜𝑛 is association rate constant (M
-1s-1), 𝑘𝑜𝑓𝑓 is dissociation rate constant (M) 
and 𝐶 is concentration of analyte in solution (M). In a real experiment, 𝑛 approaches 
its terminal value 𝑛𝑚𝑎𝑥  in an exponential manner with a time constant, 𝜏. Equation 
governs this interaction is: 
   𝑛 =  𝑛𝑚𝑎𝑥 [1 − 𝑒𝑥𝑝
(−
𝑡
𝜏𝑜𝑛
)
]  (3-2) 
where 𝑡 is time (s), 𝑛𝑚𝑎𝑥  is equal to 𝑁 ∙  
𝑘𝑜𝑛 𝐶
𝑘𝑜𝑛𝐶+ 𝑘𝑜𝑓𝑓
 and  𝜏𝑜𝑛 is described as 
1
𝑘𝑜𝑛𝐶+𝑘𝑜𝑓𝑓
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 In terms of dissociation phase, it is measured by removing the analyte 
solution and exchanging it with running buffer, which means 𝐶 is set to zero. It can 
be described as: 
    
𝑑𝑛
𝑑𝑡
=  −𝑘𝑜𝑓𝑓 ∙  𝑛   (3-3) 
  This time the conditions during the association phase are changed and the 
dissociation rate solely depends on time and the concentration of the analyte-ligand 
complex at the start of dissociation. Therefore, a different equation is used, where 
𝜏𝑜𝑓𝑓 is described as 
1
𝑘𝑜𝑓𝑓
 (equation 3-4). 
    𝑛 =  𝑛𝑚𝑎𝑥 𝑒𝑥𝑝
(−
𝑡
𝜏𝑜𝑓𝑓
)
  (3-4) 
These equations (3-1 to 3-4) can then be used to calculate the overall affinity 
constant (𝐾𝐷) (M) using equation 3-5: 
𝐾𝐷 =  
𝑘𝑜𝑓𝑓
𝑘𝑜𝑛
    (3-5) 
 According to these data, binding parameters (Ka, Kb and apparent KD) could 
be calculated. The ideal binding between a bioreceptor to an analyte should follow 
a one-site or 1:1 binding saturation model like an antibody to its analyte. Initially, a 
one-site specific binding analysis was performed. It was found that the data fitting 
for all five binders did not follow a one-site binding model (Figure 3-19, Table 3-2), 
whilst fitting a two-site specific binding model fitted the data much better (Figure 3-
20) and the 2 and R2 were improved substantially (Table 3-3). The two site model 
assumes two distinct and non-interacting binding sites within the Affimer 
population.   
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Figure 3-19 One-site binding model data fitting. The graphs show ( ) raw data 
obtained from SPR Data, whilst, ( ) fitted data is shown overlaid. Data modelled (A-
E) were from anti-Mb Affimers B5, C2, D1, F5 and H1, respectively. 
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Figure 3-20 Two-site binding model data fitting. The graphs show ( ) raw data 
obtained from SPR Data, whilst, ( ) fitted data is shown overlaid. Data modelled (A-
E) were from anti-Mb Affimers B5, C2, D1, F5 and H1, respectively. 
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Table 3-2 Data from one-site binding model. Using the one-site binding model, the 2 and R2 values reflected the poor fit seen in Figure 3-19. 
 
 
 
 
Table 3-3 Data from two-site binding model. Using this model both 2 and R2 values were improved compared with one-site model (Figure 3-20). The 
parameters for population 1 and population 2 binding are shown with the percentage describing the weighting of each site towards the overall KD value.  
 
 
Binder 
Binding site 1 Binding site 2 Global parameters 
Kon1  
(1/Ms) 
Kon1  
(1/s) 
KD1  
(M) 
Kon2 
(1/Ms) 
Koff2  
(1/s) 
KD2 (M) %site
1 
%site
2 
KD  
Total 
R2 2 
B5 1.75 x 108 6.69 x 10-3 3.82 x 10-11 1.14 x 108 6.84 x 10-2 6.00 x 10-10 60.7 39.3 4.68 x 10-10 0.975 0.805 
C2 1.12 x 107 8.83 x 10-2 7.89 x 10-9 1.28 x 107 7.42 x 10-3 5.79 x 10-10 53.0 47.0 5.06 x 10-9 0.992 0.829 
D1 9.53 x 108 1.99 x 10-2 2.09 x 10-11 3.28 x 108 8.67 x 10-2 2.64 x 10-10 50.8 49.2 1.45 x 10-10 0.916 0.267 
F5 9.48 x 106 6.66 x 10-2 7.03 x 10-9 4.11 x 107 8.20 x 10-3 2.00 x 10-10 65.7 34.3 6.11 x 10-9 0.986 0.329 
H1 1.13 x 107 2.00 x 10-3 1.76 x 10-10 2.83 x 107 4.06 x 10-2 1.44 x 10-9 49.6 50.4 9.55 x 10-10 0.996 1.336 
 
Binder Kon (1/Ms) Koff (1/s) KD (M) R2 2 
B5 5.31 x 104 1.96 x 10-2 3.69 x 10-7 0.781 5.816 
C2 5.41 x 105 4.36 x 10-2 8.05 x 10-8 0.598 12.5 
D1 3.01 x 104 3.36 x 10-2 1.12 x 10-6 0.793 2.516 
F5 2.21 x 105 3.98 x 10-2 1.80 x 10-7 0.676 3.994 
H1 2.18 x 105 1.71 x 10-2 7.87 x 10-8 0.868 13.18 
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By using the two-site specific binding model, the overall affinity constant was 
then calculated with Equation 3-5. Parameters calculated from the two-site binding 
process were given in two figures. For the association parameter, two Kons were 
given as in Kon 1 and Kon2, representing high and low affinity. Also, dissociation 
parameters (Koff) were given as Koff1 and Koff2, which represent fast and slow 
dissociation rate. In order to select the right Kon and Koff to use, the considerations 
were based on the description of binding property given to each binder in Figure 3-
17. B5 and D1 were described as ‘slow on – slow off’ binders. While, C2 and F5 were 
foreseen as ‘fast on – fast off’ binders. In terms of H1, a ‘slow on – fast off’ model 
was described. Table 3-4 reports the binding parameters (Kon, Koff and KD) derived 
from the two-site specific binding model including a percentage function describing 
the weighting of each site towards the overall KD value.  
Surprisingly, the proportion between two populations were similar (around 
50%). It might be that anti-Mb Affimers might experience stability issues, as with 
biological samples, especially proteins, there is always a certain level of 
heterogeneity. This is because in real world applications, proteins are labile and can 
contain a small proportional of “damaged” proteins within the whole population. In 
addition, myoglobin immobilised on the SPR chip itself might be altered as it is also 
a protein. This might alter the context of epitope presentation on its surface, so that 
binding kinetics become affected. Another possible explanation could be that the 
Affimers contains cysteine and dimerisation might occur, which later affects the 
binding kinetics by an increased avidity effect. Further experiments could be 
conducted to prove this hypothesis. For example, the addition of a protecting group, 
such as an alkane-maleimide, could prevent the formation of dimers before the SPR 
experiment was run.  
The overall KD denotes the apparent KD of the whole population. In terms of 
reporting kinetic parameters, it might be better to report the optimal KD for the 
whole population than the overall KD. However, in real applications, the ideal system 
is rarely found. Therefore, it is more desirable to report the overall value (Figure 3-
21), especially when the proportions of each population were close. 
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Figure 3-21 Summary of overall KD values for anti-myoglobin Affimers. 
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3.3.4 Affimer pair selection 
For nanoparticle size shift assay in this project, the main principle is based on 
the crosslinking of nanoparticle probes as discussed in Chapter 1. Bioreceptors 
immobilised on a nanobiosensor should act as crosslinkers, in other words, bind to 
two or more epitopes like a polyclonal antibody. Therefore Affimer pair ELISA was 
conducted to identify among the five selected binders whether they bind to different 
epitopes or not. The schematic in Figure 3-22 shows the Affimer pair ELISA used in 
the experiment. One Affimer was fixed onto the plate and followed by Mb as the 
analyte. Then, another biotinylated Affimer was used as the primary detection agent 
and detected with streptavidin-HRP as a secondary agent. Each Affimer was fixed 
onto the plate and tested against four different Affimers with and without Mb in 
order to quantify non-specific binding. In addition, each Affimer was tested against 
themselves to identify whether the Affimer itself can bind to more than one epitope. 
Biotinylated anti-Mb polyclonal antibody and PBS buffer were used as positive and 
negative controls for the ELISA, whilst biotinylated anti-calprotectin Affimer was 
used as non-specific binding control, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-22 Schematic of Affimer pair ELISA. One Affimer is fixed to the Nunc-
ImmunoTM MaxisorpTM 96-well plate, following by myoglobin. The second Affimer is 
used in a form of biotinylated protein as a sandwich primary detection agent. 
Streptavidin-HRP is used as secondary quantification agent and TMB substrate is 
used for detection. 
Affimer 1  
Myoglobin (Analyte) 
HRP 
Biotinylated 
Affimer 2 
Streptavidin HRP 
TMB substrate 
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The histograms in Figure 3-23 (A-E) show the pair ELISA data comparing the 
absorbance at 620 nm in the presence and absence of Mb (black and grey column, 
respectively). First, the positive controls for every Affimer showed significant binding 
signals (p < 0.05). Also, both negative and non-specific controls showed insignificant 
signal, which indicated that the systems were working properly. Figure 3-23A shows 
that when B5 was fixed to the plate, only F5 could access to its epitope and bind to 
Mb. Whereas, when F5 was fixed (Figure 3-23D), B5 could not bind to the analyte. 
This might due to the location of the B5 epitope close to the F5 epitope so when F5 
bound to myoglobin first, the position of Affimer F5 prevented Affimer B5 from 
binding to Mb. Similarly, when C2 was fixed to the plate, three binders (D1, F5 and 
H1) could bind to Mb as shown in Figure 3-23B. On the contrary, there were no 
positive data showing that C2 or other binders could bind to Mb when D1 and H1 
were fixed (Figure 3-23C and E). The possible explanations for this case is that when 
C2 binds first, the position of C2 allowed D1 and H1 to access their epitopes. But 
when D1 and H1 bound first, they hindered the C2 epitope and prevented C2 from 
binding. However, only when F5 was fixed, C2 could significantly bind to myoglobin. 
Taken together, these results suggest that among all five binders C2 and F5 are most 
likely to bind to different epitopes that are not close together or hinder each other. 
What stands out in this experiment is that when each binder was fixed and 
tested against themselves, only C2 that gave a significant binding signal (p<0.05), 
which suggests among the five selected binders C2 might bind to more than one 
epitope. That might be the reason why when C2 bound to Mb first, it allowed other 
binders to bind more. Furthermore, this might be the reason why C2 is the most 
frequently found Affimer when screened from the library as reported earlier in 
section 3.2.3. 
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Figure 3-23 Affimer pair ELISA data for anti-Mb Affimers. (A-E) showing histograms of five different fixed Affimer– B5, C2, D1, F5 and H1, respectively 
on a Nunc-ImmunoTM MaxisorpTM 96-well plate. X-axis shows the biotinylated Affimer used to test against the fixed Affimer. Y-axis shows the 
absorbance value at 620 nm. The black column represents the experiment well with Mb present. The grey column represents the negative control 
well without Mb. (*) indicates significant values tested with independent t-test between the well with Mb present and the well without Mb (p < 
0.05).   
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3.4 Discussion 
This chapter has focused mainly about the screening and production of anti-
Mb Affimers. The screening was successfully done with six different anti-Mb 
Affimers, which seems to be small number compared with the size of library of 
3x1010 clones. This might be due to the compact size of Mb itself that restricted the 
binding of Affimer. Mb is a globular monomer with Mr 17 kDa and is around 3.5 nm 
dimension. This is pretty similar to the Affimer (12 - 13 kDa, 2 - 3 nm). The process 
of subcloning and expression were optimised and established previously; 
nevertheless, it was found out that D1, E3 and H1 gave less yield compared with B5, 
C2 and F5 as mentioned earlier. By skipping the heating step during the purification 
process, the yield of those three binders could be increased, suggesting that changes 
in the 2 x 9 amino acids binding loop affects Affimer properties as they represent ~ 
20% of total sequence. Also, the purified anti-myoglobin Affimers were forming 
aggregates that might due to the formation of dimers because of the inclusion of the 
C-terminal cysteine residue for conjugation purpose. This phenomenon is normal for 
free thiols as the formation of disulphide bond provides more thermodynamically 
stable state. However, this phenomenon may also affect their thermal stability or 
other properties. Therefore, it is necessary to reduce the disulphide bond before 
using the Affimers. The selection of reducing agents was not a problem as Affimers 
contain only one cysteine. A more detailed account of this issue is given in the 
following chapter.  
Regarding selection of characterisation methods, it would be ideal to perform 
full characterisation on all the selected binders. Though, the main aim of this work is 
to identify the suitable binders for nanoparticle size-shift assay. Thus, various 
characterisations were performed to validate the Affimers for specific purposes. 
First, immunoprecipitation and direct ELISA were conducted to confirm the specific 
binding of six selected binders to Mb when they were in a form of purified proteins, 
not phage expressed proteins. All purified anti-Mb Affimers proved to bind 
specifically to Mb. With respect to direct ELISA results, Affimer E3 seemed to be 
binding with lowest response over the same concentration range. 
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SPR was selected to identify their binding kinetic parameters. The KD 
obtained for the five selected Affimers were between pM to nM range excepting 
Affimer E3 that experienced aggregation and showed no binding. This result was in 
accordance with direct ELISA data proposing that Affimer E3 might be the worst of 
the Affimers, so Affimer E3 was excluded from further analysis. As previously stated, 
the binding kinetics of the binders were not fitted well using a one-site binding model 
but they were fitted better with two-site binding model. It seems like the KD(s) 
obtained were overestimated compared with other Affimers selected from the 
library. The work presented in this chapter would have been more complete if it had 
included the results from other experiments that could identify the equilibrium KD 
as a comparison, for example, radioisotope ligand binding assay or fluorescence 
polarisation. Still, the SPR data provides comparative information about the five-
selected anti-Mb Affimers, which lead to appropriate selection of binders for the 
project together with other specific characterisations.  
Additionally, sandwich ELISA was adapted to use as a tool to find an Affimer 
pair for the project. As was pointed out in the Introduction (Chapter 1), the main 
mechanism of the size-shift assay is crosslinking between gold nanoparticles (AuNPs) 
and for this to happen, more than one binder is required. The method might not be 
able to give specific location concerning the epitope of each binder but it was enough 
for the project to move forward. According to the Affimer pair ELISA results, C2 and 
F5 were most likely to bind to different epitopes among all the selected Affimers 
despite the fact that their affinities were not the best. It was hypothesized that when 
using these two Affimers, Mb-mediated crosslinking could be occur, which lead to 
aggregation of nanoparticles that is a key feature of the assay mechanism discussed 
in Chapter 5.
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Chapter 4 Functionalisation of gold nanoparticles (AuNPs) 
4.1 Introduction 
Work in this chapter focuses on gold nanoparticle (AuNP) functionalisation 
for the dynamic light scattering (DLS) assay. As mentioned in Chapter 1, AuNPs 
possess a modifiable surface which makes them a candidate materials for biosensing 
applications. There are several methods for bioreceptor functionalisation onto the 
AuNP surface. Physical interaction is a simple method but requires a large amount 
of bioreceptor and is susceptible to the surrounding environment. A chemical 
coupling method, conversely, is more complicated for processing but preferable as 
it requires less bioreceptor and is more durable. Moreover, the method provides 
orientated immobilization, allowing ready access to the bioreceptor binding site(s). 
This is very important to maximise the bioreceptor binding function and assay 
performance (Ma et al., 2010; Jazayeri et al., 2016).  
In this project, conjugation was achieved by using the streptavidin-biotin 
interaction. It is a well-known non-covalent interaction, which is very strong with a 
KD ~ 10-15 M. Also, biotin is versatile for linking bioreceptors as it can be easily 
obtained with a number of functional moieties including maleimide, hydrazide or N-
hydroxysuccinimide (NHS) to couple to –SH, carbohydrate or –NH2 groups. Linking 
streptavidin coated AuNPs (strep-AuNPs) to biotinylated bioreceptors is an efficient 
way to produce stable nanobiosensors for DLS assays. Here, the anti-myoglobin (Mb) 
C2 Affimer was used to optimise functionalisation as it had the best expression yield. 
Findings were then applied to other Affimers.  
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4.2 Biotinylation of bioreceptors 
4.2.1 Antibodies (IgGs) 
The IgG structure contains multiple sites for modification chemistry such as 
amine-, thiol-groups or carbohydrates (Figure 4-1). For example, biotin NHS is a 
common biotinylation reagent used to couple to primary amines, which occur on 
lysine amino acids. However, there is good chance of having lysine residues in the 
antigen binding sites and the binding might be interfered with by the biotinylation 
process. Furthermore, functionalising via lysine onto the AuNP surface would be in 
random orientations and may occlude the binding sites. 
 
 
 
Figure 4-1 Antibody (IgG) structure indicating the areas for surface modification. A 
half antibody can be generated by reducing the disulphide bonds at the hinge region. 
Primary amine coupling can be performed at the lysine residues and carbohydrates 
at the Fc region also can be oxidised by sodium periodate (NaIO4) and reacted with 
the hydrazide group to form hydrazone linkage. 
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Another conjugation pathway is to use biotin maleimide to target thiol 
groups. Reduction of IgG is required to make its thiol groups available for 
conjugation. Whilst the whole IgG has multiple disulphide bonds linking light and 
heavy chains together, the disulphide bridge can be cleaved only at the hinge region 
by certain reductants and yields two –SH groups for coupling. However, half-IgG 
generation is a complex process and the conditions used depend on variations in the 
IgG structure. Makaraviciute et al. (2016) suggested that 35 mM TCEP reducing agent 
at pH 4.5 gave the best half-IgG yield for rabbit anti-Mb IgG. However, the acidic 
condition might not be an appropriate for AuNP stability and therefore, this method 
was not considered here.   
In addition to these two biotinylation reagents, biotin hydrazide is another 
linker used in IgG biotinylation. The oxidization of carbohydrates by sodium 
periodate (NaIO4) at Fc region of IgG yields reactive aldehydes, which reacts with 
biotin hydrazide forming a stable hydrazone linkage (Figure 4-2). This reaction was 
successfully used in linking hydrazide terminated liposomes (Wagh and Law, 2013) 
and PEG-dithiol linker (Kumar et al., 2008) to IgGs. To enable orientation of the IgG 
and assure that the binding site faces outwards, here, biotin hydrazide was selected 
for the biotinylation process. 
 
 
 
 
 
Figure 4-2 Biotin hydrazide reaction. Carbohydrates at the Fc region of IgG was 
oxidized by sodium periodate (NaIO4) and immediately reacted with biotin hydrazide 
to form a stable hydrazone linkage. 
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Biotinylation of anti-Mb IgG was performed by the method described in 
section 2.2.3.1. ELISA was carried out to confirm the success of biotinylation after 
unbound biotin hydrazide was removed by desalting. Figure 4-3 shows that 
biotinylation of anti-Mb IgG was successful. 
  
 
Figure 4-3 ELISA to show biotinylation of anti-myoglobin IgG (anti-Mb IgG) for AuNP 
functionaltisation. (A), showing ELISA strip for three different dilutions of 
biotinylated anti-Mb IgG 0.5 mg/ml (1, 1/10, 1/100) and negative control (PBS buffer) 
from top to bottom; (B), showing the absorbance at 620 nm of each tested samples. 
  
4.2.2 Affimers 
For Affimers, biotin malemide was selected for biotinylation since they 
contain one cysteine at their C-terminus. However, the -SH groups are likely to form 
disulphide bridges so reduction of the Affimer disulphide bonds was conducted by 
using TCEP gel. The use of TCEP as reductant avoids the needs to remove it, as would 
be the case for mild thiol reductants such as 2-mercaptoethylamine (2-MEA) (Goode 
et al., 2016). Immediately after the reduction, biotin maleimide was added and 
incubated for 2 h at RT. The reaction scheme is shown in Figure 4-4. After free biotin 
maleimide was removed by desalting, ELISA and mass spectrometry were used to 
confirm biotinylation. Figure 4-5 and 4-6 show ELISA and mass spectrometry results 
of C2 Affimers biotinylation; other Affimers results are shown in Appendix 2 – 6. 
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Figure 4-4 Schematic of biotin maleimide interaction to Affimer. 
 
 
Figure 4-5 ELISA to show biotinylation of C2 Affimer for AuNP functionalisation. (A), 
showing ELISA strip for three different dilutions of biotinylated C2 Affimer 0.5 mg/ml 
(1, 1/10 and 1/100) and negative control (PBS buffer) from top to bottom; (B), 
showing the absorbance at 620 nm of each tested samples. 
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Figure 4-6 Mass spectra of C2 Affimer. (A), showing C2 Affimer before biotinylation, the highest mass peak at 24829.10 Da corresponded to Mr of 
dimeric C2 Affimer; (B), showing after biotinylation, the highest mass peak at 12867.20 Da corresponded to Mr of C2 Affimer monomer plus biotin 
maleimide (Mr 451.54 Da). 
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Mass spectra of C2 Affimers shown in Figure 4-6A shows the highest mass 
peak at 24829.10 Da, which is twice the estimated Mr of an Affimer monomer (12 – 
13 kDa). This result supports the idea of dimerization of the Affimers due to their 
thiol group at the C-terminal cysteine. Based on the assumption that the dimer form 
presented in solution, the mass of C2 Affimer monomer form would equal to 
12414.55 Da. The mass was lower than expected Mr of C2 Affimer obtained from its 
sequence via ProtParam tool (12547.2 Da) by around 132-136 Da. This phenomenon 
was observed in other four selected Affimer mass spectrum results. Table 4-1 gives 
a summary of mass from selected Affimers obtained by mass spectrometry. The 
missing mass corresponds to the mass spectrum peak of methionine (around 132-
133 Da). In addition, it was reported that in most recombinant proteins, removal of 
the translation initiator N-terminal methionine (Met) is crucial for its function and 
stability (Liao et al., 2004). A likely explanation is that the sequence obtained from 
subcloned DNA containing Met but in the actual expressed protein, N-terminal Met 
was cleaved off. 
 
Table 4-1 Summary of all selected anti-myoglobin Affimers masses obtained by mass 
spectrometry. 
Affimer 
Mass obtained by mass 
spectrometry (Da) ProtParam calculated mass 
from DNA sequence (Da) 
Missing 
mass (Da) 
Dimer 
Calculated 
monomer 
B5 24967.55 12483.78 12619.30 135.52 
C2 24829.10 12414.55 12547.20 132.65 
D1 25003.60 12501.80 12635.40 133.60 
F5 24733.55 12366.78 12501.30 134.52 
H1 25037.30 12518.65 12650.40 131.75 
 
  
 
 
            
148 
In Figure 4-6B, the mass spectrum shows the highest mass peak at 12867.2 
Da for the C2 Affimer and no peak was found at the same position in its dimer form, 
which suggested that all C2 Affimers were reduced.  This confirmed the success of 
biotinylation as the mass difference from the monomer form of C2 Affimer alone 
was within the range of biotin maleimide Mr (451.54 Da). Table 4-2 presents the 
biotinylated masses of all selected Affimers. 
 
Table 4-2 Summary of all selected biotinylated anti-myoglobin Affimers masses 
obtained by mass spectrometry. 
Affimer 
Calculated monomer 
mass (Da) 
Biotinylated 
mass (Da) 
Mass difference 
(Da) 
B5 12483.78 12939.08 455.30 
C2 12414.55 12867.20 452.65 
D1 12501.80 12955.14 453.34 
F5 12366.78 12821.08 454.30 
H1 12518.65 12970.40 451.75 
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4.3 Preparation of AuNP nanobiosensors 
4.3.1 Streptavidin coated AuNPs 
In this project, streptavidin coated AuNPs with different core diameters (20, 
40, 60, 80 and 100 nm) were used, so their sizes were measured by DLS as baseline 
before any functionalisation. Before the measurement, the AuNP storage buffers 
were removed by centrifugation and 10 mM PBS buffer (pH 7.4) was used to 
resuspend the pellets. All strep-AuNPs used were maintained at an optical density 
(OD) of 1.0. The ODs of 20, 40, 60, 80 and 100 nm core diameter AuNPs were 
measured at 520, 529, 540, 553 and 572 nm, respectively. In addition, DLS laser 
power was adjusted for each size of AuNPs via attenuation in order to prevent 
saturation of the detector as different sizes of AuNPs provide different scattering 
intensities. AuNPs with core diameter of 20, 40 and 60 nm used attenuation numbers 
11, 10 and 9, respectively; whilst 80 and 100 nm used the same attenuation number 
8. 
Here, DLS was used as the main characterisation technique because it has 
proved to be an effective tool in studying protein-protein interaction as explained 
earlier in Chapter 1. The diameter of a streptavidin molecule is around 11.3 nm with 
a height of 2.04 nm; this was reported by Neish et al. (2002), who studied the 
dimensions using atomic force microscopy (AFM). When proteins fully adsorb onto 
the AuNP surface, the diameter of the AuNPs is expected to increase at least by twice 
the diameter of the protein molecule. Proteins have weak intrinsic light scattering 
properties that can only be detected by DLS when a high concentration is used. 
However, binding of proteins on the AuNP surface makes them measureable by DLS 
(Jans et al., 2009; James and Driskell, 2013). Therefore, it was estimated that when 
streptavidin fully coated onto AuNPs with different core diameter, the mean DH 
should increase around 22 nm. Nevertheless, it was observed from Table 4-3 that 
the size shift observed varies over the range 15 – 30 nm.  
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Table 4-3 Mean DH of streptavidin coated AuNPs (strep-AuNPs) obtained from DLS. 
Concentrations of each strep-AuNPs were kept the same as ODx* = 1 and 100 µl of 
each AuNPs were measured in a small volume cuvette. For each sample, 10 runs with 
10 s/run were performed and the average value were reported. Standard deviation 
was derived from triplicate measurements. (Note * The ODs of 20, 40, 60, 80 and 
100 nm core diameter streptavidin coated AuNPs were measured at 520, 529, 540, 
553 and 572 nm, respectively). 
Core diameter (nm) 
Mean DH 
(nm) 
SD 
(n=3) 
Size shift from core 
diameter (nm) 
20 38.74 0.50 18.74 
40 54.98 1.22 14.98 
60 84.16 1.28 24.16 
80 105.39 1.68 25.39 
100 130.21 1.67 30.21 
  
A possible explanation is due to the possible orientations of streptavidin on 
the AuNP surface. Figure 4-7 shows a graphic of possible orientations of streptavidin 
on AuNPs. Figure 4-7A represents streptavidin vertically adsorbing onto the AuNP 
surface. In this case, the size increases should be around 22 nm as expected. But 
there is also a possibility of streptavidin adsorbing at different angles as shown in 
Figure 4-7B. This might be the reason why various size shifts were witnessed in DLS 
measurements. Another possibility is when streptavidin adsorbs flat onto AuNP 
surface (Figure 4-7C), the size increases should be around 4 nm. However, this was 
not observed here. It should be noted that there was a chance of having mixed 
orientations of streptavidin on the AuNPs as well and that DLS is a technique that 
measures whole population of samples. 
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Figure 4-7 Graphics illustrate the possible orientations of streptavidin on AuNP 
surface. (A), vertical; (B), angled; and (C), flat orientations. 
 Furthermore, to confirm that the size increases of strep-AuNPs are not from 
aggregation before functionalisation, size distributions plots of each AuNP are shown 
in Figure 4-8. It is apparent from the plots that all strep-AuNPs had a narrow 
distribution, suggesting no pre-aggregation had occurred when the storage buffers 
were removed and 10 mM PBS buffer (pH 7.4) was used for resuspension. 
   
Figure 4-8 Size distribution plots of all streptavidin coated AuNPs (strep-AuNPs) with 
different core diameters. The AuNPs were centrifuged and replaced the storage 
buffer with 1 ml of 10 mM PBS buffer (pH 7.4) before DLS measurement was made; 
The core diameter of strep-AuNPs are ( ), 20 nm; ( ), 40 nm; ( ), 60 nm;               
( ), 80 nm; ( ), 100 nm. Data are obtained as described in Table 4-3. SD were 
omitted for clarity.  
 
0.1 1 10 100 1000 10000 100000
0
5
10
15
20
Size (nm)
%
 In
te
n
si
ty
            
152 
4.3.2 Conjugation of bioreceptors onto the AuNP surface 
To test the conjugation method, initially, 1 ml of streptavidin coated AuNPs 
(strep-AuNPs) with 40 nm core diameter (OD529 = 1) in 10 mM PBS buffer (pH 7.4) 
were mixed with 25 µg of each biotinylated IgG and C2 Affimer. The mixed solutions 
were incubated for 2 h at RT and free biotinylated bioreceptors were removed by 
centrifugation. Multiple wash steps were carried out to ensure that there was no 
unbound biotinylated IgG or Affimer left. Dot blotting, UV-spectrometry and DLS 
were used to confirm the conjugation. Figure 4-9 shows dot blotting results 
confirming that there were IgGs and C2 Affimers present on the AuNP surfaces. 
 
 
Figure 4-9 ECL dot blot immunoassay to check bioreceptors conjugation onto AuNPs. 
(A), left and right panels contained streptavidin coated AuNPs (strep-AuNPs) and IgG-
conjugated AuNPs (IgG-AuNPs), respectively; (B), left and right panels contained 
strep-AuNPs and C2 Affimer-conjugated AuNPs (C2-Affimer-AuNPs), respectively. 
The blots were tested for the presence of bioreceptors through an ECL immunoassay 
with goat anti-rabbit IgG HRP-conjugated and anti-His6-HRP-conjugated as primary 
antibodies (1:1000) for IgG and C2 Affimer, respectively. 
 
 Additionally, UV-spectrometry was used to confirm the conjugation process. 
The absorbance spectra of strep-AuNPs before and after functionalisation were 
measured. As shown in Figure 4-10, strep-AuNPs with 40 nm core diameter exhibited 
localised surface plasmon resonance (LSPR) peak at 529 nm. After conjugation with 
IgGs and C2 Affimers, the LSPR peak shifted to 538 and 534 nm, respectively. The 
shift to longer wavelengths after the conjugation was expected because modification 
of the NP surface could affect the local refractive index of the NPs, leading to LSPR 
changing. 
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Figure 4-10 The absorbance spectra of strep-AuNPs before and after conjugation 
with IgG or C2 Affimer. ( ), strep-AuNPs without bioreceptors; ( ), IgG conjugated 
AuNPs (IgG-AuNPs); ( ), C2 Affimer conjugated AuNPs (C2-Affimer-AuNPs); the 
expanded spectrum inset shows the shift of LSPR peaks after conjugation. The AuNPs 
were diluted 1:1 with 1X PBS buffer (pH 7.4) then 200 µl of each AuNPs were 
transferred to a 96-well plate and scanned across the wavelength of 400 – 700 nm 
using a FLUOstar Omega plate reader. 
 
Furthermore, DLS was another technique used to confirm the 
functionalisation. The average sizes of the strep-AuNPs before and after the 
conjugation were measured and are reported in Table 4-4. The mean DH of strep-
AuNPs was 54.97 ± 1.31 nm, which was consistent as previously reported in section 
4.3.1. Upon conjugation of bioreceptors to the AuNPs, the sizes shifted to different 
extents depending on whether IgG or Affimer were coupled. For IgG, it was observed 
that the size increased by around 18.83 nm. This increase in particle size was 
expected as the mean DH of IgG was reported to be 7 – 10 nm, so an increase of 15 
– 20 nm would be expected (Driskell et al., 2011). For C2 Affimer, the size shifted by 
around 7.8 nm. Again, this corresponded to around twice its diameter (~ 3 nm). 
Besides the mean DH, DLS provides size distribution data. Figure 4-11 presents the 
size distribution plots of IgG- and C2-Affimer-AuNPs compared to strep-AuNPs. A 
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narrow distribution was observed in both systems indicating no aggregation 
occurred. These data further confirm the success of functionalisation via the 
streptavidin-biotin interaction. 
Table 4-4 Mean DH of strep-AuNPs (40 nm core diameter) before and after 
conjugation with IgGs and C2 Affimers via the streptavidin-biotin interaction. 
Triplicate measurements were carried out as described in Table 4-3. 
Nanobiosensors 
Mean DH 
(nm) 
SD  
(n = 3) 
strep-AuNPs 54.97 1.31 
C2-Affimer-AuNPs 62.72 1.16 
IgG-AuNPs 73.80 1.96 
 
 
Figure 4-11 Size distribution plots of streptavidin coated AuNPs before and after 
functionalisation with IgGs and C2 Affimers. The lines represent streptavidin coated 
AuNPs: ( ),without bioreceptors; ( ), functionalised with IgGs; ( ), functionalised 
with C2 Afffimers. Data are obtained as described in Table 4-3. SD were excluded for 
clarity.  
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4.3.3 Optimising functionalisation 
Optimisation was carried out to investigate factors affecting the 
functionalisation and thereby to maximise the binding activity of the 
nanobiosensors. In this section, the time of incubation and concentration of 
bioreceptors were investigated using DLS. 
 
4.3.3.1 Time of incubation 
Incubation time between biotinylated binding proteins (IgG and C2 Affimer) 
and strep-AuNPs was studied using strep-AuNPs with 40 nm core diameter and DLS. 
The experiments were performed by mixing 50 µg of each bioreceptors with the 
AuNPs at a concentration of OD529 = 1. The mean DHs of each AuNP were recorded 
over a 2 h time period to optimise the functionalisation time. As shown in Figure 4-
12, after strep-AuNPs were mixed and incubated with the biotinylated proteins, 
there was a gradual increases of both IgG-AuNP and Affimer-AuNP sizes over time. 
For IgG-AuNPs, the size shift started to reach a maximum at around 20 nm and 
leveled off after about 1 h of incubation; whilst the Affimer system took slightly 
longer to reach its maximum shift of around 10 - 11 nm after around 1.30 h. The 
incubation time was investigated with other AuNP core diameters (20, 60, 80 and 
100 nm) as well and the data are shown in Figure 4-13. 
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Figure 4-12 Effect of incubation time on AuNP functionalisation via the streptavidin-
biotin interaction for AuNPs with 40 nm core diameter.  Size shifts of streptavidin 
coated AuNPs (1 ml of AuNPs concentration at OD529 = 1) mixed with 50 µg in a 500 
µl volume of ( ), biotinylated IgG; and ( ), biotinylated C2 Affimer were recorded 
over 3 h of incubation time. Data are mean ± SD (n = 3). 
 
The data from 20 and 60 nm AuNPs support the observation on 40 nm AuNPs 
that after 1 h and 1.30 h respectively, the IgGs and C2 Affimers size had shifted the 
maximum. This might be due to the thermodynamics of molecules trying to align 
themselves into the lowest energy conformation. Also, C2 Affimers are much smaller 
than IgGs so it is likely that more Affimers were attached to strep-AuNPs and 
required more time to orientate on the AuNP surface. However, with 80 and 100 nm 
AuNPs, it was observed that both IgG- and C2-Affimer-AuNPs size shifts had reached 
their maximum shifts faster, at 45 min and 1 h for IgG and C2 Affimer, respectively. 
Overall, these data suggested that an optimum incubation time is more than 1 and 
1.30 h for IgG and Affimer, respectively. To generalise the protocol for DLS assay, 2 
h of incubation time was used throughout the experiment in preparation of AuNP 
nanobiosensors. 
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Figure 4-13 Effect of incubation time on AuNP 
functionalisation via the streptavidin-biotin 
interaction for different sizes of AuNPs. 
Experiments were performed as described in 
Figure 4-12 with AuNPs size of (A), 20 nm; (B), 
60 nm; (C), 80 nm; and (D), 100 nm. Size shifts 
of streptavidin coated AuNPs mixed with 50 µg 
in a 500 µl volume of ( ), biotinylated IgG; 
and ( ), biotinylated C2 Affimer. Data are 
mean ± SD (n = 3). 
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4.3.3.2 Concentration of biotinylated bioreceptors 
The concentration of biotinylated bioreceptors used in functionalisation is 
also another important factor to be considered. Too few bioreceptors may lead to 
unsaturated surfaces regions on the AuNPs whilst excess protein may result in free 
bioreceptor in the system. In both cases an assay performance would possibly be 
affected. Figure 4-14 shows the size shift of strep-AuNPs with 40 nm core diameter 
(OD529 = 1) after incubation for 2 h with different amounts of biotinylated IgG and C2 
Affimer. Their maximum shifts reached ~ 16 and 8 nm for IgG and C2 Affimer, 
respectively at amounts above 25 µg. The effect of bioreceptor concentration was 
also explored with other AuNP core diameters (20, 60, 80 and 100 nm). The data are 
shown in Figure 4-15.  
 
Figure 4-14 Effect of bioreceptor concentration used in AuNP functionalisation via 
the streptavidin-biotin interaction for AuNPs with 40 nm core diameter. Size shifts 
of streptavidin coated AuNPs (1 ml of AuNPs concentration at OD529 = 1) after 
conjugation with different amount of biotinylated IgG and C2 Affimer in a total 
volume of 1.5 ml. ( ), represents IgG-AuNPs; and ( ), represents C2-Affimer-
AuNPs. Data are mean ± SD (n=3). 
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The data of 60, 80 and 100 nm show similar trends as the 40 nm AuNPs as 
above the amount of 25 µg; maximum shifts had reached and levelled off. Whereas 
for 20 nm AuNPs, the maximum shifts of IgG- and C2-Affimer-AuNPs started to level 
off at an amount above 15 µg. This might be due to their smaller size in which 
required less bioreceptor to fully cover the surface. Based on these experiments, 
surface coverage of bioreceptors was not increased by the addition of more than 25 
µg biotinylated IgG or C2 Affimer. Therefore, the amount of 25 µg biotinylated IgG 
and C2 Affimer was used in subsequent functionalisations as being the most suitable 
for a generalised protocol.
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Figure 4-15 Effect of bioreceptor 
concentration used in AuNP 
functionalisation via the streptavidin-
biotin interaction for different sizes of 
AuNPs. Experiments were performed as 
described in Figure 4-14 with AuNPs size 
of (A), 20 nm; (B), 60 nm; (C), 80 nm; and 
(D), 100 nm. Size shifts of streptavidin 
coated AuNPs after conjugation with 
different amount of biotinylated IgG and 
C2 Affimer. ( ), shows IgG-AuNPs; and 
( ), shows C2-Affimer-AuNPs. Data are 
mean ± SD (n = 3). 
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4.4 Quantification of bioreceptors on the AuNP surface 
The characterisations of nanobiosensors carried out in the previous section 
are all indirect method and these methods could not provide the actual amount of 
binding proteins conjugated onto the AuNP surface. One, indirect way to quantify 
the amount of attached bioreceptors is to quantify bioreceptors left in the 
supernatant after conjugation using the Bradford or BCA protein assays. However, 
overestimation of attached bioreceptors is commonly found when using this indirect 
method as proteins are sticky and stick to container, e.g. Eppendorf, used for 
manipulation. Therefore, a direct method is preferable despite it being a more 
complicated protocol.  
In this section, a direct method was used to quantify bioreceptors (IgGs or 
Affimers) attached to the AuNPs. This method was adapted from a study by Filbrun 
and Driskell (2016). This direct method comprises two main parts; (i), dissolution of 
AuNPs and (ii), quantification of gold and the bioreceptors. First, the IgG- and C2-
Affimer-AuNPs were prepared with 40 nm core diameter AuNPs under optimised 
conditions. Then, KI/I2 etchant solution was used to dissolve the AuNPs. Here, 
complete dissolution of gold was confirmed by ICP-MS instead of AAS, which 
provided the amount of gold in solution. IgG- and C2-Affimer-AuNPs were 
centrifuged at 4,500 xg for 30 min after the last wash step, the supernatants 
obtained were kept and sent for gold quantification by ICP-MS in order to confirm 
that all AuNPs were completely pelleted. Figure 4-16 shows the concentration of 
gold in 1 ml samples measured with ICP-MS for both IgG- and C2-Affimer-AuNPs.  
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Figure 4-16 Concentration of gold from 1 ml AuNP nanobiosensors obtained by ICP-
MS analysis. Data are mean ± SD (n = 3). 
 
 The concentrations obtained by ICP-MS indicated that all AuNPs in both IgG- 
and C2 Affimer systems were fully dissolved because there was no gold left in the 
supernatants. The number of AuNPs in the solutions was calculated using an 
information provided by the manufacturer that one nanoparticle of 40 nm core 
diameter has a gold mass of 6.47 x 10-16 g. Therefore, each IgG- and C2-Affimer-AuNP 
contained 8.39 x 1010 and 8.72 x 1010 NP/ml, respectively which were comparable to 
the manufacturer’s information which gave 8.99 x 1010 NP/ml. The number of AuNPs 
obtained from ICP-MS were less than the information given in the data sheet. This 
might be due to the loss of some AuNPs during multiple washing steps. A summary 
of all gold concentrations obtained by ICP-MS for other AuNPs are reported in Table 
4-5. The AuNPs with 20 and 60 core diatmeters showed a similar trend to the 40 nm 
AuNPs. The 80 and 100 nm AuNPs data, conversely, showed more AuNPs obtained 
from the experiment. A likely explanation is that there were batch-to-batch 
variations of AuNP production and the reported numbers from the manufacturer 
were estimates. 
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Table 4-5 Comparison of theoretical and ICP-MS measured AuNP concentrations.  
Core 
diameter 
(nm) 
Theoretical AuNP 
concentration (NP/ml) 
AuNP concentration (NP/ml) 
IgG-AuNPs C2-Affimer-AuNPs 
20 7.00 x 1011 6.44 x 1011 6.21 x 1011 
40 8.99 x 1010 8.39 x 1010 8.72 x 1010 
60 1.96 x 1010 1.11 x 1010 1.40 x 1010 
80 7.82 x 109 9.23 x 109 9.42 x 109 
100 3.84 x 109 5.95 x 109 6.00 x 109 
 
 After dissolution of the AuNPs, the IgGs and Affimers conjugated onto the 
AuNP surface were released into the solution and the concentrations of these 
proteins was measured using a fluorescent dye NanoOrange. Two sets of IgG and C2 
Affimer standard solutions were prepared to generate accurate calibration curves 
for both nanobiosensors. The calibration curves are shown in Appendix 7. Also, 
before quantification of proteins, the interferents (e.g. KI/I2) were removed by using 
a 7K MWCO spin desalting column. In this project, strep-AuNPs were used, therefore 
they were used as a baseline in the fluorescent quantification method to ensure that 
streptavidin did not interfere with the actual amount of binding protein estimated. 
The indirect method was also carried out by using the Bradford assay to determine 
the biotinylated IgG or C2 Affimers left in the supernatant. Again, two sets of 
calibration curves were generated using IgG and C2 Affimer standard solutions (the 
calibration curves are reported in Appendix 8).  
Figure 4-17 compares numbers of IgG and C2 Affimers conjugated to AuNP 
obtained by direct and indirect quantification methods. These results correlated with 
the previous study by Filbrun and Driskell (2016) in that the indirect method 
overestimated the amount of the molecules attached onto AuNP surface. For IgG-
AuNPs, the direct method estimated 280 ± 49 IgGs/NP, compared to 509 ± 91 
IgGs/NP obtained using the Bradford assay. Similar to C2-Affimer-AuNPs, the indirect 
method estimated 1014 ± 274 Affimers/NP, which was double the amount 
quantified by the direct method (565 ± 115 Affimers/NP).  
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Figure 4-17 The number of bioreceptor molecules conjugated onto AuNP surface 
compared between the direct and indirect quantification methods. (  ), shows the 
quantification using the direct method; (  ), shows the indirect method using the 
Bradford assay to quantify left over bioreceptors in supernatants. Data are mean ± 
SD (n = 3). 
  
One interesting finding is that the number of C2 Affimer molecules 
conjugated per AuNP were more than the IgG for both methods. This may be 
explained by the fact that Affimers are 3 - 4 times smaller than IgGs, so more 
molecules could fit on to the surface. However, the conjugation method used here 
was via the interaction of biotin and previously adsorbed streptavidin on the AuNP 
surface. So attachment of biotinylated molecules may be restricted by the number 
of streptavidins present.  
The number of streptavidins was quantified using the fluorescence method. 
Figure 4-18 shows the comparison between the quantified streptavidin molecules 
on the AuNP surface, compared with the theoretical number of molecules 
calculated1. The theoretical number of streptavidins was calculated based on the 
surface area of spherical NPs of a given diameter (4𝜋𝑟2) and dimension of 
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streptavidin (2 x 11.3 = 22.6 nm2) (Neish et al., 2002). Also, it was assumed that the 
proteins take up a square footprint on the surface of NPs and are perfectly packed 
so there is no surface area left to waste. The experimental data shows slightly more 
of streptavidins coated onto the NPs than the calculated data. A possible explanation 
might be that the curvature of NPs was not included in the assumption of the theory. 
It is likely that with the curvature of NPs, less steric hindrance was present and lead 
to underestimated theoretical data for streptavidin molecules packing. 
 
 
Figure 4-18 Number of streptavidin on AuNP (molecule/NP). Comparison between   
( ), the calculated data based on NP surface area and ( ), measured data 
obtained by the direct fluorescence method. Measured data are mean ± SD (n = 3). 
 
In addition, when plotting the numbers of IgG and C2 Affimer obtained from 
the direct quantification method for 20, 40, 60, 80 and 100 nm core diameters AuNP 
nanobiosensors (Figure 4-19), it was apparent that for every core diameter AuNP, C2 
Affimer numbers were higher than the IgG numbers. These results are in line with 
Ferrigno (2016) who suggested that the compact size of Affimers could increase the 
density of bioreceptors aligned on a sensor surface. Streptavidin is tetrameric and 
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contains four identical subunits each with a binding site for biotin. However, around 
1 – 2 binding pockets were estimated to be avaible for binding after coupling to the 
AuNPs.  
 
 
Figure 4-19 Number of bioreceptors on AuNP (molecule/NP). The measured data 
were obtained by the direct fluorescence method and are presented with ( ), 
streptavidin; ( ) IgG; ( ), C2 Affimer. Data are mean ± SD (n = 3). 
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4.5 Discussion 
In this section, the preparation of AuNP nanobiosensors has been explained 
together with their characterisation. Streptavidin-biotin coupling was selected as a 
main mechanism for attaching bioreceptors onto the AuNP surface. It is a very strong 
non-covalent bonding that has been successfully used for many conjugation 
processes (e.g. Aslan et al., 2004; Liu and Huo, 2009; D’Agata et al., 2017). Among a 
variety of biotin linkers, biotin hydrazide was selected for biotinylation of IgG as it 
interacts with oxidized carbohydrates at the Fc region and leads to an orientated IgG 
on the AuNPs. Whereas biotin malemide was used with Affimers as they contain a 
single cysteine at the C-terminus. The success of biotinylation was confirmed by 
ELISA. Mass spectrometry was carried out in the case of C2 Affimer; using this 
approach for IgG was not possible as it was a polyclonal reagent. However, in 
principle it could be used with a monoclonal IgG. Both techniques confirmed the 
biotinylation of IgGs and Affimers. In addition, the obtained mass spectra confirmed 
that the aggregates formed after purification of Affimers were due to their 
dimerization. 
For the functionalisation process, strep-AuNPs were mixed with biotinylated 
IgGs and Affimers and interaction allowed to occur. Dot blotting, UV-
spectrophotometry and DLS were used to confirm the functionalisation. These 
techniques are not quantitative analyses that provide the actual number of 
bioreceptors on each AuNP. However, they were rapid, easy to perform and 
provided quick characterisation of the nanobiosensors. The shift to longer 
wavelength in LSPR of IgG coated AuNPs corresponded to previous studies (Kumar 
et al., 2008; Zhang et al., 2015; D’Agata et al., 2017). In addition, C2 Affimers tagged 
AuNPs showed a similar, but smaller shift. This is probably due to the size of Affimers 
which are smaller than IgGs. DLS provided size distribution data in order to check 
whether there was no pre-aggregation occurring during the functionalisation 
process. The DLS data are in line with previous studies that when proteins are fully 
coated onto the AuNP surfaces, the mean DH increases by at least twice the diameter 
of protein used. However, orientation of proteins might affect the DH obtained and 
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therefore, a combination of techniques should be used to characterise the 
nanobiosensors produced. 
A direct quantitation method was also conducted to further study the AuNP 
functionalisation. The method was based on the dissolution of the AuNPs and direct 
quantitation of the dissolved gold by ICP-MS and released bioreceptors by a 
fluorescent method using NanoOrange dye. It proved to be more effective in 
comparison to the indirect method used which tended to overestimate the amount 
of bioreceptor conjugated onto the AuNP surface, as it mainly determined the free 
biotinylated bioreceptors left in the supernatant. However, proteins are sticky and 
could stick to the container and not just the AuNP. The data obtained from the direct 
method showed that C2 Affimers were packed more densely onto AuNPs (565 
Affimers/NP) compared to IgGs (280 IgGs/NP). This was predicted as the Affimers 
are 3 - 4 times smaller in size than IgG, despite there being a similar number of 
streptavidin molecules on the AuNP surface. This might occur due to streptavidin’s 
four binding pockets per molecule for biotin, even if being coated on AuNPs, it was 
estimated that at least two binding positions were free for interaction. An 
implication of this is the possibility that the Affimer nanobiosensors may provide 
better sensitivity in size shift assay since there are more of them attached to the 
AuNP surface. 
Various factors related to the AuNPs functionalisation were investigated as 
well. It was found out that after 1 h and 1.30 h, there was no increase in mean DH 
with longer incubations for IgGs and C2 Affimers, respectively. This might be due to 
thermodynamic of molecules trying to align themselves into the lowest energy 
conformation. This idea was supported by the quantitation of IgGs and C2 Affimers. 
With more molecules conjugated onto AuNP surface, a longer time is required in 
arranging them into their most suitable positions. Regarding the amount of 
biotinylated bioreceptor used, there was no difference between IgG and C2 Affimer 
in that the amounts higher than 25 µg of the proteins provided a stable size shift 
except with 20 nm AuNPs where at the amounts above 15 µg, the maximum shifts 
were observed in both IgG and C2 Affimer. However, it should be noted that the 
molar concentrations of IgGs and C2 Affimers used in the conjugation process were 
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different since an Affimer is about 1/12th Mr of an IgG (Mr = 12.5 kDa and 150 kDa 
for Affimer and IgG, respectively). So, a 25 µg IgG is equal to 0.16 nmol, whereas 25 
µg of C2 Affimer is equal to 2 nmol in a total volume of 1.5 ml. This might be another 
reason why C2 Affimers attached more to the surface and required more time to 
align themselves on the AuNP surface. Nevertheless, the data obtained from DLS 
showed saturation of IgG on the AuNP surface at 25 µg as well as C2 Affimer.   
Here, the optimised functionalisation was successfully established by 
incubating 25 µg of biotinylated bioreceptors with strep-AuNPs for 2 h. Dot blotting, 
UV-spectrophotometry or DLS can be used in semi-quantitative characterisation of 
the nanobiosensors. The Chapter that follows moves on to consider the design of NP 
size shift assay using the nanobiosensors prepared and DLS. 
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Chapter 5 NP-coupled DLS size shift assay 
5.1 Introduction 
Once the functionalisation of AuNPs had been successfully optimised (Chapter 
4), the nanobiosensors were prepared and used in the NP-coupled DLS assay for 
detecting our model analyte, myoglobin (Mb). In this Chapter, anti-Mb Affimers 
(Chapter 3) were used in a systemic study on Mb detection. Various factors related 
to the size shift assay have been investigated such as kinetics of aggregation, avidity 
effects of the bioreceptors, effect of NP size and concentration, stability of 
nanobiosensors and Affimers-based system compared to IgG-based system. In 
addition, the optimised method was used with other protein analytes to test the 
versatility of the assay. To avoid confusion throughout this chapter, the ‘analyte’ will 
refer to Mb unless otherwise stated. Also, ‘antibody (IgG)’ and ‘Affimer’ will refer as 
specific binding reagents for Mb. Moreover, the streptavidin coated AuNPs (strep-
AuNPs) with 40 nm core diameter were used except when the effect of size was 
tested.  
 
5.2 Kinetics study 
Regarding the NP size shift assay, it is important to understand the kinetics of 
the NP aggregation assay to properly design the assay format. The kinetics study was 
conducted by mixing Mb conjugated AuNPs (Mb-AuNPs) and Affimer conjugated 
AuNPs (Affimer-AuNPs) in a 1:1 volume ratio. Crosslinking of the AuNPs should occur 
due to the binding between Mb and Affimers (mixed C2 and F5 Affimers), leading to 
a shift in size. Streptavidin coated AuNPs (strep-AuNPs) and IgG conjugated AuNPs 
(IgG-AuNPs) were used as negative and positive controls respectively. Monitoring 
the change in size intermittently during 24 h provides an overview of the kinetics as 
well as the ability of DLS in detecting the aggregation events.  
All the nanobiosensors were prepared via streptavidin-biotin coupling, with 
Mb, Affimers and IgGs being biotinylated using biotin NHS, biotin maleimide and 
biotin hydrazide, respectively. Then, 25 µg of each biotinylated protein was 
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incubated with 40 nm core size strep-AuNPs for 2 h at RT. More details of conjugation 
process are detailed in Chapter 4. Table 5-1 shows the original sizes of all 
functionalised AuNPs used in the kinetics study. 
 
Table 5-1 Original sizes of all functionalised AuNPs used in the kinetics study 
measured by DLS. 100 µl of each AuNPs was transferred to a small volume cuvette 
and measured three times with 10 runs at 10 s/run. Data were obtained from 
triplicate measurements.  
Functionalised AuNPs 
Mean DH 
(nm) 
SD 
(n=3) 
Streptavidin coated AuNPs 55.28 1.17 
Myoglobin conjugated AuNPs 64.08 1.38 
IgG conjugated AuNPs 67.06 1.67 
Affimer conjugated AuNPs 61.88 1.47 
 
 
The mean DH after the conjugation of all funtionalised AuNPs indicated that 
each protein were fully coupled to the AuNP surfaces. As described in the earlier 
chapters, when proteins were fully coating the AuNPs, the mean DH of the particles 
is expected to increase at least by twice the diameter of that protein molecule. For 
Mb-AuNPs the size increased from 55.28 ± 1.17 to 64.08 ± 1.38 nm, which 
corresponded roughly to twice the diameter of Mb (D ~ 3.5 nm). Similarly, Affimer 
AuNPs sizes increased by around 6.6 nm, the shift in size was correlated with its 
diameter (~ 2 – 3 nm). However, the IgG-AuNP size shifted only by around 11.78 nm, 
which was slightly lower than expected, as the DH of an IgG is around 7 – 10 nm. This 
is probably due to the orientation of IgG on the AuNP surface. Still, the size 
distribution plots confirmed that the size distributions were narrow and there were 
no signs of aggregates presented (Figure 5-1).  
The mean DH values of the 1:1 volume ratio mixed solutions between Mb-
AuNPs and three different nanobiosensors are illustrated in Figure 5-2. When Mb-
AuNPs were mixed with strep-AuNPs, the mean DH remained the same and there 
was no significant increase in size even after 24 h incubation. Conversely, the size 
increased linearly in both IgG and Affimer systems during the incubation time. After 
24 h, the size of Affimer-AuNPs increased from 61.88 ± 1.47 to 118.67 ± 4.11 nm. 
Whilst, the size of IgG-AuNPs increased from 67.06 ± 1.67 to 131.90 ± 4.32 nm. The 
              
173 
 
increases in size of the AuNPs were due to specific binding events between 
IgG/Affimer and Mb on the AuNPs and eventually led to crosslinking of the particles.  
 
 
Figure 5-1 Size distribution plots of all functionalised AuNPs used in the kinetics 
study. The measurements were performed as described in Table 5-1. SD were 
excluded for clarity. (A), myoglobin conjugated AuNPs (Mb-AuNPs); (B), anti-
myoglobin IgG conjugated AuNPs (IgG-AuNPs); (C), anti-myoglobin Affimer 
conjugated AuNPs (Affimer-AuNPs); The size and size distribution of streptavidin-
AuNPs before, ( ) and after, ( ) conjugation process.    
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Figure 5-2 The average hydrodynamic diameter (DH) of a 1:1 volume ratio mixture of 
myoglobin conjugated AuNPs (Mb-AuNPs) and three different nanobiosensors over 
24 h. 50 µl of Mb-AuNPs was mixed with 50 µl streptavidin coated AuNPs, ( ); anti-
myoglobin IgG conjugated AuNPs, ( ); and anti-myoglobin Affimer conjugated 
AuNPs, ( ). Data are mean values ± SD (n=3).  
 
 
Closer inspection of data shows that the size-shift rate was much faster in the 
first 100 min of incubation. After that the size still increased but at a much slower 
rate. A possible explanation would be that dispersed AuNPs move at a certain rate 
and once dimers and trimers formed, these larger AuNPs move slowly than 
monomers, which led to a slower interaction rate. Figure 5-3 shows the mean DH of 
each mixed solution in the first hour of incubation. After 30 min, it was obvious that 
the mean DH had shifted from the baseline for both IgG and Affimer based systems.  
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Figure 5-3 The average hydrodynamic diameter (DH) of a 1:1 volume ratio mixture of 
myoglobin conjugated AuNPs (Mb-AuNPs) and three different nanobiosensors in an 
expanded scale. 50 µl of Mb-AuNPs was mixed with 50 µl streptavidin coated AuNPs, 
( ); anti-myoglobin IgG conjugated AuNPs, ( ); and anti-myoglobin Affimer 
conjugated AuNPs, ( ).The dashed lines represent the baseline DH in 0 min of each 
system. Data are mean values ± SD (n=3). (*) indicates significant values tested with 
independent t-test between experiment and their baseline DH (p < 0.05). 
In addition, Figure 5-4 shows the size distributions of all three mixed solutions 
compared at incubation times of 1 min and 24 h. It can be seen from the size 
distribution plots from Figure 5-4A that after 24 h, there was no significant shift in 
size for the negative control system, whilst, there were substantial shifts in size in 
the other two systems (Figure 5-4B and C). The size distribution plots obtained from 
DLS also provided details of the aggregates forming. In the case of the positive 
control using IgG-AuNPs, at 1 min most of NP population (> 90%) had a size < 100 
nm. At 24 h, however, a broader size distribution curve was observed with almost all 
of the population shifted to > 100 nm. This supported the idea that at 1 min the 
binding between Mb-AuNPs and IgG-AuNPs occurred to a limited extent, resulting in 
only a few dimers presence in the solution. However, after 24 h, more dimers, 
trimers and larger multimers formed, leading to a broader size distribution curve. 
The Affimer based system showed a similar trends compared to the IgG based 
nanobiosensors.  
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Figure 5-4 The size distributions of all three mixed solutions comparing at incubation 
times of 1 min, ( ); and 24 h, ( ).  (A), Mb-AuNPs + strep-AuNPs; (B), Mb-AuNPs + 
IgG-AuNPs; and (C), Mb-AuNPs + Affimer-AuNPs. Data obtained as described in 
Figure 5-2. 
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5.3 Detection of myoglobin using NP-coupled DLS size shift assay 
5.3.1 Antibody (IgG) based assay 
IgG conjugated AuNPs (IgG-AuNPs) have been successfully used in various 
affinity assays using DLS. Therefore, as a comparator, polyclonal Ab (IgG) 
functionalised AuNPs were prepared and used to detect Mb. To enable comparison 
between different nanobiosensors, the shift in size from the original AuNP size will 
be plotted instead of the absolute mean DH. Biotinylated IgG via biotin-hydrazide 
were linked to strep-AuNPs according to the method optimised in Chapter 4. The 
IgG-AuNPs prepared were characterised with DLS before used. The mean DH was 
71.08 ± 1.37 nm and the size distribution plot also showed no aggregation during the 
conjugation (Appendix 9A). The mean DH of IgG-AuNPs before and after mixing with 
the analyte over the concentration range 10 fM to 10 µM was measured by DLS after 
incubation at RT for 30 min. Strep-AuNPs were used instead of IgG-AuNPs as negative 
control. The results are shown in Figure 5-5.  
 
 
 
 
 
 
 
 
Figure 5-5 Size shift of Mb (90 µl) mixed with IgG nanobiosensors (10 µl) after 
incubating at RT for 30 min. IgG conjugated AuNPs, ( ); streptavidin coated AuNPs 
as a negative control, ( ); each DLS measurement was performed at 10 s/run for 10 
runs, data are mean values ± SD (n=3). (*) indicates significant values tested with 
independent t-test between experiment and negative control (p < 0.05). 
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It is apparent from the data that the size of strep-AuNPs remained almost the 
same with a < 5 nm shift,  whilst, for IgG-AuNPs the size shifted gradually when the 
concentration of Mb increased from 10 fM to around 10 nM in a linear response. 
Above concentrations of 10 nM, the size shift dropped substantially and showed a 
non-linear response. The data obtained from IgG-AuNPs is similar to that formerly 
reported regarding particle aggregation assays (Liu and Huo, 2009; Driskell et al., 
2011; Khan et al., 2015). A possible explanation for this might be that all the 
nanobiosensors were saturated with analytes so there were no free bioreceptors to 
crosslink between NPs. This resulted in increasing of size due to the binding of 
analytes to nanobiosensors but there was no crosslinking between AuNPs so there 
was no aggregation observed by DLS. This type of response is known as the ‘hook 
effect’ (previously explained in section 1.4.3.2.1, Chapter 1). The upper detection 
limit was restricted by the concentration at which the hook point started, in this case 
over 10 nM. 
Data was initially fitted using a one-site binding profile to derive initial values 
for the binding parameters for the system. The equation governing the one site 
model is shown as: 
𝐵 =
𝐵𝑚𝑎𝑥∗[𝐿]
𝐾𝐷+[𝐿]
+ 𝑐  (5-1) 
where 𝐵 and 𝐵𝑚𝑎𝑥 is size shift and maximum size shift (nm), respectively, [𝐿] is 
concentration of analyte (M), 𝐾𝐷 is binding constant (M) and 𝑐 is a constant value. 
However, the one-site model might not be the right choice considering the fact that 
a pAb was used in the system, which means there would be more than one 
population of receptors affecting the binding. For this reason, a multiple-site binding 
model was implemented for polyclonal reagents such as the anti-Mb IgG used. The 
equation represents the multiple-site binding kinetics is shown as: 
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𝐵 = {𝐷 ∗ (
𝐵𝑚𝑎𝑥1∗[𝐿]
𝐾𝐷1+[𝐿]
)} + {𝐸 ∗ (
𝐵𝑚𝑎𝑥2∗[𝐿]
𝐾𝐷2+[𝐿]
)} +  …  + {𝑍 ∗ (
𝐵𝑚𝑎𝑥𝑛∗[𝐿]
𝐾𝐷𝑛+[𝐿]
)} + 𝑐         (5-2) 
The multiple-site binding model allows all different populations in the system 
accountable for the binding constants (𝐷, 𝐸, 𝑍) to be calculated. By substituting a 
one-site binding model with a two-site binding model (in which equal populations of 
binders were assumed), the R2 and 2 were improved from 0.9384 and 4.438 to 
0.9953 and 1.739, respectively. The fitting curves of both models are shown in Figure 
5-6. When trying to fit with more than a two-site model (e.g. three or more), 
however, there was no difference in terms of the binding parameters. This is 
probably due to the fact that the difference in affinity was too small so they could 
not be mathematically differentiated. Therefore, two-site binding model best 
represented the data. 
Regarding the limit of detection (LOD) of the assay, it is calculated as the 
minimum concentration of analyte which provides a signal that is greater than the 
maximum signal of the negative control plus three standard deviations. According to 
the data in Figure 5-6, the maximum mean plus three SDs of strep-AuNPs was 7.62 
nm. Hence, by using equation 5-2 and parameters derived from the fitting model 
(Table 5-2), an LOD of 148 fM could be obtained for the assay. 
Table 5-2 Binding parameters derived from one- and two-site fitting models of 
myoglobin assay using IgG-AuNP nanobiosensors. KD values obtained are apparent 
KDs as they are made up of a population of IgGs. Data was analysed using GraphPad 
Prism 7.0. 
Parameters One-site model Two-site model 
Bmax1 31.25 14.4 
KD1 6.05 x 10-11 1.22 x 10-12 
Bmax2 - 22.48 
KD2 - 2.47 x 10-10 
R2 0.9384 0.9953 
2 4.438 1.739 
c 9.756 6.047 
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Figure 5-6 One-site, (A); and two-site, (B) model fittings of an assay for Mb using IgG 
conjugated AuNPs in the concentration range of 10 fM – 10 nM. Measured data was 
illustrated by ( ), for IgG-AuNPs; ( ), negative control using strep-AuNPs; ( ), 
fitted data; ( ), negative control mean values plus their three SDs (n=3); ( ), 
maximum negative control mean value plus three SD (n=3). 
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5.3.2 Paired Affimer based assay 
Here, C2 and F5 anti-myoglobin Affimers were used as bioreceptors in NP-
coupled DLS assay, since Affimer pair ELISA performed previously suggested that 
they are most likely to bind to different epitopes (see Chapter 3). Both Affimers were 
biotinylated with biotin maleimide according to the optimised method in Chapter 4. 
Then, the same amount of each Affimer was conjugated onto strep-AuNPs. The pair 
of Affimer conjugated AuNPs (paired-AuNPs) prepared were characterised with DLS 
before use. The mean DH was 62.36 ± 2.01 nm and their size distribution plots 
showed no aggregation (Appendix 9B). Detection of Mb was performed using the 
paired-AuNPs in the same way as for the IgG based system. Figure 5-7 shows the size 
shift of paired-AuNPs in the presence of 10 fM to 10 µM Mb as compared to IgG-
AuNPs and strep-AuNPs.  
 
Figure 5-7 Size shift of Mb (90 µl) mixed with paired Affimer nanobiosensors (10 µl) 
after incubating at RT for 30 min in comparison with negative control. Paired Affimer 
conjugated AuNPs, ( ); streptavidin coated AuNPs as a negative control, ( ); each 
DLS measurement was performed at 10 s/run for 10 runs, data are mean values ± SD 
(n=3). (*) indicates significant values tested with independent t-test between 
experiment and negative control (p < 0.05). 
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From this data, there was a proportional response between the paired-
AuNPs size shift and concentration of Mb added until at a certain point when the size 
shift dropped and was no longer related to the concentration. This phenomenon 
again could be explained by the hook effect. In comparison to IgG-AuNPs, the size 
shift of paired-AuNPs showed a similar trend. The hook point started at the same 
concentration, which was 10 nM. However, the size shift of the paired Affimer 
system was less than with IgG-AuNPs at the same concentration of Mb. The 
maximum shift of IgG-AuNPs was 41.57 ± 3.31 nm, whereas paired-AuNPs maximum 
size-shift was only 24.36 ± 3.16 nm. 
 Because two different Affimers were used in this experiment, it was first 
assumed that a two-site binding model would be more suitable than a one-site 
binding model. Nevertheless, when a two-site model was used, there was no 
difference in terms of parameters derived, only slight change in 2 from 0.675 to 
0.954 (Table 5-3 and Figure 5-8). This is almost certainly due to the fact that the 
affinities of both C2 and F5 Affimers are similar and could not be distinguished from 
each other. Apparent KDs from SPR data reported earlier (see Chapter 3) are 5.06 
and 6.11 nM for C2 and F5, respectively. The LOD of paired-AuNPs in detection of 
Mb was 41.6 pM, which means the sensitivity of the assay was less than IgG-AuNPs 
that possessed an LOD of 148 fM. 
 
Table 5-3 Binding parameters derived from one- and two-site fitting models of 
myoglobin assay using paired-AuNP nanobiosensors. Data was analysed using 
GraphPad Prism 7. 
Parameters One-site model Two-site model 
Bmax1 21.05 10.52 
KD1 2.16 x 10-10 2.16 x 10-10 
Bmax2 - 10.52 
KD2 - 2.16 x 10-10 
R2 0.9962 0.9962 
2 0.675 0.954 
c 4.219 4.219 
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Figure 5-8 One-site, (A); and two-site, (B) model fittings of an assay for Mb using 
paired Affimers conjugated AuNPs in the concentration range of 10 fM – 10 nM. 
Measured data was illustrated by ( ), paired-AuNPs; ( ), negative control using 
strep-AuNPs; ( ), fitted data; ( ), negative control mean values plus their three SDs 
(n=3); ( ), maximum negative control mean value plus three SD (n=3). 
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5.3.3 Multiple Affimer based assay 
To increase the sensitivity of the Affimer based assay, a multiple Affimer 
based approach was investigated. Antibodies used in the positive control were 
polyclonal, which were selective to the analyte but bound at multiple binding sites. 
The high sensitivity of the antibody based system might result from this factor. A key 
aspect of using more than two Affimers as bioreceptors in NP-coupled DLS assay is 
to replicate the binding characteristics of a pAb. Therefore, all five Affimers available 
(see Chapter 3) were conjugated onto AuNPs using the same methods and used for 
Mb detection. The mean DH of multiple Affimer-functionalised AuNPs was 63.14 ± 
1.98 nm and the size distribution plot showed no aggregation before use (Appendix 
9C). The same assay format as IgG and paired-Affimer nanobiosensors was carried 
out. The size shifts of multiple-AuNPs in the presence of 10 fM to 10 µM Mb along 
with paired-AuNPs, IgG-AuNPs and strep-AuNPs are presented in Figure 5-9.  
 
Figure 5-9 Size shift of Mb (90 µl) mixed with multiple Affimer nanobiosensors (10 
µl) after incubating at RT for 30 min in comparison with negative control. Multiple 
Affimer conjugated AuNPs, ( ); streptavidin coated AuNPs as a negative control,    
( ); each DLS measurement was performed at 10 s/run for 10 runs, data are mean 
values ± SD (n=3). (*) indicates significant values tested with independent t-test 
between experiment and negative control (p < 0.05). 
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 As expected, multiple-AuNPs detected Mb when compared to strep-AuNPs. 
The data for multiple-AuNPs had the same trend as IgG-AuNPs and paired-AuNPs 
presented previously. However, the hook effect of multiple Affimer system occurred 
at a lower concentration of 1 nM. This might be because pAbs have many IgG clones 
that can bind to different epitopes and facilitate crosslinking between NPs before 
the hook effect occurred, whilst with five different Affimers, there were more limited 
opportunities for this effect. However, the paired Affimer nanobiosensor with only 
two different clones also showed the hook point at concentration above 10 nM. 
Therefore it is more likely that the AuNP concentration might affect the hook point 
as suggested by Driskell et al. (2011). In the preparation of the nanobiosensors, 
multiple washing steps were involved which could alter the NP concentration in 
multiple Affimer based system. Nevertheless, multiple-AuNPs showed a larger size 
shift as compared to paired-AuNPs. The maximum size-shift was 35.21 ± 3.32 nm, 
which is around 10 nm more than the paired-AuNPs. However, the response was still 
less than for IgG based systems. 
 Again, the measured data of multiple-AuNPs were fitted with both one- and 
two-site fitting models. When changing from a one-site to a two-site model, the R2 
and 2 were improved from 0.9577 and 3.231 to 0.9981 and 1.179, respectively 
(Table 5-4). The fitting curves of both models are shown in Figure 5-10. The result 
corresponded to the IgG based assay system. The LOD of the multiple Affimer based 
system was 554 fM. 
 
Table 5-4  Binding parameters derived from one- and two-site fitting models of 
myoglobin assay using multiple Affimer-AuNP nanobiosensors. Data was analysed 
using GraphPad Prism 7. 
Parameters One-site model Two-site model 
Bmax1 31.95 8.20 
KD1 1.05 x 10-10 3.18 x 10-13 
Bmax2 - 29.36 
KD2 - 2.06 x 10-10 
R2 0.9577 0.9981 
2 3.231 1.179 
c 6.005 2.681 
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Figure 5-10 One-site, (A); and two-site, (B) model fittings of an assay for Mb using 
multiple Affimer conjugated AuNPs in the concentration range of 10 fM – 10 nM. 
Measured data was illustrated by ( ), multiple-AuNPs; ( ), negative control using 
strep-AuNPs; ( ), fitted data; ( ), negative control mean values plus their three SDs 
(n=3); ( ), maximum negative control mean value plus three SD (n=3).  
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Once more, more than two-site fitting models were also tested as there were 
five Affimers present in the system. However, there was no significant difference 
when more than a two-site fitting model was used. This result is explained by their 
apparent KDs from SPR data. The KDs are reported in Table 5-5. The Affimers can be 
grouped into two subgroups according to their KDs; (i), B5, D1 and H1 with the KD of 
around 0.1 – 0.7 nM and (ii), C2 and F5 with the KD of around 5 – 6 nM. The two 
subgroups have a maximum 40 times KD difference between extremes (i.e. D1 vs F5). 
It is possible, therefore, that the overall binding characteristic of multiple-AuNPs 
could be explained by these two populations of Affimers. Interestingly, the 
parameters obtained from multiple-AuNPs fitting was correlated with the paired-
AuNPs. According to the data in Table 5-4, one of the apparent KDs obtained from 
the multiple-AuNPs was almost equal to the one obtained from paired Affimer based 
system; 2.06 x 10-10 and 2.16 x 10-10 M, respectively. These results further support 
the idea that if the difference in affinities are small, they cannot be mathematically 
differentiated.  
 
Table 5-5 Apparent KDs of five selected anti-myoglobin Affimers from SPR data. 
Affimer KD (M) 
B5 4.68 x 10-10 
C2 5.06 x 10-9 
D1 1.45 x 10-10 
F5 6.11 x 10-9 
H1 6.95 x 10-10 
 
5.3.4 TEM images 
To understand the assay further, size distribution plots of Mb mixed with 
multiple Affimer nanobiosensors at different concentrations were obtained (Figure 
5-11A-D). TEM were introduced in order to visualise the AuNPs undergoing 
aggregation. Representative TEM images at each Mb concentration together with 
their size distribution plots except for with 1 pM of Mb as there were no good quality 
images obtained (Figure 5-11E-H).  
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Figure 5-11 Size distribution plots of multiple Affimer nanobiosensors with and 
without Mb and their corresponded TEM images. Panels (A-D) shows the size 
distribution plots of multiple-AuNPs without Mb and with 1 pM Mb, 1 nM Mb and 
100 nM Mb, respectively; panels (E-H) shows representative TEM images for no Mb, 
1 nM Mb and 100 nM, respectively; multiple-AuNPs without Mb, ( ); with Mb 
present, ( ); H(1) and H(2) were from the same TEM grid but from different areas.
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The size distribution of multiple-AuNPs was characteristically narrow, 
suggesting that there was no aggregation prior to the addition of Mb. Accordingly, 
there were no clusters observed in the corresponding TEM image as well (Figure 5-
11A and E). When a low concentration of Mb (1 pM) was added, the size distribution 
became broader and shifted slightly to the right, indicating a binding event between 
the nanobiosensors and the analyte (Figure 5-11B). Still, the binding was not enough 
to crosslink the NPs into clusters and the shift in size observed might be due to some 
formation of dimers or trimers. At 1 nM Mb, which was equal to the hook point of 
multiple-AuNPs reported in the last section, the size distribution curves extensively 
shifted to the right (Figure 5-11C), suggesting there were aggregates forming. A TEM 
image of the sample confirmed this speculation (Figure 5-11G) where clusters were 
seen.  
Another concentration tested was in the region above the hook point (100 
nM). The size distribution curve obtained from this region (Figure 5-11D) was similar 
to the one obtained from mixed solution of the nanobiosensors and 1 pM Mb (Figure 
5-11B). Also, their mean DHs were almost equivalent, 73.73 and 72.54 nm for 100 
nM and 1 pM, respectively. It is likely that the abundance of Mb in the system fully 
saturated all Affimers on the AuNP surfaces and left no bioreceptor to enable AuNP-
crosslinking. This result was confirmed by the TEM image in Figure 5-11H(1), showing 
single AuNP coated with a thick protein layer. Closer inspection of the curve in Figure 
5-11D, however, shows that there was a small peak around 200 – 300 nm, indicating 
the formation of some larger AuNP clusters in the system. This result suggested that 
at above the hook point concentration, crosslinking might be able to occur but to a 
lesser extent as compared to the lower concentrations. This result corresponded to 
another area of the same TEM grid (Figure 5-11H(2)) where dimers, trimers or 
clusters were seen. 
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5.4 Non-specific control 
To investigate the selectivity of the assay, bovine serum albumin (BSA) was 
used as an analyte instead of Mb. Multiple-AuNPs and strep-AuNPs were used to 
detect BSA over 10 fM – 10 µM. The size-shifts of both nanobiosensors are shown in 
Figure 5-12. Both systems show similar trends, there was a slight shift in AuNP size 
in the presence of BSA after 30 min incubation. However, the shifts were less than 
10 nm and only above BSA concentration present > 10 nM, where the size shifts 
greater. At these concentrations was the range where the hook effect started when 
multiple-AuNPs were incubated with Mb. These results suggest that the system 
selective for Mb. 
 
 
Figure 5-12 Size shift of BSA (90 µl) mixed with multiple anti-myoglobin Affimer 
nanobiosensors (10 µl) after incubating at RT for 30 min. Multiple Affimers 
conjugated AuNPs, ( ); streptavidin coated AuNPs as a negative control, ( ); each 
DLS measurement was performed at 10 s/run for 10 runs, data are mean values ± SD 
(n=3). No significant difference (p<0.05) found between experiment and negative 
control. 
 
Previously, different protein analytes were used with the anti-Mb Affimer 
AuNPs to eliminate non-specific binding of the nanobiosensors to Mb. Here, anti-
calprotectin Affimers instead of anti-Mb Affimers were conjugated to AuNPs to 
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exclude non-specific binding of Mb itself. The anti-calprotectin Affimers 4 and 15 
were tested using direct ELISA (see Chapter 3) and showed no binding to Mb. Anti-
calprotectin Affimers conjugated AuNPs (cal-Affimer-AuNPs) were prepared and 
characterised. The mean DH of cal-Affimer-AuNPs was 62.91 ± 2.14 nm and the size 
distribution plot showed no aggregation before use (Appendix 9D). The cal-Affimer-
AuNPs were used as nanobiosensors in the presence of 10 fM to 10 µM Mb in the 
same manner as IgG and anti-Mb Affimer nanobiosensors. The results are shown in 
Figure 5-13. 
 
 
 
 
 
 
 
Figure 5-13 Size shift of Mb (90 µl) mixed with anti-calprotectin Affimer 
nanobiosensors (10 µl) after incubating at RT for 30 min. Anti-calprotectin Affimer 
conjugated AuNPs, ( ); streptavidin coated AuNPs as a negative control, ( ); each 
DLS measurement was performed at 10 s/run for 10 runs, data are mean values ± SD 
(n=3). No significant difference (p<0.05) found between experiment and negative 
control.  
   
It is apparent from the data that there was a slight increase in size (around 5-
6 nm). However, there was no significant difference found between the cal-Affimer-
AuNP and strep-AuNP response in terms of size shift after Mb was added to the 
system. Again, the size slightly shifted further when the concentration of Mb was > 
10 nM. This may be due to the fact that proteins such as BSA or Mb themselves have 
intrinsic scattering property and could be detected by DLS at high concentrations. 
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5.5 Effect of NP size 
According to the Mie theory, light scattering intensity is proportional to the 
6th power of the radius of the particle (Yguerabide and Yguerabide, 1998). Hence, it 
is hypothesized that with larger NPs, a larger scattering intensity could be detected. 
This might enhance the sensitivity of a size shift assay using DLS. Strep-AuNPs with a 
gold core diameter of 20, 40, 60, 80 and 100 nm were used to investigate the effect. 
To understand the effect of size better, IgG-AuNP nanobiosensors were prepared 
and tested along with the Affimers. The nanobiosensors were prepared and 
characterized according to the optimized method developed (Chapter 4). All of the 
nanobiosensors were used at 1x concentration as received. Figure 5-14 shows the 
size shift response curves from IgG- and multiple Affimer nanobiosensors. 
According to the data, the assay performance improved when the AuNP core 
diameter was changed from 20 to 40 nm in both systems. Nevertheless, when the 
core sizes of AuNPd were further increased to 60, 80 and 100 nm, there was no 
significant further effect. In addition, there was also no difference in the 
concentration where the hook effect started for multiple-AuNPs, but for IgG 
nanobiosensors, 20 nm AuNPs, the hook point was shifted slightly higher, from 10 
nM to 100 nM. In 80 and 100 nm core diameters AuNP, conversely, the hook points 
were decreased from 10 nM to 1 nM. These shifts were also reported in the size 
study by Driskell et al. (2011), which suggested that it might be due to different AuNP 
concentrations used. Further details about NP concentration will be discussed in the 
next section. 
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Figure 5-14 Effect of AuNP size on the DLS assay for Mb detection. The experiments 
were performed by mixing different concentration of Mb (90 µl) with 10 µl of each 
AuNP and incubated for 30 min before DLS measurement. (A) and (B) represents IgG- 
and multiple-AuNPs, respectively; line graph represents AuNP core diameters of (
), 20 nm;  ( ), 40 nm; ( ), 60 nm; ( ), 80 nm and ( ), 100 nm. The mean responses 
of triplicate experiments were reported but SD bars were omitted for clarity. Full 
data are shown in Appendix 10. 
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The LODs for each nanobiosensor preparation (20 to 100 nm AuNPs) were 
calculated by fitting a two-site binding model in the same manner as previous. Figure 
5-15 shows the LODs comparing between IgG and multiple Affimer based systems. 
The data confirm what was observed from the response curves earlier in that 40 nm 
core diameter provided a better sensitivity than 20 nm. The LODs were improved 
from 49.1 pM to 148 fM and 34.2 pM to 554 fM for IgG and Affimer AuNPs, 
respectively, whilst the LODs of 60, 80 and 100 nm AuNPs were slight better than 20 
nm AuNPs, still the sensitivities of both IgG- and multiple-AuNPs were not superior 
to the 40 nm AuNP nanobiosensors. 
  
 
Figure 5-15 Limit of detections (LODs) of DLS assay for Mb detection using different 
AuNP core diameters. ( ), IgG-based; and ( ), multiple-based nanobiosensors. 
This finding is contrary to most previous studies, which have suggested that 
increasing AuNP size could improve the sensitivity of the assay (Nietzold and Lisdat, 
2012; Wang et al., 2012). However, these data are in line with two studies by Driskell 
et al. (2011) and Huang et al. (2015). The first study compared influenza virus 
detection by 30, 60 and 80 nm AuNP core diameter sensors; anti-virus IgGs were 
used as bioreceptors. It was reported that the best sensitivity was obtained from the 
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30 nm AuNPs. There were two explanations; the concentration of NPs used were 
different and the steric hindrance of larger probes could restrict binding between 
biorecoptors and analytes, which lead to less aggregation. This particular reason was 
also used to explain of the results found by Huang et al. (2015) when they used AuNP 
core diameters of 30, 70 and 100 nm to detect the bacteria Listeria monocytogenes. 
The 30 nm AuNPs showed better responses in terms of size shift. In this case, Mb is 
a globular protein with the size of 3.5 nm, therefore, it could be that when large NPs 
like 60, 80 or 100 nm AuNP nanobiosensors were used, access to the binding epitope 
was restricted by steric hindrance which affects the binding stoichiometry. It is 
possible that using a linker to distance the Affimer from the AuNP surface may help 
here. Another interesting observation from this data is that when 20 nm core 
diameter AuNPs were used, the Affimer nanobiosensors provided better sensitivity 
compared to IgG-AuNPs. It is possible that since Affimers are smaller than IgGs, when 
larger AuNPs were used, there was a restrictions in binding to the Mb, leading to less 
sensitivity observed. 
 
5.6 Effect of NP concentration 
NP concentration is expected to be one of the important factors affecting a 
DLS assay as DLS measures the whole population of particles. When concentrated 
nanobiosensors are used, a higher concentration of analyte is required to crosslink 
all of the nanobiosensors and it is likely to have individual AuNPs in the system. 
Conversely, it is estimated that a greater shift in size could be obtained from dilute 
nanobiosensors as there are fewer single AuNPs left in the system and lead to better 
sensitive assay. To investigate the effect of NP concentration, the DLS assay was 
conducted using four different concentrations of IgG- and multiple Affimer-AuNPs. 
The data are shown in Figure 5-16. 
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Figure 5-16 Effect of AuNP nanobiosensor concentration on the DLS assay for Mb 
detection. The experiments were performed by mixing different concentration of 
Mb (90 µl) with 10 µl of each nanobiosensor and incubated for 30 min before DLS 
measurement. (A) and (B) represents IgG- and multiple-AuNPs, respectively; line 
graphs represents four different concentrations of AuNPs used in Mb detection;           
( ), 0.01x AuNP (8 x 108 NP/ml);  ( ), 0.1x AuNP (8 x 109 NP/ml); ( ), 1x AuNP (8 
x 1010 NP/ml); ( ), 10x AuNP (8 x 1011 NP/ml). The experiments were performed by 
mixing 10 Data are mean values ± SD (n=3). 
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To obtain more dilute nanobiosensors, PBS was used to dilute the stock; 
whilst concentrated nanobiosensors were obtained by centrifugation and 
redispersion in a smaller volume of the same buffer. In Figure 5-16A, the data were 
in accordance with the hypothesis that a larger size shift could be obtained with 
more dilute AuNP nanobiosensors at concentrations below the hook point. For the 
Affimer based system, however, when the nanobiosensors were further diluted to 
0.01x (8 x 108 NP/ml), there was no different in sensitivity as compared to 0.1x (8 x 
109 NP/ml). In terms of hook effect, the concentrations at which hook point occurred 
decreased with diluted nanobiosensors. These data provide support for the 
explanation of the hook effect given in Chapter 1. With less AuNPs in the solution, 
there will be less bioreceptors present and saturation can occur at lower 
concentration of analyte.   
Figure 5-17 shows the dynamic range of each nanobiosensor concentration 
for both IgG- and Affimer system. Again, the LODs of each nanobiosensor were 
calculated by fitting with a two-site binding model, whilst the maximum detection 
point could be obtained from the hook point. As expected, different dynamic ranges 
could be obtained by changing the AuNP nanobiosensor concentration. Surprisingly, 
the LODs were contradict the prediction that better sensitive should be achieved 
from the most dilute concentration. A likely explanation is that when further diluting 
the AuNPs, scattering intensities may be reduced as there was too much.  
When the dynamic range of both nanobiosensor systems are compared, IgG-
AuNPs provided a wider detection range, especially with more concentrated 
nanobiosensors (Figure 5-17A). It is possible that these data may be due to steric 
hindrance. As Affimers are small, they were attached closer to the AuNP surface than 
IgGs would be, so when there were too many nanobiosensors in the solution, these 
AuNPs could block each other from binding Mb. 
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Figure 5-17 Dynamic ranges of DLS assay for Mb detection using four different 
nanobiosensor concentrations. (A) and (B) represents IgG- and multiple Affimer-
AuNPs, respectively; The nanobiosensor concentrations were: ( ), 8 x 108 NP/ml;     
( ), 8 x 109 NP/ml; ( ), 8 x 1010 NP/ml; ( ), 8 x 1011 NP/ml. 
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5.7 Stability of nanobiosensors 
To study the stability of nanobiosensors used in DLS assay, IgG- and multiple 
Affimer-AuNPs were prepared on day 1 and were used for Mb detection on days 1, 
3, 7 and 35. The sensors were kept at 4 C protected from light between uses. The 
AuNP sizes were determined before every use and the results are shown in Figure 5-
18; whilst the size shift response curves are shown in Figure 5-19.  
 
 
 
Figure 5-18 Mean DH of AuNP probes used in stability study. Mean DH of (A) IgG-
AuNPs and (B) multiple Affimer-AuNPs before assay day 1, (  ); day 3, (  ); day 7, ( 
 ); day 35, (   ). 
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Figure 5-19 DLS assay for Mb detection performed on day 1, 3, 7 and 35 to study the 
stability of nanobiosensors. The calibration curves obtained from (A), IgG-AuNPs; 
and (B), multiple Affimer-AuNPs performed on day 1, ( ); day 3, ( ); day 7, ( ); 
and day 35, ( ); The experiments were performed as described in Figure 5-9 and 
Mb solution were prepared freshly each day from stock solution. AuNP 
nanobiosensors were stored at 4 ºC protected from light between uses. Data are 
mean values ± SD (n=3). 
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There was slight increase of AuNP sizes at day 3 and day 7 for both systems. 
However, these changes were not significant compared with day 1 AuNP sizes. The 
performance curves of day 1, 3 and 7 showed the same characteristics for both 
systems, suggested that the assays were reproducible. Moreover, the hook points of 
day 1, 3 and 7 assays also occurred at the same concentration. However, it is 
apparent from Figure 5-19 that when the nanobiosensors were kept longer, to day 
35, calibration curves could not be obtained from both IgG and Affimer AuNPs. At 
day 35, the mean DH of both IgG and Affimer nanobiosensors shifted around 15 – 16 
nm from day 1 sizes. This indicated some aggregation of the AuNPs, suggesting that 
both nanobiosensors were not stable up to 35 days. It may be that the 
nanobiosensors were stable up to some intermediate point, between 7 and 35 days 
but this experiment suggested that both IgG and Affimer nanobiosensors were stable 
and could be used within 1 week without any preservatives added. 
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5.8 Versatility of NP-coupled DLS size shift assay using Affimers 
Here, the optimised assay was used with Clostidium difficile toxin B. In 
comparison to Mb, it is a much larger protein (Mr 270 kDa) so it is a good analyte to 
investigate the versatility of the assay platform. Also, anti-toxin B Affimers have been 
screened, well-characterised and were ready to use. However, there were only two 
Affimers provided, which were Affimer 18C and 45C. These two Affimers were 
confirmed as a binding pair, binding to different epitopes. Therefore, toxin B assay 
was performed as paired Affimer assay. In this section, the term “Affimer” will refer 
as anti-toxin B Affimer, unless stated otherwise. 
To begin the process, both 18C and 45C Affimers were biotinylated using 
biotin maleimide to couple to the C-terminal Cys –SH. The prepared anti-toxin B 
Affimer AuNPs (txB-Affimer-AuNPs) were characterised with DLS. The mean DH of 
the nanobiosensors was 63.31 ± 1.69 nm, confirming the success of functionalisation 
as the size shift was around 8 nm which corresponds to around twice the diameter 
of an Affimer (~ 3 nm). Also, the size distribution plot showed no aggregation during 
the conjugation (Appendix 9E). Detection of toxin B was performed as for the Mb 
assay. The mean DH of txB-Affimer-AuNPs before and after mixing with toxin B over 
the range 10 fM to 10 µM was measured by DLS after incubation at RT for 30 min. 
Strep-AuNPs were used as negative control. 
Figure 5-20 shows the size shift of txB-Affimer-AuNPs in the presence of 10 
fM to 10 µM toxin B compared with strep-AuNPs. There was a proportional response 
between txB-Affimer nanobiosensors size shift over the concentration range 10 pM 
to 10 nM before the hook effect started. Within this range, there was no responses 
observed in the negative control system but after the hook point, there was an 
increased shift for strep-AuNPs. This may be due to the large size of toxin B, which 
will have a greater intrinsic scattering property than Mb. 
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Figure 5-20 Size shift of toxin B (90 µl) mixed with anti-toxin B paired Affimer 
nanobiosensors (10 µl) after incubating at RT for 30 min. Anti-toxin B paired Affimers 
conjugated AuNPs, ( ); streptavidin coated AuNPs as negative control, ( ); each 
DLS measurement was performed at 10 s/run for 10 runs, data are mean values ± SD 
(n=2). (*) indicates significant values tested with independent t-test between 
experiment and negative control (p < 0.05). 
 
 The measured data was fitted with a two-site binding model since two 
different Affimers were used and the R2 and 2 are reported in Table 5-6. The fitting 
curves of this model is shown in Figure 5-21. The LOD of txB-Affimer-AuNPs in 
detection of toxin B was around 30 nM, which was less sensitive as compared to the 
Mb assay. A likely explanation is that with larger analyte protein present in the DLS 
system, the scattering property of the protein will affect the size shift response. This 
was observed from the negative control system in which the size increased with 
higher concentration of toxin B in the solution.  
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Table 5-6 Binding parameters derived from a two-site fitting model of toxin B assay 
using anti-toxin B paired Affiimer nanobiosensors. Data was analysed using 
GraphPad Prism 7. 
Parameters Two-site model 
Bmax1 18.93 
KD1 1.46 x 10-9 
Bmax2 3.08 
KD2 4.09 x 10-12 
R2 0.9973 
2 0.6651 
c 3.273 
 
 
Figure 5-21 Two-site model fitting of an assay for toxin B using anti-toxin B paired 
Affimer conjugated AuNPs in the concentration range of 10 fM - 10 nM. Measured 
data was illustrated by ( ), anti-toxing B paired Affimer-AuNPs; ( ), negative 
control using strep-AuNPs; ( ), fitted data; ( ), negative control mean values plus 
their three SDs (n=2); ( ), maximum negative control value plus three SD (n=2). 
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5.9 Discussion 
Data presented in this chapter has highlighted the ability of Affimers to act 
as bioreceptors for a NP-coupled DLS size shift assay. It was demonstrated in the 
kinetics study that Affimer-AuNPs could bind to Mb-AuNPs and exhibited similar 
kinetics to IgG-AuNPs. This result corresponded to that presented in a kinetic study 
by Liu and Huo (2009) who studied the capability of DLS to monitor aggregation 
caused by immunoaffinity induced-interaction. DLS provided not only the average 
DH size but it could provide details regarding the aggregation state. These preliminary 
data have shown that aggregation was affected by the incubation time and suggest 
that a minimum of 30 min incubation time should be applied in designing the assay 
format. 
 In Mb detection assay using nanobiosensors, IgGs were used as a positive 
control in order to understand the mechanism of the assay before moving on to use 
the Affimers. There was a linear relationship observed between the size shift 
responses and increased Mb concentrations. IgG nanobiosensors were able to detect 
Mb with a detection range of 148 fM – 10 nM. The most important information 
achieved from the positive control system is that the NP-coupled DLS assay also 
showed the hook effect in reduced response and no relationship found with Mb 
concentrations. This hook point will determine the assay’s upper limit of detection. 
In addition, a two-site binding model was proved to be best representing the 
parameter calculation.  
The paired Affimer based system proved to be selective for Mb compared to 
negative controls (strep-AuNPs) and the size shift response curve showed a similar 
trend to IgG based system and had the same hook point. However, the sensitivity of 
the paired Affimer-AuNPs was much lower as compared to IgG system (LOD = 41.6 
pM). To increase the sensitivity of the Affimer system, all five selected Affimers were 
used to “replicate” a polyclonal IgG on the AuNP surface. It was shown here that the 
sensitivity was improved to 554 fM. A possible explanation would be that the 
multiple Affimer based system may benefit from the avidity effect. Also, previous 
studies on the size shift assays using DLS for monomeric analytes mostly used pAbs 
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(Liu and Huo, 2009; Wang et al., 2012). Therefore the finding of this study suggest 
that a number of selective clones of a particular binding reagent on an AuNP, i.e. for 
the same target protein but to different epitope, may be the key factor to enhance 
the sensitivity of the assay for monomeric analytes. Moreover, the selectivity of the 
assay was also examined by using different analytes with anti-Mb Affimer 
nanobiosensors and using different Affimer nanobiosensors with Mb. These results 
show that the assay was selective to Mb. 
Furthermore, factors related with AuNP were investigated. Regarding the 
effect of NP size; when changing the AuNP core diameter from 20 to 40 nm, the 
results are in line with the hypothesis that a larger size NP could provide a stronger 
scattering intensity and therefore better sensitivity. However, when the size of NPs 
was further increased, the outcome was contrary to this hypothesis and some 
previous findings (Nietzold and Lisdat, 2012; Wang et al., 2012). A possible 
explanation may be due to the steric effect of the nanobiosensor and analyte. Mb is 
a compact protein with a size around 3.5 nm, with larger AuNPs, there might be some 
blocking effects. This outcome was shown for IgG-AuNPs too. It can therefore be 
assumed that steric hindrance plays an important role in the binding activity and 
assay performance which also depends on the analyte itself. 
Another factor investigated was the NP concentration, as DLS measures the 
whole population of NPs. The results obtained from IgG-AuNPs were in accordance 
with previous studies that a larger size shift could be obtained with more dilute AuNP 
nanobiosensor at concentrations below the hook point. However, with Affimer-
AuNPs, when diluted the concentration to around 0.01x of stock concentration, 
there was no difference seen and LODs were not lowered. This may be due to 
scattering intensities being reduced. These data are consistent with those of Driskell 
et al. (2011) who studied the effect of AuNP concentration in their DLS assay for 
influenza virus detection. By adjusting the concentration of NPs, different detection 
range could be obtained. 
 The objective of this project is to improve the stability of nanobiosensors in 
aggregation assay using DLS, so the stability of Affimer and IgG nanobiosensors were 
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tested and compared. Both systems were stable for one week but not when kept for 
35 days; similar findings were reported by Driskell et al. (2011) who also focused on 
functionalised AuNP stability. In their study, the IgG conjugated AuNPs were 
prepared on day 1 and used on day 2, 3 and 4, consecutively. All three assays showed 
a high level of reproducibility and had the same hook point concentration. It was 
suggested that the functionalised AuNPs should be prepared and used within one 
week. Nevertheless, there was no report of functionalised AuNP stability in other 
studies. It would have been better if measurements were done at day 10, 15 for 
better understanding of the stability characteristics. In addition, a biocide such as 
sodium azide (NaN3) should be added to the system to prevent degradation of 
proteins by microbial attack.  
 Overall, these results show that Affimers can be used in a NP size shift assay 
using DLS with Mb and show the same range of sensitivity compared with a IgG based 
system. In addition, the assay platform was tested against a much larger analyte, 
toxin B. The LOD of the assay was 30 nM, which was inferior to that Mb. Nonetheless, 
these results showed that the platform could be used with different analytes apart 
from Mb. 
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Chapter 6 General discussion 
6.1 General discussion 
In recent years, there have been several reports evidencing the potential of 
nanoparticle (NP) coupled dynamic light scattering (DLS) size shift assays in detecting 
a wide variety of analytes. These are summarised in Chapter 1 of this thesis. The 
challenge in this assay field is to produce nanobiosensors whose binding activity can 
be maintained under various conditions and over a longer term since the key 
mechanism of the assay is based on a specific binding event between bioreceptor 
and analyte. To date, the bioreceptors used in the assays were antibodies, 
oligonucleotides or DNA-aptamers; whereas synthetic binding proteins have not 
been investigated. 
 The main objective of this project was to develop a NP size shift assay 
coupling to DLS by using non-antibody binding proteins, Affimers, as bioreceptors. 
Most synthetic binding proteins have been investigated as therapeutic agents as an 
alternative to monoclonal antibody, or have been explored for in vivo imaging. 
However, the work in this thesis has been focused on using the Affimers as 
bioreceptors for sensing purposes. A previous study by Raina et al. (2015) showed 
that an Affimer could be used as a bioreceptor on an electrochemical impedimetric 
biosensor for detection of an anti-myc tag antibody. In addition, Xie et al., (2017) 
reported the use of an Affimer together with a monoclonal Ab in a chemiluminescent 
assay for detection of glypican-3 (GPC3), which is a protein biomarker for 
hepatocellular carcinoma. Therefore, it was hypothesized that Affimers could be 
used as biorecepotrs in a NP-based DLS size shift assay. Here, the Affimers were 
immobilised onto the AuNP surface which were then used as nanobiosensors to 
detect specific proteins. Fundamental parameters affecting the NP-coupled DLS size 
shift assay were explored. 
  
              
210 
 
6.2 Affimer production and characterisation 
Myoglobin (Mb) was selected as a model analyte in this project as it is an 
inexpensive protein with good availability and has well understood structure and 
properties. It should be stressed here that the use of Mb was not for a final 
application since biosensing platform development requires extensive investigation 
before moving on to practical use. Six different Affimers against Mb were 
successfully selected by biopanning of a phage display library. The selected Affimers 
were subcloned from phagemid DNA into a bacterial expression vector for protein 
expression. Although the Affimers could be easily produced by prokaryotic 
expression system, the work carried out in this thesis demonstrated that amongst 
the six anti-Mb Affimers, their physicochemical properties are differed. These 
properties included level of expression, thermal stability, association and 
dissociation constants. 
The general protocol for Affimer production included a 20 min heating step 
to eliminate non-specific proteins based on finding that the Affimer scaffold can 
tolerated temperatures over 70 ºC (Raina et al., 2015; Tiede et al., 2014; Tiede et al., 
2017). However, it was found out that three of the anti-Mb Affimers (D1, E3 and H1) 
were not tolerant to this temperature as without heating step, expression yields 
were higher. This result corresponded to the suggestion by Nygren and Skerra (2004) 
that property of the wild-type scaffold may be affected by changes within the 
structure, such as in the binding loops. With Affimers, around 20 % of the total 
sequence is contributed by the two, nine residue binding loops. 
In addition, a single cysteine was successfully inserted to the C-terminus of 
the Affimers to facilitate the immobilization of the Affimer onto a sensor surface. 
However, the thiol side chain (-SH) of the cysteine residue tended to form a 
disulphide bridge between two Affimers and caused aggregation, as observed after 
the purification of the proteins. This was proved by mass spectroscopy of anti-Mb 
Affimers (Figure 4-6 and Appendix 3 - 6) and the fact that the aggregates could be 
redispersed with reducing agents such as TCEP. For characterisation of Affimers, 
immunoprecipitation (pull-down assay), ELISA and SPR methods were used for all of 
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the anti-Mb Affimers, except Affimer E3 that aggregated out of solution when SPR 
was performed and so it was excluded from the project. The aggregation issue was 
similar to that reported by Raina et al. (2015) who screened the Affimer library for 
anti-myc tag antibodies; they also found that some Affimer clones aggregated and 
had to be excluded. In this project, a modified sandwich ELISA was also used to 
identify pairs of Affimers for crosslinking AuNPs in the size shift assay. 
Overall, the production of Affimers is similar to monoclonal antibody since 
once Affimer DNA is obtained the protein can be expressed, although Affimers use 
much simpler prokaryotic systems. Protein could then be produced without the 
batch-to-batch variation found in pAbs. In addition, no animals were used as well as 
special cell culture media or complex equipment. There may be some issues 
regarding Affimer production, such as low expression yield, aggregation, but in 
general, it seems that the limiting process for Affimer production is screening for the 
best binders suitable for a particular application. Therefore, combinations of 
characterisation methods should be implemented earlier in screening stages to 
distinguish the best Affimers. 
 
6.3 Nanoparticle (NP) coupled dynamic light scattering (DLS) size shift 
assay using synthetic binding proteins    
Functionalisation of bioreceptors onto the AuNP surface was an important 
process for generating nanobiosensors for the NP-coupled size shift assay. Coupling 
via the streptavidin-biotin interaction was selected as it is more durable than 
physical adsorption and requires fewer bioreceptors in the process. It was previously 
used by Gestwicki et al. (2000) and Liu and Huo (2009) for AuNP functionalisation. 
After the Affimers were produced and tested, functionalisation of the AuNP surface 
with Affimers was carried out to generate Affimer nanobiosensors. Biotin maleimide 
was used to biotinylate Affimers via the thiol group on the Affimer C-terminus that 
was provided by an engineered cysteine. In contrast, biotin hydrazide was used for 
biotinylation of IgG at the oxidized Fc region carbohydrate. Streptavidin coated 
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AuNPs (strep-AuNPs) were then mixed with the biotinylated bioreceptors. Factors 
related to the functionalisation were examined which were time of incubation and 
concentration of the biotinylated IgGs and Affimers (Chapter 4). 
Once the nanobiosensors had been successfully fabricated, a combination of 
techniques was used to confirm the presence of the bioreceptors on the AuNPs. 
Conventional methods such as UV-spectrophotometry, dot blotting and DLS were 
used in combination to verify the success of functionalisation. However, these 
methods could not quantify the number of Affimers or antibodies attached to each 
AuNP. Therefore, the direct fluorescence method proposed by Filbrun and Driskell, 
(2016) was adapted and used to quantify IgGs and Affimers attached to the AuNPs. 
The experimental data showed that Affimers packed more densely onto the AuNP 
surface (565 Affimers/NP) compared to IgGs (280 IgGs/NP). This supports the idea 
that the smaller size of Affimers allows them to be immobilised more densely, which 
leads to the enhancement of the sensing system sensitivity (Ferrigno, 2016). 
The kinetics study between Affimers conjugated AuNPs (Affimer-AuNPs) and 
myoglobin conjugated AuNPs (Mb-AuNPs) was conducted in order to understand the 
overall aggregation process compared to established IgG nanobiosensors (IgG-
AuNPs). The data showed that Affimer-AuNPs had similar kinetics to IgG-AuNPs. The 
binding event required at least 30 min to reach equilibrium but the maximum size 
shift response of Affimer nanobiosensors was typically less than IgG system. This 
data helped in designing an appropriate assay protocol.  
The NP-coupled DLS size shift assay using the Affimers as bioreceptors was 
successfully developed and used to detect Mb to prove the principle. The response 
curves obtained from Affimer- and IgG-AuNPs showed similar trends. A linear 
response was observed with an increase concentrations of Mb until the hook point 
was reached. The hook effect was found in both systems. It is a phenomenon that 
occurs when larger amounts of analyte is present in the system at the same time and 
all bioreceptors on the AuNPs are occupied. This leads to decrease in crosslinking. 
The effect has been reported in previous NP-coupled DLS assays and the hook point 
determines the upper limit of detection (Liu and Huo, 2009; Driskell et al., 2011; 
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Huang et al., 2015). The hook effect is seen in a number of different binding assays 
including the ELISA. The Affimer nanobiosensors prepared were selective for Mb and 
showed no response when BSA added. Also, the size shift responses were due to 
specific binding between the Affimers and Mb: when non-specific (control) Affimers 
were used, there was no significant response. 
Initially, two Affimer clones were used as bioreceptors as they should be able 
to crosslink between AuNPs. It was proved that paired Affimer nanobiosensors could 
be used for Mb detection but the sensitivity (LOD = 41.6 pM) was lower as compared 
to IgG-nanobiosensors (LOD = 148 fM) even when there were more molecules of 
Affimer attached on the AuNPs. Nevertheless, it should be noted that the IgG used 
was a polyclonal antibody. The Affimers are monoclonal and bind to a single epitope. 
Therefore, multiple Affimers were used as bioreceptors in the assay to mimic the 
polyclonal characteristics of IgG used. The sensitivity of the assay was improved 
substantially from 41.6 pM to 554 fM LOD, which was in the same range of IgG-
AuNPs for Mb detection. 
The effect of NP size was also examined since the Mie theory predicts that 
light scattering intensity is proportional to the 6th power of the radius of the particle 
(Yguerabide and Yguerabide, 1998) and previous studies have shown the sensitivity 
of the assay could be improved by using larger AuNPs (Nietzold and Lisdat, 2012; 
Wang et al., 2012). The findings of our study suggested that it was not always the 
case that larger AuNPs provide better sensitivity. The data corresponded to two 
previous studies by Driskell et al. (2011) and Huang et al. (2015), who reported that 
sensitivity was not necessarily improved with increasing AuNP size. The explanations 
given in both studies were pretty similar that this might be due to different 
concentration of AuNPs being used and steric hindrance between larger AuNPs and 
the analytes may have prevented binding. The analytes from both researches were 
influenza virus and bacteria Listeria monocytogenes, respectively, which are large 
biomolecules. Here, conversely, Mb is a small protein with around 3.5 nm diameter. 
However, the steric effect that blocked the binding might come from the AuNPs 
themselves. Larger particles could prevent each other from binding to Mb and 
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changing the binding stoichiometry. Also, it is worth pointing out that with small 
AuNPs (20 nm), the LOD of the Affimer based system was slightly better than for IgG-
AuNPs (Figure 5-15). This data further supported the idea that steric hindrance is an 
important factor to consider as Affimers are smaller than IgGs. With smaller AuNPs 
the Affimers were not restricted by the size of the NPs in binding to Mb. 
AuNP concentration was another factor investigated in this thesis, as DLS 
measures the whole population of the samples. It was expected that more dilute 
AuNPs suspension could provide better sensitivity because all the AuNPs should be 
involved in crosslinking and forming aggregates. As a result, there should be less 
unbound nanobiosensors left in solution, giving a larger shift in size (Driskell et al., 
2011; Zheng et al., 2016). The experimental data for both IgG and Affimer 
nanobiosensors corresponded to the theory except when very dilute AuNPs (8 x 108 
NP/ml) was used. This is likely because the scattering intensities reduced due to 
limited scattering material. These results are consistent with the report by Driskell 
et al. (2011). These findings suggest that the detection range of the size shift assay 
can be adjusted by varying the AuNP concentration. This factor should be considered 
alongside the size of AuNPs used. 
Additionally, Affimer nanobiosensors for Clostidium difficile toxin B were 
prepared and used in the same assay format to investigate the versatility of the 
Affimer size shift assay. Toxin B was selected as it is a large biomolecules (Mr ~ 270 
kDa) and there were anti-toxin B Affimers available and well-characterised. 
However, the sensitivity of the toxin B detection was in the nM range and the hook 
point occurred at a higher concentration compared to the detection of Mb. Also, it 
should be noted that only two anti-toxin B Affimers were used and the sensitivity 
might be improved if multiple Affimers are used. Another interesting point from this 
work is that with toxin B present in the control system (strep-AuNPs) larger size shift 
responses were seen, especially at higher concentrations, as compared to the 
changes seen with Mb. This might be related to the fact that the analyte itself can 
be measured directly by DLS because proteins possess a weak light scattering 
property. 
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Taken together, these findings suggest that in general the NP-coupled DLS 
size shift assay works optimally with bioreceptors that can bind to multiple epitopes 
of the analyte. The current data highlight the potential importance of avidity effects 
on the DLS size shift assay over the number of bioreceptors on the AuNP surface. In 
addition, the detection range of the assay can be tailored to each analyte by selecting 
appropriate AuNP size and concentration. With large biomolecules, their intrinsic 
light scattering property could interfere with the size shift assay. Therefore, it is best 
to conduct a DLS measurement for the large biomolecules alone without the AuNPs 
to determine the concentrations at which the weak scattering effect does not 
interfered. For smaller biomolecules, the steric effect is the main factor to be 
considered as binding between Affimers and analytes can be hindered by the size of 
AuNPs used. These observations are based on experiments carried out in PBS buffer 
and the buffer used and matrix in which the analyte is presented (e.g. serum, urine) 
should also be considered.  
Regarding the stability of nanobiosensors, previous work in NP-coupled DLS 
size shift assays have not dealt with the long term stability of the nanobiosensors 
used. Only one study examined the stability of their antibody functionalised AuNPs 
(Driskell et al., 2011). In this thesis, the stability test was conducted for around five 
weeks. Both IgG-AuNPs and Affimer-AuNPs showed no significant difference and 
were stable over a week when kept at 4 ºC protected from light (Figure 5-19). It may 
be that they were stable beyond this, however, the next time point assayed was 35 
day at which their performance had deteriorated. The data here correlated with the 
stability data of Driskell et al. (2011). A limitation of the stability test was that it could 
not differentiate the cause of instability; whether coming from AuNP 
functionalisation or bioreceptor damage. For instance, if sodium azide was added to 
the storage buffer it might help prevent degradation of proteins by microbial action. 
This should be carried out as part of any future assay development. 
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6.4 Future work and opportunities 
This study has demonstrated that synthetic binding proteins, Affimers, could 
be used in NP-coupled DLS size shift assays. The findings of this research provide 
insights for assay development and show its versatility for various bioreceptors.  We 
have also shown that Affimers can be used in optical sensing systems in addition to 
their applications in molecular and cell biology, as reported by Tiede et al. (2017). 
Additionally, NP-coupled DLS size shift assays are not restricted to proteins but can 
be designed for other analytes. At present, Tiede et al. (2017) have been able to 
screen Affimers against small organic compounds, such as 2,4,6-trinitrobenzene 
(TNT). This opens up another opportunity to develop NP-coupled DLS size shift assays 
in a competitive assay format for detection of small molecules (e.g. drugs, 
pesticides). Therefore, future work needs to be carried out to establish whether the 
Affimer based nanobiosensors are effective in a competitive format. 
The opportunity to develop the NP-coupled DLS size shift assays further, lies 
in two key areas; the feasibility of using the assays with samples in various matrices 
(e.g. serum) and stability of the nanobiosensors (Pierre-Pierre and Huo, 2015). In 
terms of background signal, the assay has mostly been reported for laboratory rather 
than “real world” applications. It was suggested by Jans and Huo (2012) that to 
overcome the matrix scattering intensities from blood samples, at least 100 nm 
diameter AuNPs should be used. It would be interesting to assess the effects of 
background matrices on the Affimer based NP-system. Affimers might also be a 
solution to the stability of the nanobiosensors since they are much more thermally 
stable than IgG (Tiede et al., 2014; Tiede et al., 2017).  
It is very important that the binding activity between the bioreceptor and 
target analyte is maintained to ensure the qualitative and quantitative efficiency of 
the assay over time. Also, the assay requires the use of polyclonal reagents in 
crosslinking AuNPs. Polyclonal antibodies, although easily available suffer from 
batch-to-batch variability, whereas using multiple monoclonal antibodies would be 
too expensive for assay development. The production of Affimers is easier and 
cheaper with no batch-to-batch variation as they are clonal reagents. Further 
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research might explore the screening process for multiple Affimers that bind to 
different epitopes on the target protein in order to replicate polyclonal reagents. In 
addition, more research is needed to better understand the stability of the Affimer-
nanobiosensors and whether the functionalisation alters the binding efficacy or 
stability in long term use. The company Nano Discovery Inc.2 in the US is currently 
commercializing the NP-coupled DLS size shift technology under the name D2DxTM. 
However, the AuNP sensors are sold in the form of conjugation kits for antibody 
immobilization. The antibodies are not provided and the conjugation has to be 
performed before the assay. With Affimers, that are stable thermodynamically and 
chemically, development of ready-to-use assay kits might be easier to make without 
the extra conjugation steps. 
In summary, the analytical science and specifically biosensing fields have 
increasingly shifted towards label-free systems. The main advantages of these assays 
over others is that no labelling of the target or ligand is needed. Therefore, the assay 
is less complicated and true interactions can be obtained. The NP-coupled DLS size 
shift assay is another optical label-free technique that proved useful for many 
applications such as biomarker detection and studies on protein-protein interaction. 
In comparison to conventional optical label-free techniques such as SPR, DLS is rapid 
and assay results can be obtained within minutes. Additionally, homogeneous assays 
can be performed as there is no need to separate the nanobiosensors and analytes 
before measurement take place. The equipment itself is cheaper as well as the 
consumables required for measurements. DLS can be operated with cuvettes or 96-
well plates, which cost less than SPR chip. Glass cuvettes are also available for reuse 
if needed. Although the use of AuNPs might be costly as the nanobiosensors are 
single-use for each measurement, the NP-coupled DLS size shift assay only requires 
a small volume of AuNPs per sample (around 20 µl/sample). Overall, in a long-term 
consideration for small laboratories or industries with limited budget, DLS might be 
a better option for protein-protein interaction as DLS can be used for protein and 
                                                     
2 http://www.nanodiscoveryinc.com/ 
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particle size analysis as well. This technique also has a potential to be developed into 
a high-throughput format as DLS plate readers are now available.
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Appendices 
1. KingFisher Flex protocol ‘Phage_display_pH_elution’ 
Protocol Step Plate Volume (ul) Settings 
Tipcomb  96 DW tip comb   
Pick-Up: Tipcomb KingFisher 96 KF 
plate 
  
Collect Beads Plate: Binding 
Microtiter DW 96 
plate 
 Collect count 1 
Collect time (s) 1 
Binding Plate: Binding 
Microtiter DW 96 
plate 
300 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:00:10 
Speed: fast 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 1 Plate: Wash 1 
Microtiter DW 96 
plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 2 Plate: Wash 2 
Microtiter DW 96 
plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 3 Plate: Wash 3 
Microtiter DW 96 
plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
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Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 4 Plate: Wash 4 
Microtiter DW 96 
plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
pH Elution Plate: pH elution 
KingFisher 96 KF 
plate 
100 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:07:30 
Speed: slow 
Postmix[hh:mm:ss]: 00:00:05 
Speed: Bottom mix 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Triethylamine 
Elution 
Plate: Triethylamine 
KingFisher 96 KF 
plate 
100 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:03:30 
Speed: slow 
Postmix[hh:mm:ss]: 00:00:05 
Speed: Bottom mix 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Leave: Tipcomb 96 DW tip comb   
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2. ELISA results of biotinylated Affimers 
 
 
 
 
 
 
 
 
 
ELISA to validate biotinylation of Affimers B5, D1, F5 and H1 for AuNP functionalisation. (A), showing ELISA strip for three different dilutions of 
biotinylated Affimers 0.5 mg/ml (1, 1/10 and 1/100) and negative control (PBS buffer) from top to bottom; (B), showing the absorbance at 620 nm 
of each tested samples 
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3. Mass spectrum of Affimer B5 and biotinylated Affimer B5 
 
 
 
 
 
 
 
 
 
Mass spectrum of B5 Affimer. (A), showing B5 Affimer before biotinylation, highest peak at 24967.55 Da corresponding to Mr of dimeric B5 Affimer; 
(B), showing after biotinylation, highest peak at 12939.08 Da corresponding to Mr of B5 Affimer monomer plus biotin maleimide (Mr 451.54 Da).
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4. Mass spectrum of Affimer D1 and biotinylated Affimer D1 
 
 
 
 
 
 
 
 
 
Mass spectrum of D1 Affimer. (A), showing D1 Affimer before biotinylation, highest peak at 25003.60 Da corresponding to Mr of dimeric D1 Affimer; 
(B), showing after biotinylation, highest peak at 12955.14 Da corresponding to Mr of D1 Affimer monomer plus biotin maleimide (Mr 451.54 Da). 
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5. Mass spectrum of Affimer F5 and biotinylated Affimer F5 
 
 
 
 
 
 
 
 
 
Mass spectrum of F5 Affimer. (A), showing F5 Affimer before biotinylation, highest peak at 24733.55 Da corresponding to Mr of dimeric F5 Affimer; 
(B), showing after biotinylation, highest peak at 12821.08 Da corresponding to Mr of F5 Affimer monomer plus biotin maleimide (Mr 451.54 Da). 
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6. Mass spectrum of Affimer H1 and biotinylated Affimer H1 
 
 
 
 
 
 
 
 
 
Mass spectrum of H1 Affimer. (A), showing H1 Affimer before biotinylation, highest peak at 25037.30 Da corresponding to Mr of dimeric H1 Affimer; 
(B), showing after biotinylation, highest peak at 12970.40 Da corresponding to Mr of H1 Affimer monomer plus biotin maleimide (Mr 451.54 Da). 
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7. Calibration curves prepared using NanoOrangeTM fluorescent dye 
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8. Calibration curves prepared using Bradford reagent 
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9. Size distribution plots of all nanobiosensors used 
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The nanobiosensors used were: (A), 
IgG conjugated AuNPs; (B), anti-Mb 
paired Affimer-AuNPs; (C), anti-Mb 
multiple Affimer-AuNPs; (D), anti-
calprotectin Affimer-AuNPs; and (E), 
anti-toxin B Affimer-AuNPs. 
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10. Effect of AuNP size on the NP-coupled DLS size shift assay 
 
Effect of AuNP size on the DLS assay for Mb detection. (A) and (B) represents IgG- 
and multiple-AuNPs, respectively; line graph represents AuNP core diameters of            
( ), 20 nm;  ( ), 40 nm; ( ), 60 nm; ( ), 80 nm and ( ), 100 nm. Data are mean 
values ± SD (n=3). 
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11. Poster presented at World Congress on Biosensors 2016 (Gothenburg, 
Sweden) 
 
 
 
 
A new analytical platform for biomolecules:
Nanoparticle size shift assay using synthetic binding proteins
Thanisorn Mahatnirunkul1*, Darren Tomlinson2, Michael McPherson2 and Paul Millner1
1 The Leeds Bionanotechnology Group, School of Biomedical Sciences, University of Leeds, UK.
2 Leeds BioScreening Technology Group and Astbury Centre for Structural Molecular Biology.
sm12tm@leeds.ac.uk *
 Detection of biomolecules usually involves labelling analytes with 
chromophores, fluorophores or radiolabels, which sometimes interfere 
with analytes and their molecular interactions.
 The tagging process also makes the established method complicated, 
complex, time-consuming and expensive.
Proposed applications for a new analytical platform: 
screening new drugs within the pharmaceutical industry 
cheap and rapid diagnostic purposes by label-free approaches that 
minimize processing steps
1. Why a new analytical platform?
 Proposed assay is based on principle of optical biosensing.
 Synthetic binding proteins, which replicate antibody function, are 
conjugated onto nanoparticles (NPs) as bioreceptor elements.
 When the target analytes are added to the system, the binding of 
the target and immobilised binding protein will lead to 
aggregation of the NPs.
 The aggregation can be measured by dynamic light scattering (DLS) 
for complete quantitation
 Dynamic light scattering (DLS): analytical tool used routinely for 
measuring the hydrodynamic size of nanoparticles and colloids in a 
liquid environment.
 Advantages: 
short duration analysis, no special expert required, cheap,     
sensitive to small change in size 
2. What is the principle?
Linker
Synthetic binding protein
Analytes
Dynamic light scattering (DLS)
Figure 1: 
X-ray crystal structure 
of scaffold1.
 It is an artificial protein that replicates antibody function 
selected by phage display.
 Library has around 1.3 x 1010 clones to be selected.
 Characterizes by ELISA and biolayer interferometry.
 Compared with antibody:
Inexpensive production system; genetic engineering 
and prokaryotic expression system
Better stability
Monomeric, small molecule
Do not contain internal cysteine 
Nanoparticle aggregationNanoparticle probes
3. Affimer vs Antibody
4. Nanoparticle size shift assay for myoglobin 
 Myoglobin from equine heart was used as a model analyte.
 common, cheap,  have a lot of information  and good supply availability 
Reference:
[1] C. Tiede et al, Protein Engineering Design and Selection, 2014,  27.
[2] X. Liu and Q. Huo, J. Immunol. Methods, 2009, 349, 38-44.
[3] S. Dodig, Biochem. Medica., 2009, 19, 50-62.
 These preliminary results show a potential of anti-myoglobin Affimer
nanoparticles probe in detection of myoglobin in the concentration range 
from 0.1 – 10 nM, which was similar to antibody nanoparticles probe.
 Optimisation of the system is under investigation.
5. Conclusion 
Figure 2: Mean DH of streptavidin AuNPs and 
different Affimer-conjugated AuNPs.
Triplicate measurements were performed.
Figure 3: Mean DH of Affimer-conjugated AuNPs
and AuNPs aggregates measured via DLS as a 
function of myoglobin concentration.
Triplicate measurements were performed.
Streptavidin AuNPs (StrepAuNPs)
Myo-AbAuNPs
Myo-AdAuNPs
Cal-AdAuNPs
Saturated 
probe
Myo-AbAuNPs
Myo-AdAuNPs
Cal-AdAuNPs
500 nm 500 nm
500 nm500 nm
500 nm 500 nm
Without myoglobin With myoglobin 10 nM
A
B
C
D
E
F
Streptavidin AuNPs
Anti-myoglobin antibody AuNPs
Anti-myoglobin Affimer AuNPs
Figure 4: TEM images compared      
between the absence and presence of 
myoglobin 10 nM.
A-C) show the TEM images without 
myoglobin of StrepAuNPs, Myo-
AbAuNPs and Myo-AdAuNPs, 
respectively.
D-F) show the TEM images 
with myoglobin 10 nM of StrepAuNPs, 
Myo-AbAuNPs and Myo-AdAuNPs, 
respectively.
TM is sponsored by Royal Thai Government Scholarship.
.
Preparation of nanoparticle probes
Results and Discussion 
 The DLS data (Figure 2) shows slight shift in size of both antibody and 
Affimer probes with narrow size distribution, which correlates to the TEM 
images (Figure 4A-C) that show no aggregation of the particles. 
 The DLS results in Figure 3 show an increase in mean hydrodynamic 
diameter (DH) with an increase in myoglobin up to 100 and 10 nM for anit-
myoglobin antibody and Affimer systems, respectively.
 There was a slight shift in anti-calprotectin Affimer system (Control, Figure 
3, blue line)
 Greater concentrations of myoglobin led to a decrease in DH. This is 
probably due to the commonly observed phenomenon reported before2,3, 
when all the bioreceptors are saturated with the analyte and lead to 
prevention of cross-linking between particles. 
 TEM images in Figure 4 confirm the presence of aggregates in the anti-
myoglobin antibody and Affimer system, also the absence of the 
aggregates in streptavidin AuNPs alone without bioreceptors when 
myoglobin 10 nM was added.
Labeling
Affimers
with biotin
Streptavidin 
AuNPs
(OD 1)
Affimer-
conjugated 
AuNPs
probes
Myoglobin
10 pM – 10 µM
Myoglobin
10 nM
DLS
TEM
• Anti-myoglobin antibody AuNPs
• Positive control
Myo-
AbAuNPs
• Anti-myoglobin Affimer AuNPs
Myo-
AdAuNPs
• Anti-calprotactin Affimer AuNPs
• Non-specific control
Cal-
AdAuNPs
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(Riva del Garda, Italy) 
 ne-step gold nanopar cle si e-shi  assay 
using synthe c  inding protein and dyna ic light sca ering 
Thanisorn Mahatnirunkul1*, Darren Tomlinson2, Michael McPherson2 and Paul Millner1 
1 The Leeds Bionanotechnology Group, School of Biomedical Sciences,  niversity of Leeds,  K.  
2 Leeds BioScreening Technology Group and Astbury Centre for Structural Molecular Biology.  
   is sponsored  y Royal  hai o ern ent Scholarship  
   Principle o  the assay 
   er gold nanopar cle pro es  rosslin ing o  pro es 
 Proposed assay is based on principle of op cal biosensing. 
 Synthe c binding proteins (A mers), which replicate an body func on, are  conjugated onto 
gold nanopar cles (AuNPs) as bioreceptor elements. 
 When the target analytes are added to the system, the  inding o  the target and    er ill 
lead to aggrega on o  the  Ps. 
 Without separa on of the excess probes, the mean AuNP probe/aggregate size is determined 
via dynamic light sca ering (DLS) for complete quan ta on.  
 DLS is an analy cal tool used rou nely for measuring the hydrodynamic size of NPs and colloids 
in a liquid  environment. 
  d antages: short dura on analysis, no special expert required, cheap and sensi ve to small 
change in size. 
   ethodology  Results and Discussions 
      er (  )  s  n  ody (  ) 
 A mer1 is a non-an body binding protein. 
 The library has around 1.3 x 1010 clones to 
be selected by phage display  
 Small, monomeric and no cysteine residue 
 High thermal stability  
   (Tm of 70  C to 100  C) 
 Inexpensive produc on system  
   (Prokaryo c expression system) 
 No batch to batch variability 
 nser on 
Site   
 nser on 
Site   
           
A mer structure (PDB: 4N6 ) 
   ) Produc on o     er 
   ) Func onalisa on o   u Ps 
  3) Si e-shi   ssay  or   
 Myoglobin (Mb) was selected as a model analyte.  
    Common, cheap, good availability 
 5 myoglobin A mer binders were selected from phage display library. 
 Characterisa on was done by surface plasmon resonance (SPR). 
 SPR data (Figure 2) con rms that the A mers bind to myoglobin and 
have KD in the range of pM to nM. 
3   o  ina on o   u P     er and D S 
Reduc on of cost with consistency of reagent quality 
Homogenous assay, no need to separate excess probes 
No interference with the true binding interac on 
High throughput system possible 
 e   a el- ree  naly cal Pla or  
           
Summary of KD of myoglobin 
A mers obtained from SPR 
 ncreasing  
 inding ac  ity 
 Amount of bioreceptors adsorbed per AuNP were determined using                 
 uorescence method reported by Filburn and Driskell2. 
 It was observed that there were more A mer/NP compared with an body/NP. 
This is due to the small size of A mer (Figure 2). 
 Probes were prepared using 50 µg of protein and original probe size (DH) of 4 
di erent prepared probes were reported using DLS (Table 1). 
           
Amount of bioreceptor per AuNP a er adding 
di erent amount of Ab (     ) and Af (     ) 
Pro es DH SD 
Streptavidin 
coated NPs 
38.74 0.50 
An -myoglobin 
AbNPs 
61.80 1.96 
An -myoglobin  
AfNPs 
46.49 1.16 
An -Calprotec n  
AfNPs 
47.40 0.62 
         Hydrodynamic diameter (DH) of  
4 di erent probes used in the experiment  
          
Mean DH size shi  from their  
original probe size for the 4 systems 
measured via DLS as a func on of  
myoglobin concentra on. 
An -myoglobin A mer NPs 
An -myoglobin An body NPs 
Streptavidin NPs 
An -calprotec n A mer NPs 
 The DLS data from Table 1 shows slight shi  in size of each probe with narrow size 
distribu on, which correlated to the TEM image (Figure 5A-C) that show no        
aggrega on of the NP probes.  
 The DLS results in Figure 4 show an increase in DH with an increase in Mb upto 100 
and 10 nM for an -MbAb and an -MbAf systems, respec vely. TEM images in           
Figure 5 con rm the presence of aggregates when 10 nM Mb was added. 
 Greater concentra ons of Mb led to a decrease in DH. This is probably due to the 
commonly observed phenomenon reported before3,4, when all the bioreceptors 
are saturated with the analytes and lead to preven on of the crosslinking.  
 There were a slight shi  in an -calprotec n A mer system and streptavidin NPs, 
which represented non-speci c and nega ve controls, respec vely. 
  onclusion:    er can  e used as  ioreceptor in si e-shi  assay ith si ilar 
e cacy co para le to an  ody  or    
Ini al screening for industries: environment, food or agriculture 
Alterna ve biosensing pla orm for small scale laboratory 
Simultaneous kine c study of mul ple samples 
Screening process for drug discovery 
 pplica ons 
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        :  
TEM images compared between the 
absence and presence of myoglobin. 
  
 - ) show the TEM images without 
myoglobin of streptavidin NPs,           
an -Mb-AbNPs and Mb-AfNPs,               
respec vely.  
D-F) show the TEM images  
with 10 nM myoglobin of streptavidin 
NPs, an -Mb-AbNPs and Mb-AfNPs,  
respec vely.  
Re erence   
 1  C. Tiede et al,  rotein  n ineerin   esi n an   elec on, 2014,   .  
 2  S.L. Filbrun and  .D. Driskell, Analyst  2016,    , 3851-3857.   
 3   . Liu and  . Huo  J   mmunol  etho s, 2009, 3  , 38-44.  
 4  S. Dodig, Biochem. e ica   2009,   , 50-62.  
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